As filed with the Securities and Exchange
Commission on November 26, 2024
Registration No. 333-277351
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM F-3/A
Amendment No. 1
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
Akso Health Group
(Exact name of registrant as specified in its
charter)
Cayman Islands |
|
Not applicable |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification Number) |
Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building,
No. 44, Moscow Road, Qianwan Bonded Port Area,
Qingdao Pilot Free Trade Zone, China (Shandong)
Tel: +86 152 1005 4919
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Puglisi & Associates
850 Library Avenue, Suite 204
Newark, DE 19711
302-738-6680
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Joan Wu, Esq.
Hunter Taubman Fischer & Li LLC
950 Third Avenue, 19th Floor
New York, NY 10022
212-530-2208
Approximate date of commencement of proposed sale
to the public: From time to time after the effective date of the registration statement.
If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
☒
If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant
to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging growth company ☐
If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities
Act. ☐
| † | The term “new or revised
financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards
Codification after April 5, 2012. |
The Registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until this registration statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section 8(a), may determine.
The information in
this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an
offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION,
DATED NOVEMBER 26, 2024
PROSPECTUS
Akso Health Group
$400,000,000
Class A Ordinary Shares
Class A Ordinary Shares
in the Form of American Depositary Shares,
Debt Securities, Warrants, Rights and Units
We may, from time to time,
in one or more offerings, offer and sell up to US$400,000,000 of any combination, together or separately, of our Class A ordinary shares,
par value US$0.0001 per share, ordinary shares in the form of American Depositary Shares, or ADSs, debt securities, warrants, or any
combination of the foregoing, either individually or as units comprised of one or more of the other securities. Each ADS represents three
ordinary shares. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that
offering. For general information about the distribution of the securities offered, please see “Plan of Distribution” in
this prospectus.
This prospectus provides a
general description of the securities we may offer. We will provide the specific terms of the securities offered in one or more supplements
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings.
The prospectus supplement and any related free writing prospectus may add, update or change information contained in this prospectus.
You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the
documents incorporated or deemed to be incorporated by reference, before you invest in any of our securities. This prospectus may not
be used to offer or sell any securities unless accompanied by the applicable prospectus supplement.
Pursuant to General Instruction
I.B.5. of Form F-3, in no event will we sell the securities covered hereby in a public primary offering with a value exceeding more than
one-third of the aggregate market value of our ordinary shares in any 12-month period so long as the aggregate market value of our outstanding
ordinary shares held by non-affiliates remains below US$75,000,000. During the 12 calendar months prior to and including the date of this
prospectus, we have not offered or sold any securities pursuant to General Instruction I.B.5 of Form F-3.
On January 26, 2021, we filed
with the SEC a registration statement on Form F-3 (File No. 333-252434) utilizing a shelf registration process, which registration statement
was declared effective on February 25, 2021 (the “2021 F-3”). Under this shelf registration process, we were initially entitled
to, from time to time, sell up to $50 million in the aggregate of ordinary shares, ordinary shares in the form of ADSs, and warrants.
As of the date of this prospectus, we have not sold any securities under the 2021 F-3.
The 2021 F-3 expires on February
25, 2024 and therefore, we are filing this registration statement as a new shelf registration statement, with unsold securities and fees
paid under the “expiring” registration statement rolled over herein.
Our ADSs are listed on
The NASDAQ Capital Market, or NASDAQ, under the symbol “AHG.” On November 20, 2024, the last reported sale price of the ADSs
on NASDAQ was US$0.88 per ADS.
Investing in the ADSs
involves risks. See “Risk Factors” beginning on page 26 of this prospectus and risk factors set forth in our most recent
Annual Report on Form 20-F and in other reports incorporated herein by reference. We may include specific risk factors in an applicable
prospectus supplement under the heading “Risk Factors.”
We may offer and sell the
securities from time to time at fixed prices, at market prices or at negotiated prices, to or through underwriters, to other purchasers,
through agents, or through a combination of these methods. If any underwriters are involved in the sale of any securities with respect
to which this prospectus is being delivered, the names of such underwriters and any applicable commissions or discounts will be set forth
in a prospectus supplement. The offering price of such securities and the net proceeds we expect to receive from such sale will also be
set forth in a prospectus supplement. See “Plan of Distribution” elsewhere in this prospectus for a more complete description
of the ways in which the securities may be sold.
Akso Health Group is a
holding company incorporated in the Cayman Islands in April 2016 and not a Chinese or Hong Kong operating company. As a holding company
with no material operations of our own, we conduct our business primarily through our U.S. subsidiaries, PRC subsidiaries in China and
within the last fiscal year, the former variable interest entities based in China. The contracts relating to the former variable interest
entities have not been tested in court. The former variable interest entity structure was used to provide investors with exposure to
foreign investment in China-based companies where Chinese law prohibits direct foreign investment in the operating companies. Our current
corporate structure involves unique risks to investors. Our securities are securities of Akso Health Group, the offshore holding company
in the Cayman Islands, instead of securities of our subsidiaries. Investors may never hold equity interests in our subsidiaries.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus
is November 26, 2024.
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of
a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a “shelf” registration
process. Under this shelf process, we may, from time to time, sell the securities described in this prospectus in one or more offerings,
up to a total offering amount of US$400,000,000. We have provided to you in this prospectus a general description of the securities we
may offer. Each time we sell securities under this shelf registration, we will, to the extent required by law, provide a prospectus supplement
that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to
be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing
prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any
documents that we have incorporated by reference into this prospectus. To the extent there is a conflict between the information contained
in this prospectus and the prospectus supplement or any related free writing prospectus, you should rely on the information in the prospectus
supplement or the related free writing prospectus; provided that if any statement in one of these documents is inconsistent with a statement
in another document having a later date – for example, a document filed after the date of this prospectus and incorporated by reference
into this prospectus or any prospectus supplement or any related free writing prospectus – the statement in the document having
the later date modifies or supersedes the earlier statement.
We have not authorized any
dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus and any accompanying prospectus supplement, or any related free writing prospectus that we may authorize to be provided
to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying
prospectus supplement, or any related free writing prospectus that we may authorize to be provided to you. This prospectus and the accompanying
prospectus supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the
registered securities to which they relate, nor do this prospectus and the accompanying prospectus supplement constitute an offer to sell
or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or
any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any
information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference
(as our business, financial condition, results of operations and prospects may have changed since that date), even though this prospectus,
any applicable prospectus supplement or any related free writing prospectus is delivered or securities are sold on a later date.
As permitted by SEC rules
and regulations, the registration statement of which this prospectus forms a part includes additional information not contained in this
prospectus. You may read the registration statement and the other reports we file with the SEC at its website or at its offices described
below under “Where You Can Find More Information.”
Unless the context otherwise
requires, all references in this prospectus to “AHG”, “Akso Health Group,” “we,” “us,”
“our,” “the Company” or similar words refer to Akso Health Group, together with our subsidiaries.
COMMONLY USED DEFINED TERMS
Unless otherwise indicated or the context
otherwise requires in this prospectus:
| ● | “ADSs”
are to our American depositary shares, each of which represents three Class A ordinary shares; |
| ● | “App”, “Xiaobai
Maimai” are to Xiaobai Maimai application; |
| ● | “big data” are to
voluminous structured and unstructured data from multiple sources and in multiple formats; |
| ● | “CAGR” are to compound
annual growth rate; |
| ● | “China” or the “PRC”
are to the People’s Republic of China, including Hong Kong Special Administrative Region and the Macau Special Administrative Region,
unless referening specific laws and regulatioins adopted by the PRC and other legal or tax matters only applicable to mainland China,
and excluding, for the purposes of this prospectus only, Taiwan; |
| ● | “CSRC” are to China
Securities Regulatory Commission; |
| ● | “GMV” or “Gross
Merchandise Value” are to the value of confirmed orders of products and services on our platform, regardless of how, or whether,
the buyer and seller settle the transaction; |
| ● | “Hexin Digital”
are to Hexin Digital Technology Co., Ltd.; |
| ● | “Hexin E-commerce”
are to Hexin E-Commerce Co. Ltd.; |
| ● | “Hexin Fengze” are
to Hexin Fengze Asset Management (Beijing) Co., Ltd.; |
| ● | “Hexin Jinke” are
to Hexin Jinke Group Co., Ltd.; |
| ● | “Hexin Jiuding”
are to Beijing Hexin Jiuding Technology Co., Ltd. |
| ● | “Wusu Company” are
to Wusu Hexin Yongheng Commercial and Trading Co., Ltd. (formerly known as Wusu Hexin Internet Small Loan Co., Ltd.); |
| ● | “Hexin Yongheng”
are to Beijing Hexin Yongheng Technology Development Co., Ltd.; |
| ● | “Kuaishangche” are
to Kuaishangche Automobile Leasing Co., Ltd.; |
| ● | “Akso Online MediTech”
are to Akso Online MediTech Co., LTD. |
| ● | “MAU” are to monthly
active users; |
| ● | “MIIT” are to the
Ministry of Industry and Information Technology; |
| ● | “Ordinary
shares” are to our Class A ordinary shares of par value US$0.0001 per share; |
| ● | “Our former variable interest
entities” or “former VIEs” are to Hexin Jiuding, Wusu Company and Hexin Digital; |
| ● | “PCAOB” are to the
Public Company Accounting Oversight Board; |
| ● | “Platforms” are
to the e-commerce platforms that Hexin Digital cooperates with; |
| ● | “RMB” and “Renminbi”
are to the legal currency of China; |
| ● | “SAMR” are to the
PRC State Administration for Market Regulation (formerly known as the SAIC); |
| ● | “US$,” “U.S.
dollars,” “$” and “dollars” are to the legal currency of the United States; |
| ● | “U.S. GAAP” are
to accounting principles generally accepted in the United States; |
| ● | “Akso Health,” “our
company”, or “the Company” are to Akso Health Group (formerly known as Xiaobai Maimai Inc.), an exempted company incorporated
in the Cayman Islands with limited liability. |
| ● | “we,” “us,”
“our company” and “our” refer to Akso Health Group and its consolidated subsidiaries. |
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and our SEC
filings that are incorporated by reference into this prospectus contain or incorporate by reference forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical
fact are “forward-looking statements,” including any projections of earnings, revenue or other financial items, any statements
of the plans, strategies and objectives of management for future operations, any statements concerning proposed new projects or other
developments, any statements regarding future economic conditions or performance, any statements of management’s beliefs, goals,
strategies, intentions and objectives, and any statements of assumptions underlying any of the foregoing. The words “believe,”
“anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “could,”
“should,” “potential,” “likely,” “projects,” “continue,” “will,”
and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements reflect our current views with respect to future events, are based
on assumptions and are subject to risks and uncertainties. We cannot guarantee that we actually will achieve the plans, intentions or
expectations expressed in our forward-looking statements and you should not place undue reliance on these statements. There are a number
of important factors that could cause our actual results to differ materially from those indicated or implied by forward-looking statements.
These important factors include those discussed under the heading “Risk Factors” contained or incorporated by reference in
this prospectus and in the applicable prospectus supplement and any free writing prospectus we may authorize for use in connection with
a specific offering. These factors and the other cautionary statements made in this prospectus should be read as being applicable to all
related forward-looking statements whenever they appear in this prospectus. Except as required by law, we undertake no obligation to update
publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Permissions
Required from the PRC Authorities for the Operations and Securities Offerings of
PRC Subsidiaries and Consolidated Affiliated Entities
Akso Health Group is a
holding company incorporated in the Cayman Islands in April 2016 and not a Chinese or Hong Kong operating company. As a holding company
with no material operations of our own, we conduct our business primarily through our U.S. subsidiaries, PRC subsidiaries in China and
within the last fiscal year, the former variable interest entities based in China. The contracts relating to the former variable interest
entities have not been tested in court. The former variable interest entity structure was used to provide investors with exposure to
foreign investment in China-based companies where Chinese law prohibits direct foreign investment in the operating companies. Our current
corporate structure involves unique risks to investors. Our securities are securities of Akso Health Group, the offshore holding company
in the Cayman Islands, instead of securities of our subsidiaries. Investors may never hold equity interests in our subsidiaries. Our
operations in China are governed by PRC laws and regulations. As of the date of this prospectus, all of our PRC subsidiaries have obtained
the requisite licenses and permits from the PRC government authorities for the business operations of our holding company, our subsidiaries,
including, business licenses, a Class II Medical Device Selling Record Certificate and a Class III Medical Device Operation License.
All of our PRC subsidiaries are required to obtain, and have obtained, their respective Business Licenses. However, given the uncertainties
of interpretation and implementation of relevant laws and regulations and the enforcement practice by government authorities, we cannot
assure you that we have obtained all the permits or licenses required by the PRC government authorities for conducting our business in
China. We may be required to obtain additional licenses, permits, filings or approvals for the functions to operate our business in the
future. The PRC government has significant oversight and discretion over the conduct of our operations
and may intervene or influence our operations as the government deems appropriate to further regulatory, political and social goals.
The PRC government has recently published new policies that significantly affected certain industries such as the internet industries
and private education industries, and we cannot rule out the possibility that it will in the future release regulations or policies or
take regulatory actions regarding our industry that could adversely affect our business, financial condition and results of operations.
See “Item 3. Key Information — D. Risk Factors — Risks Relating to Doing Business in the People’s Republic of
China — Any actions by the Chinese government, including any decision to intervene or influence the operations of the operating
entities or to exert control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may
cause us to make material changes to the operations of the PRC operating entities, may limit or completely hinder our ability to offer
or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless.”
of our annual report.
We
are subject to legal and operational risks associated with being based in and having the majority of our operations in China. These risks
may result in a material change in our operations, or a complete hindrance of our ability to offer or continue to offer our securities
to investors, and could cause the value of such securities to significantly decline or become worthless. Recently, the PRC government
initiated a series of regulatory actions and statements to regulate business operations in China with little advance notice, including
cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas using
variable interest entity structure, and adopting new measures to extend the scope of cybersecurity reviews. On July 6, 2021, the General
Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued an announcement to
crack down on illegal activities in the securities market and promote the high-quality development of the capital market, which, among
other things, requires the relevant governmental authorities to strengthen cross-border oversight of law-enforcement and judicial cooperation,
to enhance supervision over China-based companies listed overseas, and to establish and improve the system of extraterritorial application
of the PRC securities laws. On November 14, 2021, the Cyberspace Administration of China (the “CAC”) published the Security
Administration Draft, which provides that data processing operators engaging in data processing activities that affect or may affect
national security must be subject to network data security review by the relevant Cyberspace Administration of the PRC. According to
the Security Administration Draft, data processing operators who possess personal data of at least one million users or collect data
that affects or may affect national security must be subject to network data security review by the relevant Cyberspace Administration
of the PRC. The deadline for public comments on the Security Administration Draft was December 13, 2021. The Security Administration
Draft has not been fully implemented as of the date of this prospectus. On December 28, 2021, the CAC, together with 12 other governmental
departments of the PRC, jointly promulgated the Cybersecurity Review Measures, which became effective on February 15, 2022. The Cybersecurity
Review Measures require that an online platform operator which possesses the personal information of at least one million users must
apply for a cybersecurity review by the CAC if it intends to be listed in foreign countries. As confirmed by our PRC counsel, Hebei
Changjun Law Firm since we are not an online platform operator that possesses over one million users’ personal information,
we are not subject to the cybersecurity review with the CAC under the Cybersecurity Review Measures, and for the same reason, we will
not be subject to the network data security review by the CAC if the Draft Regulations on the Network Data Security Administration (Draft
for Comments) are enacted as proposed. There remains uncertainty, however, as to how the Cybersecurity Review Measures will be interpreted
or implemented and whether the PRC regulatory agencies, including the CAC, may adopt new laws, regulations, rules, or detailed implementation
and interpretation related to the Cybersecurity Review Measures. For further details, see “Item 3. Key Information — D. Risk
Factors — Risks Relating to Doing Business in the People’s Republic of China — We may become subject to a variety of
laws and regulations in the PRC regarding privacy, data security, cybersecurity, and data protection.” of our latest annual report.
In
addition, since 2021, the Chinese government has strengthened its anti-monopoly supervision, mainly in three aspects: (1) establishing
the National Anti-Monopoly Bureau; (2) revising and promulgating anti-monopoly laws and regulations, including: the Anti-Monopoly Law
(draft Amendment published on October 23, 2021 for public opinion; the newly revised Anti-Monopoly Law was promulgated on June 24, 2022,
and became effective on August 1, 2022), the anti-monopoly guidelines for various industries, and the detailed Rules for the Implementation
of the Fair Competition Review System; and (3) expanding the anti-monopoly law enforcement targeting Internet companies and large enterprises.
As of the date of this prospectus, the Chinese government’s recent statements and regulatory actions related to anti-monopoly concerns
have not impacted our ability to conduct business, accept foreign investments, or list on a U.S. or other foreign exchange, because neither
the Company nor its PRC operating entities engage in monopolistic behaviors that are subject to these statements or regulatory actions.
On
February 17, 2023, the China Securities Regulatory Commission (the “CSRC”) released the Trial Administrative Measures of
Overseas Securities Offering and Listing by Domestic Companies, or the Overseas Listing Trial Measures, and five supporting guidelines,
which came into effect on March 31, 2023. The Overseas Listing Trial Measures regulate both direct and indirect overseas offering and
listing by PRC domestic companies by adopting a filing-based regulatory regime. Pursuant to the Overseas Listing Trial Measures, domestic
companies that seek to offer or list securities overseas, whether directly or indirectly, should fulfill the filing procedures and report
relevant information to the CSRC within three working days after submitting listing applications and subsequent amendments. According
to the Notice on the Administrative Arrangements for the Filing of the Overseas Securities Offering and Listing by Domestic Companies
from the CSRC, or the CSRC Notice, the domestic companies that have already been listed overseas before the effective date of the Overseas
Listing Trial Measures (i.e. March 31, 2023) shall be deemed to be existing issuers (the “Existing Issuers”). Existing Issuers
are not required to complete the filing procedures immediately, and they shall be required to file with the CSRC for any subsequent offerings.
Further, according to the CSRC Notice, domestic companies that have obtained approval from overseas regulatory authorities or securities
exchanges (for example, the effectiveness of a registration statement for offering and listing in the U.S. has been obtained) for their
overseas offering and listing prior March 31, 2023 but have not yet completed their overseas issuance and listing, are granted a six-month
transition period from March 31, 2023 to September 30, 2023. Those that complete their overseas offering and listing within such six-month
period are deemed to be Existing Issuers and are not required to file with the CSRC for their overseas offerings and listings. Within
such six-month transition period, however, if such domestic companies fail to complete their overseas issuance and listing, they shall
complete the filing procedures with the CSRC. Our PRC counsel, Hebei Changjun Law Firm, has advised us that, since we obtained approval
from both the SEC and The Nasdaq Capital Market (“Nasdaq”) to issue and list our ordinary share on the Nasdaq prior to March
31, 2023, we are not required to make the filing with the CSRC pursuant to the Overseas Listing Trial Measures. We shall be required,
however, to file with the CSRC for any subsequent offerings. Given the current PRC regulatory environment, it is uncertain whether we
or our PRC subsidiaries will be required to obtain approvals from the PRC government to offer securities to foreign investors in the
future, and whether we would be able to obtain such approvals. If we are unable to obtain such approvals if required in the future, or
inadvertently conclude that such approvals are not required then the value of our ordinary shares may depreciate significantly or become
worthless. See “Item 3. Key Information — D. Risk Factors —Risks Relating to Doing Business in the People’s Republic
of China — The PRC government exerts substantial influence over the manner in which we and our PRC subsidiaries must
conduct our business activities. We are currently not required to obtain approval from Chinese authorities to list on U.S. exchanges,
however, if we or our PRC subsidiaries are required to obtain approval in the future and are denied permission from Chinese authorities
to list on U.S. exchanges, we will not be able to continue listing on U.S. exchanges, which would materially affect the interest
of the investors.” of our annual report.
Pursuant
to the Basic Law, which is a national law of the PRC and the constitutional document for Hong Kong, national laws of the PRC shall not
be applied in Hong Kong except for those listed in Annex III of the Basic Law and applied locally by promulgation or local legislation.
The Basic Law expressly provides that the national laws of the PRC which may be listed in Annex III of the Basic Law shall be confined
to those relating to defense and foreign affairs as well as other matters outside the autonomy of Hong Kong. The basic policies of the
PRC regarding Hong Kong as a special administrative region of the PRC are reflected in the Basic Law, providing Hong Kong with a high
degree of autonomy and executive, legislative and independent judicial powers, including that of final adjudication under the principle
of “one country, two systems”. However, in light of the PRC government’s recent expansion of authority in Hong Kong,
we may be subject to uncertainty about any future actions of the PRC government or authorities in Hong Kong, and it is possible that
all the legal and operational risks associated with being based in and having operations in the PRC may also apply to operations in Hong
Kong in the future. There is no assurance that there will not be any changes in the economic, political and legal environment in Hong
Kong. The PRC government may intervene or influence our current and future operations in Hong Kong at any time, or may exert more control
over overseas offerings and listing and/or foreign investment in issuers like ourselves. Such governmental actions, if and when occurred:
(i) could significantly limit or completely hinder our ability to continue our operations; (ii) could significantly limit or hinder our
ability to offer or continue to offer our ADSs to investors; and (iii) may cause the value of our ADSs to significantly decline or be
worthless.
Cash
dividends, if any, on our ordinary shares, will be paid in U.S. dollars. If we are considered a PRC tax resident enterprise for
tax purposes, any dividends we pay to our overseas shareholders may be regarded as China-sourced income and, as a result, may be subject
to PRC withholding tax at a rate of up to 10.0%. Pursuant to the Arrangement between Mainland China and the Hong Kong Special Administrative
Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the Double Tax Avoidance Arrangement, the 10% withholding tax
rate may be lowered to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC project. The 5% withholding tax rate,
however, does not automatically apply and certain requirements must be satisfied, including without limitation that (a) the Hong Kong
project must be the beneficial owner of the relevant dividends; and (b) the Hong Kong project must directly hold no less than
25% share ownership in the PRC project during the 12 consecutive months preceding its receipt of the dividends. In current practice,
a Hong Kong project must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding
tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot assure you
that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential
withholding tax rate of 5% under the Double Taxation Arrangement with respect to any dividends paid. As of the date of this prospectus,
we have not applied for the tax resident certificate from the relevant Hong Kong tax authority. Our Hong Kong subsidiaries
intend to apply for the tax resident certificate if and when our PRC subsidiaries plan to declare and pay dividends to our Hong Kong
subsidiaries.
According
to the Companies Ordinance of Hong Kong, a Hong Kong company may only make a distribution out of profits available for distribution or
other distributable reserves. Dividends cannot be paid out from share capital. In addition, there can be no assurance that in the future
the PRC government will not intervene or impose restrictions on our Hong Kong subsidiary’s ability to transfer or distribute
cash/assets to entities outside of Hong Kong, which could result in an inability or prohibition on making transfers or distributions
to Akso Health and adversely affect our business. As of the date of this prospectus, there are no restrictions or limitations
imposed by the Hong Kong government on the transfer of capital within, into and out of Hong Kong (including funds from Hong Kong to the
PRC), except for the transfer of funds involving money laundering and criminal activities. See “Item 3. Key Information —
D. Risk Factors — Risks Relating to Doing Business in the People’s Republic of China — To the extent cash or assets
of our business, or of our PRC or Hong Kong subsidiaries, is in PRC or Hong Kong, such cash or assets may not be available to fund operations
or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of restrictions and limitations by the PRC
government to the transfer of cash or assets.
OUR BUSINESS
History and Development of the Company
In April 2016, Hexindai Inc.
was incorporated in Cayman Islands as a holding company. We provided online microlending business and P2P marketplace business from 2017
to 2019. As part of our major business restructuring and disposition of our P2P marketplace business in and around December 2020, which
is described in greater detail below, we changed our name from Hexindai Inc. to Xiaobai Maimai Inc. to reflect our business that was built
upon our social e-commerce platform. On December 3, 2021, we changed our name from Xiaobai Maimai Inc. to Akso Health Group in recognition
of our focus on our new business development in the health sector. As of the date of this prospectus, we are no longer engaged in the
P2P marketplace businesses and are not making any new loans under the microlending business, and are solely focused on our social e-commerce
platform business, cancer therapy and radiotherapy oncology service provider business, and the sale of COVID-19 Rapid Antigen Tests.
In March 2014, our founders
Mr. Xiaobo An and Mr. Xiaoning An, along with Mr. Xiaobin Zhai, established Hexin E-Commerce Co. Ltd in China, or Hexin E-Commerce, which
at the time of its inception was not under our control and jointly owned by the individuals named above.
In order to obtain control
of Hexin E-Commerce, in November 2016, we entered into a series of contractual arrangements with Hexin E-Commerce and its then-shareholders
and became Hexin E-commerce’s primary beneficiary. Prior to our disposal of Hexin E-Commerce in December 2020, we conducted our
P2P marketplace businesses primarily through Hexin E-Commerce.
In May 2016, we established
a wholly-owned subsidiary in Hong Kong, Hexindai HK, and further established Beijing Hexin Yongheng Technology Development Co. Ltd., or
Hexin Yongheng, which to this date remains Hexindai HK’s wholly-owned subsidiary in China, in August 2016.
In August 2017, we established
Wusu Company to conduct online microlending business. At the time of Wusu Company’s inception, Hexin E-Commerce, Mr. Ming Jia and
Mr. Shiwei Wu were the shareholders of Wusu Company. On January 1, 2018, Hexin Yongheng, Wusu Company, Hexin E-Commerce, Mr. Ming Jia
and Mr. Shiwei Wu entered into a series of agreements (the “2018 Wusu VIE Agreements”), and as a result of which, Hexin Yongheng
became the primary beneficiary of and controlled Wusu Company.
On November 3, 2017, our ADSs
commenced trading on the NASDAQ Global Market under the symbol “HX.”
As part of our strategy to
expand our investment, in June 2018, we incorporated HX Asia Investment Limited (“HX Asia”), a wholly-owned subsidiary in
the British Virgin Islands, to acquire a 19.99% equity stake in Musketeer Group Inc, an Indonesian online lending platform that offers
consumption instalment loans. We completed the acquisition in August 9, 2018 as part of our strategy to explore overseas opportunities
by leveraging our extensive experience and expertise in new high-growth markets.
As part of our strategy to
diversify funding sources for our P2P marketplace and online microlending businesses (which we are no longer engaged in), in December
2018, Hexin E-Commerce established Trust 1 with an independent third-party trust company. At the time of establishing Trust 1, Hexin E-Commerce
was still an entity under our control. As part of our business restructuring in December 2020 and our disposal of Hexin E-commerce, we
are no longer a beneficiary to Trust 1.
In January 2019, we incorporated
HX China Investment Limited (“HX China”), also our wholly-owned subsidiary in the British Virgin Islands, for the purpose
of acquiring a 5.88% equity stake in Phoenix Intelligent Credit Group Ltd. As part of that acquisition, we established Tianjin Haohongyuan
in China in May 2018 to synergize the investment by way of providing loan assistance functions such as borrower assessment to Phoenix
Intelligent Credit Group Ltd. At the time of our acquisition, Phoenix Intelligent Credit Group Ltd was an operator of one of China’s
leading P2P lending platforms and a wholly-owned subsidiary of Phoenix Financial Group Ltd., which was unrelated to us.
On August 1, 2019, Hexin Digital,
which was established on September 9, 2017 with the provision of technology consultancy and technological services as its principal business,
was acquired by Hexin Jinke from an independent third party, and Hexin Digital had minimal activities before being acquired by us. We
obtained control and became the primary beneficiary of Hexin Digital in August 2019 by entering into a series of contractual arrangements
with Hexin Digital and Hexin Jinke. Hexin Digital is 100% owned by Hexin Jinke. Hexin Digital holds the requisite licenses necessary to
conduct our online marketplace business which is subject to restrictions under current PRC laws and regulations. We operate our newly
launched social e-commerce platform Xiaobai Maimai through Hexin Digital.
On September 30, 2019, we
changed Wusu Company’s principal businesses from microlending to trading, provision of technological promotion services, and import
and export.
On July 15, 2020, we incorporated
Hexin Investment Private Limited in Singapore with a view to engage in future investment activities.
As part of our corporate restructurings
prior to our disposal of Hexin E-Commerce in December 2020, Mr. Ming Jia and Mr. Shiwei Wu transferred their equity interests of Wusu
Company to Hexin E-Commerce, and therefore, Hexin E-Commerce became the sole shareholder of Wusu Company on November 20, 2020. On November
20, 2020, Hexin Yongheng, Wusu Company, Hexin E-Commerce, Mr. Ming Jia and Mr. Shiwei Wu entered into a VIE termination agreement, which
terminated all rights and obligations with respect to each party thereto under the 2018 Wusu VIE Agreements. On December 1, 2020, Wusu
Company and its shareholder, Hexin E-Commerce, entered into a new series of contractual arrangements with Hexin Yongheng, and as a result
of which, Hexin Yongheng remains the primary beneficiary of and controls Wusu Company.
On December 16, 2020, Hexin
Yongheng and Kuaishangche, a company not directly associated with the Company but controlled by Mr. Xiaobo An, and Hexin E-Commerce entered
into an assignment and assumption agreement. Pursuant to the Agreement, Hexin Yongheng agreed to assign and transfer to Kuaishangche the
control over Hexin E-Commerce, in exchange for cash consideration of RMB5.0 million (US$726,781).
On July 8, 2021, we incorporated
WE HEALTH LIMITED in New York.
On December 15, 2021, we established
We Healthy Limited in Hong Kong. WE HEALTH LIMITED owns 51% equity of We Healthy Limited.
On December 30, 2021, we incorporated
Akso Health Treatment Center Inc. in the State of Massachusetts, and on January 10, 2022 we changed the name from Akso Health Treatment
Center Inc. to Akso First Health Treatment Center Inc.
On January 3, 2022, we incorporated
Akso Remote Medical Consultation Center Inc. in Wyoming.
On January 26, 2022, we established
Qingdao Akso Health Management Co., Ltd, which is a wholly-owned subsidiary of We Healthy Limited (“Qingdao Akso”).
On January 4, 2022, we incorporated
Akso Online MediTech Co., Ltd. (“Akso Online MediTech”) in Wyoming.
Akso First Health Treatment
Center Inc., Akso Remote Medical Consultation Center Inc. and Akso Online MediTech Co., Ltd. are 100% owned by We Health Limited.
On November 15, 2023,
we established Akso Medical Cloud Limited in British Virgin Island, which is 100% owned by Akso Health Group.
On December 4, 2023, we
established Akso Medi-care Limited in Hong Kong, China, which is 100% owned by Akso Medical Cloud Limited.
On January 16, 2024, we
established Tianjin Akso Enterprise Management Co., Ltd. in Tianjin Province, China, which is owned by Akso Medi-care Limited.
On March 5, 2024, Tianjin
Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements with four shareholders
of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The transaction closed on
April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including health consultancy
services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin Deyihui Online Hospital
Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd.
On April 30, 2024, the
shareholders of the Company approved and adopted an second amendment and restatement to our memorandum and articles of association (the
“Amended M&A”), which changed the authorized issued share capital of the Company from US$500,000 divided into 5,000,000,000
ordinary shares, par value US$0.0001 each, to US$500,000 divided into 4,500,000,000 Class A ordinary shares, par value US$0.0001 each
and 500,000,000 Class B ordinary shares, par value US$0.0001 each (the “Re-Designation of the Authorized Capital”). Each
Class A ordinary share is entitled to one (1) vote and each Class B ordinary share is entitled to twenty (20) votes. In connection with
the Re-Designation of the Authorized Capital, 7,980,800 ordinary shares owned by Webao Limited then and 492,019,200 authorized but unissued
ordinary shares were converted into Class B ordinary shares on a one-for-one basis. 4,500,000,000 authorized ordinary shares (including
320,770,660 issued and outstanding ordinary shares held by all shareholders other than Webao Limited) were converted into Class A ordinary
shares on a one-for-one basis.
Business Restructuring and Disposition
Prior to our disposition of
Hexin E-Commerce, on November 20, 2020, Mr. Ming Jia and Mr. Shiwei Wu transferred their equity interest in Wusu Company to Hexin E-Commerce,
which resulted in Wusu Company becoming a wholly-owned entity of Hexin E-Commerce. On November 20, 2020, Hexin Yongheng, Wusu Company,
Hexin E-Commerce, Mr. Ming Jia and Mr. Shiwei Wu entered into a VIE termination agreement, which terminated all rights and obligations
with respect to each party thereto under the 2018 Wusu VIE Agreements.
On December 1, 2020, Hexin
Yongheng, our wholly-owned subsidiary, entered into a new series of contractual arrangements with Wusu Company and Hexin E-Commerce whereby
Hexin Yongcheng retained its interests as the primary beneficiary to Wusu Company.
On December 16, 2020, Hexin
Yongheng, Kuaishangche, Hexin E-Commerce, Xiaobo An, Xiaoning An, and Xiaobin Zhai entered into an assignment and assumption agreement.
Pursuant to this agreement, Hexin Yongheng has agreed to assign and transfer to Kuaishangche the control over Hexin E-Commerce, in exchange
for cash consideration of RMB 5 million. Upon the closing of the disposition, Kuaishangche became the primary beneficiary of and obtained
control of Hexin E-Commerce, and as a result, assume all assets and liabilities of Hexin E-Commerce and subsidiaries owned or controlled
by Hexin E-Commerce, excluding any rights, titles, interests or claims that Hexin E-Commerce had in Wusu Company, which remained a consolidated
variable interest entity of the Hexin Yongheng by way of the December 1, 2020 contractual arrangements. We closed the disposition of Hexin
E-Commerce on December 30, 2020. As a result of the disposition, we are no longer conducting the P2P marketplace business and instead
are focusing on developing and investing resources into our social e-commerce platform, Xiaobai Maimai.
On December 16, 2020, our
shareholders approved our name change from “Hexindai Inc.” to “Xiaobai Maimai Inc.” to reflect our business transition.
On January 1, 2021, Hexin
Yongheng, our wholly-owned subsidiary, obtained control and became the primary beneficiary of Hexin Jiuding by entering into a series
of contractual arrangements with Hexin Jiuding and Hexin Fengze, the shareholder of Hexin Jiuding and a wholly-owned subsidiary of Hexin
Jinke.
On December 3, 2021, our shareholders
approved our name change from “Xiaobai Maimai Inc.” to “Akso Health Group” to reflect our business transition.
On May 10, 2023, the Company,
HX Asia, HX China, and Hexindai HK (together with HX Asia and HX China, the “Targets”), and Umbrella Capital Investment Co.,
Ltd, a British Virgin Islands company which is not affiliate of the Company of any of its directors or officers (the “Purchaser”)
entered into certain share purchase agreement (the “Disposition SPA”). Pursuant to the Disposition SPA, the Purchaser agreed
to purchase the Targets in exchange for cash consideration of US$215,000 (the “Purchase Price”). The Disposition closed on
May 19, 2023. Upon the closing of the Disposition, the Buyer became the sole shareholder of the Targets and as a result, assume all assets
and liabilities of the Targets and subsidiaries owned or controlled by the Target.
On
March 5, 2024, Tianjin Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements
with four shareholders of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The
transaction closed on April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including
health consultancy services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin
Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd.
Business Overview
Historically,
the Company generated revenues primarily from our loan facilitation services, post-origination services, and other related services (the
“P2P Business”). On December 30, 2020, we completed the disposal of the P2P Business and transitioned into a
social e-commerce platform operator in China, offering high-quality and affordable branded products. Since the fourth quarter of 2021,
the Company started exploring healthcare equipment and product trading and related healthcare services business. On January 4, 2022,
we incorporated Akso Online Meditech in the State of Wyoming and have been engaged in the sale of COVID-19 Rapid Antigen test kits through
Akso Online Meditech. In February 2022, Akso Online Meditech entered into a supply agreement to purchase “iHealth” branded
COVID-19 Rapid Antigen test kits from its supplier and sells these test kits to distributers in the United States. On January 26, 2022,
we incorporated Qingdao Akso in Shandong Province, China and started the sales of medical devices through Qingdao Akso since April 2022.
Qingdao Akso has entered into supply agreements to purchase medical devices such as defibrillators, anesthesia laryngoscope from its
supplier and sells these devices to distributers or end-users in China. In May 2023, the Company completed the disposition of its social
e-commerce business. The Company has since then focused on exploring other area of healthcare sector other than the medical devices and
supplies.
Recently,
we begun exploring online hospital and chain pharmacies segments in China. We plan to acquire online hospital(s) in certain cities of
China which provides online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases,
providing patients with an efficient and convenient solution to manage their health online through their smartphones or computers. Typically,
the online hospitals are closely connected with and supported by traditional hospitals and outpatient clinics, and their main sources
of revenue are from fees charged to patients for both online and offline consultations and the marketing and sales of a variety of health
products including medicine, medical equipment and supplements.
In
addition to our plan to acquire online hospital(s), we believe that traditional independent pharmacies in China currently face serious
competition and bottlenecks in sales growth, which is why we also plan to acquire multiple independent pharmacies nationwide throughout
China, integrating and operating the pharmacies as a chain using our extensive offline resources and IT solutions. We plan to build a
new type of pharmacy operation and management system, as well as digital operation and sales solutions for our pharmacies, thereby enhancing
our competitiveness and overcoming the current difficulties in the industry.
On
March 5, 2024, Tianjin Akso Enterprise Management Co., Ltd., our PRC subsidiary, entered into certain securities purchase agreements
with four shareholders of Tianjin Wangyi Cloud Co., Ltd. and acquired 50% of the equity interests of Tianjin Wangyi Cloud Co., Ltd. The
transaction closed on April 15, 2024. Tianjin Wangyi Cloud Co., Ltd. engages in the business of providing online hospital services including
health consultancy services and online sales of medicines and health products through its two wholly owned PRC subsidiaries, Tian Jin
Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd.
The social e-commerce industry
We were formally known as
Hexindai Inc., and used to be engaged in the business of providing online facilitation related services via our consumer lending marketplace
in China, facilitating loans to meet the increasing consumption demand of the emerging middle class in China from 2017 to 2019. Hexindai
Inc. was a mobile e-commerce and consumer lending platform in China until it disposed of Hexin E-Commerce in December 2020 and changed
its name to Xiaobai Maimai Inc. As part of its transition into the social e-commerce platform business, in May 2020, we launched a new
form of social e-commerce mobile platform, Xiaobai Maimai App, offering high-quality and affordable branded products. Xiaobai Maimai leverages
its cooperation with major domestic e-commerce platforms and services marketplaces as part of its integrated buyer resources to select
and source the most desirable goods and services. Xiaobai Maimai rewards customers with a small commission for every purchase, share or
recommendation of a product made to friends.
In August 2020, Xiaobai Maimai
underwent an upgrade to offer an even wider variety of high-quality products covering food and beverage, wine, cosmetic products, fashion
and apparel, entertainment, houseware, home appliances and cost-saving promotions at petrol gas stations nationwide. On Xiaobai Maimai
App, customers can easily compare superior products at competitive prices without having to change their shopping preferences or switch
between different online merchants. It is also a convenient, one-stop platform for customers to not only save big on daily necessities
when they shop online, but also stay informed of the latest promotions with attractive discounts, coupons and rebates on the application.
As of June 30, 2022, Xiaobai Maimai had approximately 288,858 active customer accounts (an active customer account refers to a customer
account that has made at least one purchase) since its launch. In May 2023, the Company entered into a Disposition SPA to dispose the
social e-commerce business.
Healthcare equipment and products trading and radiation oncology
service business
Sales of medical devices
Through
our operating subsidiaries, Akso Online Meditech and Qingdao Akso, we are mainly specialized in the sales of medical devices both in China
and in the United States.
On
January 4, 2022, we incorporated Akso Online MediTech in the State of Wyoming and have begun the sale of COVID-19 Rapid Antigen test kits
through Akso Online Meditech since March, 2022. Akso Online Meditech has entered into a supply agreement to purchase “iHealth”
branded COVID-19 Rapid Antigen test kits from its supplier in Hong Kong and sells these test kits to distributors in the United States.
Since
April 2022, the Company has engaged in the sale of medical devices such as defibrillators and anesthesia laryngoscope through its subsidiary,
Qingdao Akso, in China. Qingdao Akso purchases these medical devices in bulk from its suppliers and distributes the products to downstream
distributors and end-users.
Pursuant
to the Regulation on the Supervision and Administration of Medical Devices (2021 Revision) promulgated on January 4, 2000 and came into
effect on June 1, 2014 (the “Supervision and Administration of Medical Devices”), which was latest amended on February 9,
2021 and came into effect on June 1, 2021, medical devices are classified into the following three categories based on the degree of risk.
| ● | “Class I medical devices”
means the medical devices with low risks, whose safety and effectiveness can be ensured through routine administration. As of September
30, 2022, we and our subsidiaries do not sell Class I medical devices. |
| ● | “Class II medical devices”
means the medical devices with moderate risks, which shall be strictly controlled and administered to ensure their safety and effectiveness.
For example, the anesthesia laryngoscope that Qingdao Akso currently may sell are Class II medical devices. |
| ● | “Class III medical devices”
means the medical devices with relatively high risks, which shall be strictly controlled and administered through special measures to
ensure their safety and effectiveness. For example, the defibrillators Qingdao Akso currently may sell are Class III medical devices. |
Pursuant
to the Administrative Measures on the Operation Supervision of Medical Devices, filing and licensing are not required for the operation
of Class I medical devices. Operators engaged in the operation of Class II medical devices are subject to filing administration and will
receive a Class II Medical Device Selling Record Certificate upon satisfaction of filing requirement and no pre-approval of authorities
is needed. Operators engaged in the operation of Class III medical devices are subject to pre-approval licensing administration and will
receive a Class III Medical Device Operation License upon the authorities’ approval. A Class II Medical Device Selling Record Certificate
will be effective in the long term until it is revoked or canceled by the issuing authorities. A Class III Medical Device Operation License
is valid for five years and may be renewed six months prior to its expiration date.
As
of the date of this registration statement, Qingdao Akso has received from the PRC authorities all requisite licenses, permissions or
approvals needed to engage in the resale of medical devices businesses currently conducted in China, and no permission or approval has
been denied. Such licenses and permissions include business licenses, a Class II Medical Device Selling Record Certificate and a Class
III Medical Device Operation License (as defined below). Pursuant to the Administrative Measures on the Operation Supervision of Medical
Devices, filing and licensing are not required for the operation of Class I medical devices. Operators engaged in the resale of Class
II medical devices are subject to filing administration and will receive a Class II medical device selling record certificate upon satisfaction
of filing requirement and no pre-approval of the authorities is needed (the “Class II Medical Device Selling Record Certificate”).
Operators engaged in the resale or distribution of Class III medical devices are subject to pre-approval licensing administration and
will a receive medical device operation license upon the authorities’ approval (the “Class III Medical Device Operation License”).
A Class III Medical Device Operation License is valid for five years and may be renewed six months prior to its expiration date. A Class
II Medical Device Selling Record Certificate will be effective in the long term until it is revoked or canceled by the issuing authorities.
Qingdao Akso obtained a Class II Medical Device Selling Record Certificate on Feburay 25, 2022 , and a Class III Medical Device Operation
License, and such license expired on March 2, 2022.
Revenue attributable to
the sales of medical equipment for the fiscal year ended March 31, 2024 was $2.4 million, representing 100% of the Company’s total
revenue.
Akso Health’s radiation oncology
services business
On
September 24, 2021, the Board of Directors approved our new business plan to enter the radiation oncology services market in the U.S.
On September 26, 2021, we signed a product purchase agreement with a third-party supplier to purchase equipment for the new cancer therapy
and radiation oncology business. The total price of the equipment was approximately US$12.7 million. We prepaid 80% of the purchase price
and planned to pay the balance after the equipment was received and installed. In February 2022, affected by the continuous influence
of COVID-19 and the global chip shortage, we terminated the purchase agreement and the prepayment for equipment purchase has been refunded.
In the future, the Company will develop its cancer therapy and radiation oncology market in the U.S. We plan to open 2 vaccine research
centers for AIDS and Covid-19 and 100 radiation oncology centers on the east coast of the U.S. catering to cancer patients at varying
stages of treatment. This will include specialized radiation therapy centers for radiotherapy (RT), personalized consultation, conventional
treatment planning, and other related services for a wide variety of cancer therapy treatments.
On
October 22, 2021, we announced the appointment of Dr. Yingxian Liu as the medical consultant to the Company. Dr. Liu has extensive experience,
and is highly respected in the pathology field. We believe Dr. Liu’s insights and guidance will support our mission in assembling
the necessary team and infrastructure to build a best-in-class practice that’s scalable and delivers safe and high-quality cancer
treatments for our patients. We intend to keep pursuing business opportunities in this sector under the guidance of Dr. Yingxian Liu.
The following diagram illustrates
our current corporate structure:
Corporate Information
Our principal executive offices
are located at Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, No. 44, Moscow Road, Qianwan Bonded Port Area, Qingdao Pilot Free Trade
Zone, China (Shandong). Our telephone number at this address is +86 152 1005 4919. Our registered office in the Cayman Islands is located
at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104. Our agent for service of process
in the United States is Puglisi & Associates, located at 850 Library Avenue, Suite 204, Newark, DE 19711. Our telephone number +86
152 1005 4919. We maintain a website http://www.ahgtop.com/en/index.html. that contains information about our Company, though no information
contained on our website is part of this prospectus.
Transfer of Cash through our Organization
The Company can transfer
cash to its subsidiaries through capital contributions and/or intercompany loans, and the Company’s subsidiaries can transfer cash
to the Company through dividends or other distributions and/or intercompany loans. Additionally, the Company’s subsidiaries can
transfer cash to the VIE through loans, service fees and the VIE can transfer cash to the Company as service fees under the VIE agreements
(the “VIE Agreements”) and/or through loans. We intend to settle amounts owed under the VIE Agreements. The aforesaid transactions
including capital injection and loans, would be eliminated upon consolidation.
Our cash primarily consists
of cash on hand and cash in banks in the PRC, Hong Kong and USA, which is unrestricted for withdrawal and use and is deposited with banks
in China. As of March 31, 2023 and March 31, 2022, we had approximately USD7.9 million and USD18.4 million of cash in bank, respectively,
and the loan due to related parties is USD9.7 million and USD37.2 million, respectively. Funds are transferred between our WFOE, Beijing
Hexin Yongheng Technology Development Co., Ltd, Tianjin Haohongyuan Technology Co., Ltd. and Qindao Akso Health Management Co., Limited
and the VIE for their daily operation purposes.
There is no assurance
that the PRC government will not intervene or impose restrictions on the ability of us, our subsidiaries and the VIE to transfer cash.
Most of our cash is in Renminbi, and the PRC government could prevent the cash maintained from leaving the PRC, could restrict deployment
of the cash into the business of the VIE and its subsidiaries and restrict the ability to pay dividends. For details regarding the restrictions
on our ability to transfer cash between us, our subsidiaries and the VIE, see “Item 3. Key Information—D. Risk Factors—Risks
Related to Doing Business in the People’s Republic of China” of our annual report.
We currently do not have
cash management policies that dictate how funds are transferred between us, our subsidiaries, and the VIE. For more detailed information,
see “Item 3. Key Information—D. Risk Factors—Risks Relating to Doing Business in the People’s Republic of China—
In light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly
for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity
and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business,
our listing on Nasdaq, financial condition, and results of operations,” and “Risk Factors—Risks Relating to Doing Business
in the People’s Republic of China—The Opinions, the Trial Measures, and the revised Provisions recently issued by the PRC
authorities may subject us to additional compliance requirements in the future.” of our annual report.
Contractual Arrangements and Corporate
Structure
Akso Health Group, formerly
known as Xiaobai Maimai Inc., is a limited company incorporated under the laws of the Cayman Islands and currently conducts substantially
all of our business operations in the PRC through our wholly foreign owned entities (“WFOEs”) incorporated in the PRC and
certain business operations through the PRC consolidated variable interest entity (“VIE”). Due to PRC legal restrictions
on foreign ownership and investment in the value-added telecommunications market, we rely on a series of contractual arrangements among
the VIE and its shareholders to operate our online and mobile platforms in China. These contractual arrangements entered into with the
VIE allow us to (i) exercise effective control over the VIE, (ii) receive substantially all of the economic benefits of the VIE, and
(iii) have an exclusive option to purchase all or part of the equity interests in the VIE when and to the extent permitted by PRC law.
These contractual arrangements include an exclusive business cooperation agreement, exclusive option agreement, equity interest pledge
agreement, and a power of attorney. As a result of these contractual arrangements, we exert effective control over, and are considered
the primary beneficiary of, the VIE and consolidate its operating results in our financial statements under U.S. GAAP. As used in this
prospectus, unless otherwise indicated, “we,” “us,” “our,” the “Company” and “Akso
Health” refer to Akso Health Group, a company organized in the Cayman Islands; “we,” “us,” “our,”
“our company,” the “Company” or similar terms refer to Cayman Islands and/or its consolidated subsidiaries, other
than the variable interest entity, Beijing Hexin Yongheng Technology Development Co., Ltd., a PRC company, and its subsidiaries, unless
the context otherwise indicates; and the “VIE” refers respectively to the variable interest entity and its subsidiaries,
Wusu Hexin Yongheng Trading Co., Ltd , Hexin Digital Technology Co., Ltd. and Beijing Hexin Jiuding Technology Co., Ltd.
As a result of such series
of contractual arrangements, the Company and its subsidiaries become the primary beneficiary of the VIE for accounting purposes and the
VIE is deemed as a PRC consolidated entity under U.S. GAAP. We consolidate the financial results of the VIE and its subsidiaries in our
consolidated financial statements in accordance with U.S. GAAP. Neither we nor the Company’s investors own any equity ownership
in, direct foreign investment in, or control through such ownership/investment of the VIE. These contractual arrangements have not been
tested in a court of law in the PRC. As a result, investors in the Company’s ADSs are not purchasing an equity interest in the
VIE or its subsidiaries but instead are purchasing an equity interest in the Company, the Cayman Islands holding company.
The diagram below shows
our corporate structure as of the date of March 31, 2023, including the WFOEs, the VIE and its subsidiaries. However, investors are cautioned
that the enforceability of such VIE Agreements has not been tested in a court of law. The Company conducts operations in China primarily
through WFOEs and its subsidiaries in China, including the VIE. As a result, the Company does not conduct any business on its own. The
VIE structure is used to provide investors with contractual exposure to foreign investment in China-based companies where Chinese law
prohibits or restricts direct foreign investment in the operating companies. Due to PRC legal restrictions on foreign ownership in internet-based
businesses, we do not have any equity ownership of the VIE, instead we receive the economic benefits of the VIE’s business operations
through certain contractual arrangements. As a result of such series of contractual arrangements, the Company and its subsidiaries become
the primary beneficiary of the VIE for accounting purposes and the VIE as a PRC consolidated entity under U.S. GAAP. We consolidate the
financial results of the VIE and its subsidiaries in our consolidated financial statements in accordance with U.S. GAAP. Neither we nor
the Company’s investors own any equity ownership in, direct foreign investment in, or control through such ownership/investment
of the VIE. Investors are purchasing an interest in the Company, the Cayman holding company.
The
former variable interest entities or former VIEs refer to Beijing Hexin Jiuding Technology Co., Ltd (“Hexin Jiuding”), Wusu
Hexin Yongheng Commercial and Trading Co., Ltd. (“Wusu Company”) and Hexin Digital Technology Co., Ltd. (“Hexin Digital”).
Contractual Arrangements
with Wusu Company, Hexin Digital and Hexin Jiuding
The
following is a summary of the currently effective (i) contractual arrangements by and among our wholly-owned subsidiary, Beijing
Hexin Yongheng Technology Development Co., Ltd. (“Hexin Yongheng”), the consolidated variable interest entity, Wusu Company,
and Hexin E-Commerce Co. Ltd. (“Hexin E-Commerce”), the shareholder of Wusu Company, (ii) contractual arrangements by
and among our wholly-owned subsidiary, Hexin Yongheng, the consolidated variable interest entity, Hexin Digital and Hexin Jinke Group
Co., Ltd. (“Hexin Jinke”), the shareholder of Hexin Digital, and (iii) contractual arrangements by and among our wholly-owned
subsidiary, Hexin Yongheng, our consolidated variable interest entity, Hexin Jiuding and Hexin Fengze Asset Management (Beijing) Co.,
Ltd. (“Hexin Fengze”), the shareholder of Hexin Jiuding.
Agreements that
Provide us Effective Control over Wusu Company
Internal
Reorganization of Wusu Company. Prior to the internal reorganization of Wusu Company, Hexin E-Commerce, Jia Ming and Wu Shiwei,
each held 94%, 5% and 1% of the equity interest of Wusu Company, respectively. On January 1, 2018, Hexin Yongheng, Wusu Company,
Hexin E-Commerce, Jia Ming and Wu Shiwei entered into a series of agreements (the “2018 Wusu VIE Agreements”), and as a result
of which, Hexin Yongheng became the primary beneficiary of and controlled Wusu Company. On November 20, 2020, for the purpose of
internal reorganization and conducted under the sole and continuous control of Hexin Yongheng and us, Jia Ming and Wu Shiwei transferred
5% and 1% of equity interest of Wusu Company registered under their names to Hexin E-Commerce, which in turn and became the legal title
owner of 100% of the equity interest of Wusu Company. On November 20, 2020, Hexin Yongheng, Wusu Company, Hexin E-Commerce, Jia
Ming, Wu Shiwei and Wang Huan, the spouse of Jia Ming, entered into a VIE termination agreement, which terminated all rights and obligations
with respect to each party thereto under the 2018 Wusu VIE Agreements. On December 1, 2020, Wusu Company, Hexin E-Commerce and Hexin
Yongheng entered into new contractual agreements, and as a result of which, Hexin Yongheng remains the primary beneficiary of and controls
Wusu Company.
Equity
Interest Pledge Agreements. Pursuant to the equity interest pledge agreements, Hexin E-Commerce, the shareholder of Wusu Company,
has pledged all of its equity interest in Wusu Company to guarantee the shareholder’s and Wusu Company’s performance of their
obligations under the exclusive business cooperation agreement, exclusive option agreement and power of attorney. If Wusu Company or
Hexin E-Commerce breaches their contractual obligations under these agreements, Hexin Yongheng, as pledgee, will be entitled to certain
rights regarding the pledged equity interests, including being paid in priority based on the monetary valuation that the equity interest
is converted into or receiving proceeds from the auction or sale of the pledged equity interests of Wusu Company in accordance with the
PRC law. Hexin E-Commerce agrees that, during the term of the equity interest pledge agreements, it will not transfer the pledged equity
interests or place or permit the existence of any security interest or encumbrance on the pledged equity interests without the prior
written consent of Hexin Yongheng. The equity interest pledge agreements remain effective until Wusu Company and Hexin E-Commerce discharge
all of their obligations under the contractual arrangements. We have registered the equity pledge with the relevant office of the Administration
for Industry and Commerce in accordance with the PRC Property Rights Law.
Powers
of Attorney. Pursuant to the powers of attorney, Hexin E-Commerce has irrevocably appointed Hexin Yongheng to act as such shareholder’s
exclusive attorney-in-fact to exercise all shareholder rights, including, but not limited to, voting on all matters of Wusu Company requiring
shareholder approval, disposing of all or part of Hexin E-Commerce’s equity interest in Wusu Company, and appointing directors
and executive officers. Hexin Yongheng is entitled to designate any person to act as such Hexin E-Commerce’s exclusive attorney-in-fact
without notifying or the approval of Hexin E-Commerce, and if required by PRC law, Hexin Yongheng shall designate a PRC citizen to exercise
such right. Each power of attorney will remain in force for so long as Hexin E-Commerce remains a shareholder of Wusu Company. Hexin
E-Commerce has waived all the rights which have been authorized to Hexin Yongheng and will not exercise such rights.
Agreement that
Allows us to Receive Economic Benefits from Wusu Company
Exclusive
Business Cooperation Agreement. Under the exclusive business cooperation agreement between Hexin Yongheng and Wusu Company,
Hexin Yongheng has the exclusive right to provide Wusu Company with technical support, consulting services and other services. Without
Hexin Yongheng’s prior written consent, Wusu Company agrees not to accept the same or any similar services provided by any third
party. Hexin Yongheng may designate other parties to provide services to Wusu Company. Wusu Company agrees to pay service fees on a monthly
basis and at an amount determined by Hexin Yongheng after taking into account multiple factors, such as the complexity and difficulty
of the services provided, the time consumed, the content and commercial value of services provided and the market price of comparable
services. Hexin Yongheng owns the intellectual property rights arising out of the performance of this agreement. In addition, Wusu Company
has granted Hexin Yongheng an irrevocable and exclusive option to purchase any or all of the assets and businesses of Wusu Company at
the lowest price permitted under PRC law. Unless otherwise agreed by the parties or terminated by Hexin Yongheng unilaterally, this agreement
will remain effective permanently.
Agreements
that Provide us with the Option to Purchase the Equity Interest in Wusu Company
Exclusive
Option Agreements of Wusu Company. Pursuant to the exclusive option agreements, Hexin E-Commerce has irrevocably granted Hexin Yongheng
an exclusive option to purchase, or have its designated person or persons to purchase, at its discretion, to the extent permitted under
PRC law, all or part of Hexin E-Commerce’s equity interests in Wusu Company. The purchase price is RMB10 (US$1.4) or the minimum
price required by PRC law. If Hexin Yongheng exercises the option to purchase part of the equity interest held by Hexin E-Commerce, the
purchase price shall be calculated proportionally. Wusu Company and Hexin E-Commerce have agreed to appoint any persons designated by
Hexin Yongheng to act as Wusu Company’s directors. Without Hexin Yongheng’s prior written consent, Wusu Company shall not
amend its articles of association, increase or decrease the registered capital, sell or otherwise dispose of its assets or beneficial
interest, create or allow any encumbrance on its assets or other beneficial interests, provide any loans to any third parties, enter
into any material contract with a value of more than RMB100,000 (US$14,123) (except those contracts entered into in the ordinary course
of business), merge with or acquire any other persons or make any investments, or distribute dividends to Hexin E-Commerce. Hexin E-Commerce
has agreed that, without Hexin Yongheng’s prior written consent, it will not dispose of its equity interests in Wusu Company or
create or allow any encumbrance on its equity interests. These agreements will remain effective until all equity interests of Wusu Company
held by Hexin E-Commerce have been transferred or assigned to Hexin Yongheng or its designated person(s).
Agreements
that Provide us Effective Control over Hexin Digital
Equity
Interest Pledge Agreement. Pursuant to the equity interest pledge agreement dated August 1, 2019, Hexin Jinke has pledged
all of its equity interest in Hexin Digital to guarantee Hexin Jinke’s and Hexin Digital’s performance of their obligations
under the exclusive business cooperation agreement, loan agreement, exclusive option agreement and power of attorney. If Hexin Digital
or Hexin Jinke breaches their applicable contractual obligations under these agreements, Hexin Yongheng, as pledgee, will be entitled
to certain rights regarding the pledged equity interests, including being paid in priority based on the monetary valuation that the equity
interest is converted into or receiving proceeds from the auction or sale of the pledged equity interests of Hexin Digital in accordance
with the PRC law. Hexin Jinke agrees that, during the term of the equity interest pledge agreements, it will not transfer the pledged
equity interests or place or permit the existence of any security interest or encumbrance on the pledged equity interests without the
prior written consent of Hexin Yongheng. The equity interest pledge agreements remain effective until Hexin Digital and Hexin Jinke discharge
all of their obligations under the contractual arrangements. We have registered the equity pledge with the relevant office of the Administration
for Industry and Commerce in accordance with the PRC Property Rights Law.
Powers
of Attorney. Pursuant to the power of attorney dated August 1, 2019, Hexin Jinke has irrevocably appointed Hexin Yongheng
to act as its exclusive attorney-in-fact to exercise all shareholder rights, including, but not limited to, voting on all matters of
Hexin Digital requiring shareholder approval, disposing of all or part of the shareholder’s equity interest in Hexin Digital, and
appointing directors and executive officers. Hexin Yongheng is entitled to designate any person to act as such shareholder’s exclusive
attorney-in-fact without notifying or the approval of such shareholder, and if required by PRC law, Hexin Yongheng shall designate a
PRC citizen to exercise such right. The power of attorney will remain in force for so long as Hexin Jinke remains a shareholder of Hexin
Digital. Hexin Jinke has waived all the rights which have been authorized to Hexin Yongheng and will not exercise such rights.
Agreement
that Allows us to Receive Economic Benefits from Hexin Digital
Exclusive
Business Cooperation Agreement. Under the exclusive business cooperation agreement dated August 1, 2019 between Hexin Yongheng
and Hexin Digital, Hexin Yongheng has the exclusive right to provide Hexin Digital with technical support, consulting services and other
services. Without Hexin Yongheng’s prior written consent, Heixn Digital agrees not to accept the same or any similar services provided
by any third party. Hexin Yongheng may designate other parties to provide services to Hexin Digital. Hexin Digital agrees to pay service
fees on a monthly basis and at an amount determined by Hexin Yongheng after taking into account multiple factors, such as the complexity
and difficulty of the services provided, the time consumed, the content and commercial value of services provided and the market price
of comparable services. Hexin Yongheng owns the intellectual property rights arising out of the performance of this agreement. In addition,
Hexin Digital has granted Hexin Yongheng an irrevocable and exclusive option to purchase any or all of the assets and businesses of Hexin
Digital at the lowest price permitted under PRC law. Unless otherwise agreed by the parties or terminated by Hexin Yongheng unilaterally,
this agreement will remain effective permanently.
Agreements
that Provide us with the Option to Purchase the Equity Interest in Hexin Digital
Exclusive
Option Agreements of Hexin Digital. Pursuant to the exclusive option agreement dated August 1, 2019, Hexin Jinke, shareholder
of Hexin Digital, has irrevocably granted Hexin Yongheng an exclusive right to purchase, or have its designated person or persons to
purchase, at its discretion, to the extent permitted under PRC law, all or part of the shareholder’s equity interests in Hexin
Digital. The purchase price is RMB10 (US$1.4) or the minimum price required by PRC law. If Hexin Yongheng exercises the option to purchase
part of the equity interest held by a shareholder, the purchase price shall be calculated proportionally. Hexin Digital and Hexin Jinke
have agreed to appoint any persons designated by Hexin Yongheng to act as Hexin Digital’s directors. Without Hexin Yongheng’s
prior written consent, Hexin Digital shall not amend its articles of association, increase or decrease the registered capital, sell or
otherwise dispose of its assets or beneficial interest, create or allow any encumbrance on its assets or other beneficial interests,
provide any loans to any third parties, enter into any material contract with a value of more than RMB100,000 (US$14,123) (except those
contracts entered into in the ordinary course of business), merge with or acquire any other persons or make any investments, or distribute
dividends to the shareholders. Hexin Jinke has agreed that, without Hexin Yongheng’s prior written consent, it will not dispose
of its equity interests in Hexin Digital or create or allow any encumbrance on its equity interests (except as permitted under the power
of attorney or the equity interest pledge agreement). These agreements will remain effective until all equity interests of Hexin Digital
held by its shareholder have been transferred or assigned to Hexin Yongheng or its designated person(s).
Loan
Agreement of Hexin Digital. Pursuant to the loan agreement between Hexin Yongheng and Hexin Jinke dated August 1, 2019, Hexin
Yongheng made loans in an aggregate amount of RMB100.0 million (US$14.1 million) to Hexin Jinke solely for the capitalization of Hexin
Digital. Pursuant to the loan agreement, the method of repayment shall be at the sole discretion of Hexin Yongheng. At the option of
Hexin Yongheng, Hexin Jinke shall repay the loans by the transfer of all its equity interest in Hexin Digital to Hexin Yongheng or its
designated person(s) pursuant to its respective exclusive option agreement. Hexin Jinke must pay all of the proceeds from sale of
such equity interests to Hexin Yongheng. In the event that Hexin Jinke sells its equity interests to Hexin Yongheng or its designated
person(s) with a price equivalent to or less than the amount of the principal, the loans will be interest free. If the price is
higher than the amount of the principal, the excess amount will be paid to Hexin Yongheng as the loan interest. The loan must be repaid
immediately under certain circumstances, including, among others, if a foreign investor is permitted to hold majority or 100% equity
interest in Hexin Digital and Hexin Yongheng elects to exercise its exclusive equity purchase option. The term of the loans is ten years
and can be extended upon mutual written consent of the parties.
Agreements
that Provide us Effective Control over Hexin Jiuding
Equity
Interest Pledge Agreement. Pursuant to the equity interest pledge agreement dated January 1, 2021, Hexin Fengze has pledged
all of its equity interest in Hexin Jiuding to guarantee Hexin Fengze’s and Hexin Jiuding’s performance of their obligations
under the exclusive business cooperation agreement, exclusive option agreement and power of attorney. If Hexin Fengze or Hexin Jiuding
breaches their applicable contractual obligations under these agreements, Hexin Yongheng, as pledgee, will be entitled to certain rights
regarding the pledged equity interests, including being paid in priority based on the monetary valuation that the equity interest is
converted into or receiving proceeds from the auction or sale of the pledged equity interests of Hexin Jiuding in accordance with the
PRC law. Hexin Fengze agrees that, during the term of the equity interest pledge agreements, it will not transfer the pledged equity
interests or place or permit the existence of any security interest or encumbrance on the pledged equity interests without the prior
written consent of Hexin Yongheng. The equity interest pledge agreements remain effective until Hexin Fengze and Hexin Jiuding discharge
all of their obligations under the contractual arrangements. We have registered the equity pledge with the relevant office of the Administration
for Industry and Commerce in accordance with the PRC Property Rights Law.
Powers
of Attorney. Pursuant to the power of attorney dated January 1, 2021, Hexin Fengze has irrevocably appointed Hexin Yongheng
to act as its exclusive attorney-in-fact to exercise all shareholder rights, including, but not limited to, voting on all matters of
Hexin Jiuding requiring shareholder approval, disposing of all or part of the shareholder’s equity interest in Hexin Jiuding, and
appointing directors and executive officers. Hexin Yongheng is entitled to designate any person to act as such shareholder’s exclusive
attorney-in-fact without notifying or the approval of such shareholder, and if required by PRC law, Hexin Yongheng shall designate a
PRC citizen to exercise such right. The power of attorney will remain in force for so long as Hexin Fengze remains a shareholder of Hexin
Jiuding. Hexin Fengze has waived all the rights which have been authorized to Hexin Yongheng and will not exercise such rights.
Agreement
that Allows us to Receive Economic Benefits from Hexin Jiuding
Exclusive
Business Cooperation Agreement. Under the exclusive business cooperation agreement dated January 1, 2021 between Hexin
Yongheng and Hexin Jiuding, Hexin Yongheng has the exclusive right to provide Hexin Jiuding with technical support, consulting services
and other services. Without Hexin Yongheng’s prior written consent, Heixn Jiuding agrees not to accept the same or any similar
services provided by any third party. Hexin Yongheng may designate other parties to provide services to Hexin Jiuding. Hexin Jiuding
agrees to pay service fees on a monthly basis and at an amount determined by Hexin Yongheng after taking into account multiple factors,
such as the complexity and difficulty of the services provided, the time consumed, the content and commercial value of services provided
and the market price of comparable services. Hexin Yongheng owns the intellectual property rights arising out of the performance of this
agreement. In addition, Hexin Jiuding has granted Hexin Yongheng an irrevocable and exclusive option to purchase any or all of the assets
and businesses of Hexin Jiuding at the lowest price permitted under PRC law. Unless otherwise agreed by the parties or terminated by
Hexin Yongheng unilaterally, this agreement will remain effective permanently.
Agreements
that Provide us with the Option to Purchase the Equity Interest in Hexin Jiuding
Exclusive
Option Agreements of Hexin Jiuding Pursuant to the exclusive option agreement dated January 1, 2021, Hexin Fengze, shareholder
of Hexin Jiuding, has irrevocably granted Hexin Yongheng an exclusive right to purchase, or have its designated person or persons to
purchase, at its discretion, to the extent permitted under PRC law, all or part of the shareholder’s equity interests in Hexin
Jiuding. The purchase price is RMB10 (US$1.4) or the minimum price required by PRC law. If Hexin Yongheng exercises the option to purchase
part of the equity interest held by Hexin Fengze, the purchase price shall be calculated proportionally. Hexin Jiuding and Hexin Fengze
have agreed to appoint any persons designated by Hexin Yongheng to act as Hexin Jiuding’s directors. Without Hexin Yongheng’s
prior written consent, Hexin Jiuding shall not amend its articles of association, increase or decrease the registered capital, sell or
otherwise dispose of its assets or beneficial interest, create or allow any encumbrance on its assets or other beneficial interests,
provide any loans to any third parties, enter into any material contract with a value of more than RMB100,000 (US$14,123) (except those
contracts entered into in the ordinary course of business), merge with or acquire any other persons or make any investments, or distribute
dividends to the shareholders. Hexin Fengze has agreed that, without Hexin Yongheng’s prior written consent, it will not dispose
of its equity interests in Hexin Jiuding or create or allow any encumbrance on its equity interests (except as permitted under the power
of attorney or the equity interest pledge agreement). These agreements will remain effective until all equity interests of Hexin Jiuding
held by its shareholder have been transferred or assigned to Hexin Yongheng or its designated person(s).
Dissolution of Former
VIE Structure
On
May 10, 2023, the Company, HX Asia Investment Limited, a British Virgin Islands company (“HX Asia”), HX China Investment
Limited, a British Virgin Islands company (“HX China”), and Hexindai Hong Kong Limited, a Hong Kong company (“Hexindai
HK”) (together with HX Asia and HX China, the “Targets”), and Umbrella Capital Investment Co., Ltd, a British Virgin
Islands company which is not affiliate of the Company of any of its directors or officers (the “Purchaser”) entered into
certain share purchase agreement (the “Disposition SPA”). Pursuant to the Disposition SPA, the Purchaser agreed to purchase
the Targets in exchange for cash consideration of US$215,000 (the “Purchase Price”). The disposition closed on May 19, 2023.
Upon the closing of the disposition, the Purchaser became the sole shareholder of the Targets and as a result, assume all assets and
liabilities of the Targets and subsidiaries owned or controlled by the Target. As Hexin Yongheng is a wholly-owned subsidiary of Hexindai
HK, the disposition of Hexindai HK results in the termination of the VIE agreements that Hexin Yongheng had entered into with the former
VIEs, leading to the dissolution of the former VIE structure. As a result of the disposition, the Company will cease to conduct its social
E-commerce business and focus on developing and investing resources into its medical devices business.
As
of May 2023, the Company disposed its social E-commerce business. The following diagram illustrates
our corporate structure, including our subsidiaries and consolidated affiliated entities as of the date of this prospectus. Our
current corporate structure does not contain any variable interest entity in mainland China and we do not have intention establishing
any VIEs in mainland China in the future.
VIE Financial Information
Set
forth below is selected consolidated statements of operations and cash flows for the fiscal years ended March 31, 2024, 2023, 2022 and
2021, and selected balance sheet information as of March 31, 2024, 2023 and 2022 showing financial information for the parent company
Akso Health Group, the WFOE (as defined below) and WFOE’s subsidiaries (as defined below), the VIE and VIE’s subsidiaries,
eliminating entries and consolidated information (in dollars). In the tables below, the column headings correspond to the following entities
in the organizational diagram on page 17. See also VIE and consolidated financial information in Note 3 of our financial statements.
For
the purposes of this section:
| ● | “Parent
company” refers to Akso Health Group; |
| ● | “WFOE”
refers to Beijing Hexin Yongheng Technology Development Co., Ltd., Tianjin Haohongyuan Technology
Co., Ltd. and Qindao Akso Health Management Co., Limited, Tianjin Akso Enterprise Management
Co., Ltd |
| ● | “VIE”
refers to Wusu Hexin Yongheng Trading Co., Ltd, Hexin Digital Technology Co., Ltd., Beijing
Hexin Jiuding Technology Co., Ltd. |
| ● | “Other
subsidiaries” refers to HX Asia Investment Limited, HX China Investment Limited, We
Health Limited, We Healthy Limited ,Akso Online MediTech Co., Ltd, Akso Medical Cloud Limited
and Akso Medi-care Limited |
Selected
Condensed Consolidation Schedule of Balance Sheet
| |
As of March 31, 2024 | |
| |
Parent Company | | |
Other Subsidiaries | | |
WOFE and WOFE’s
Subsidiary | | |
VIE and VIE’s Subsidiary | | |
Elimination
Entries and Reclassification Entries (1) | | |
Consolidated Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Cash and cash equivalents | |
| 2,279 | | |
| 74,791,108 | | |
| 10,530,935 | | |
| 880,073 | | |
| (1,030,378 | ) | |
| 85,174,017 | |
Intercompany receivables (1) | |
| 141,456,064 | | |
| - | | |
| - | | |
| 20,383,406 | | |
| (161,839,470 | ) | |
| - | |
Total current assets | |
| 141,458,343 | | |
| 75,194,606 | | |
| 73,158,083 | | |
| 25,636,634 | | |
| (173,429,549 | ) | |
| 142,018,117 | |
Total Assets | |
| 141,458,343 | | |
| 85,195,260 | | |
| 73,158,419 | | |
| 25,661,413 | | |
| (183,455,318 | ) | |
| 142,018,117 | |
Intercompany payables (1) | |
| - | | |
| 121,749,699 | | |
| 60,538,415 | | |
| - | | |
| (182,288,114 | ) | |
| - | |
Total Liabilities | |
| 3,090,959 | | |
| 122,266,987 | | |
| 67,354,488 | | |
| 17,647 | | |
| (189,136,158 | ) | |
| 3,593,923 | |
Total Shareholders’ Equity | |
| 138,367,384 | | |
| (37,128,537 | ) | |
| 5,803,931 | | |
| 25,643,766 | | |
| 5,680,840 | | |
| 138,367,384 | |
Non-controlling interests | |
| - | | |
| 56,810 | | |
| - | | |
| - | | |
| - | | |
| 56,810 | |
Total Liabilities and Equity | |
| 141,458,343 | | |
| 85,195,260 | | |
| 73,158,419 | | |
| 25,661,413 | | |
| (183,455,318 | ) | |
| 142,018,117 | |
| |
As of March 31, 2023 | |
| |
Parent Company | | |
Other Subsidiaries | | |
WOFE and WOFE’s
Subsidiary | | |
VIE and VIE’s Subsidiary | | |
Elimination Entries and
Reclassification Entries (1) | | |
Consolidated Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Cash and cash equivalents | |
| 4,472 | | |
| 43,321 | | |
| 8,466,219 | | |
| 678,691 | | |
| (1,268,235 | ) | |
| 7,924,468 | |
Intercompany receivables (1) | |
| 11,303,978 | | |
| - | | |
| - | | |
| 26,206,288 | | |
| (37,510,266 | ) | |
| - | |
Total current assets | |
| 11,314,245 | | |
| 7,658,371 | | |
| 12,030,076 | | |
| 26,938,820 | | |
| (37,481,213 | ) | |
| 20,460,299 | |
Total Assets | |
| 11,314,245 | | |
| 17,659,025 | | |
| 12,030,429 | | |
| 26,967,518 | | |
| (47,510,918 | ) | |
| 20,460,299 | |
Intercompany payables (1) | |
| - | | |
| 39,340,009 | | |
| 4,915,930 | | |
| - | | |
| (44,255,939 | ) | |
| - | |
Total Liabilities | |
| 2,588,941 | | |
| 47,468,686 | | |
| 5,798,567 | | |
| 19,806 | | |
| (44,255,217 | ) | |
| 11,620,783 | |
Total Shareholders’ Equity | |
| 8,725,304 | | |
| (29,923,873 | ) | |
| 6,231,862 | | |
| 26,947,712 | | |
| (3,255,701 | ) | |
| 8,725,304 | |
Non-controlling interests | |
| - | | |
| 114,212 | | |
| - | | |
| - | | |
| - | | |
| 114,212 | |
Total Liabilities and Equity | |
| 11,314,245 | | |
| 17,659,025 | | |
| 12,030,429 | | |
| 26,967,518 | | |
| (47,510,918 | ) | |
| 20,460,299 | |
| |
As of March 31, 2022 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and WOFE’s
Subsidiary | | |
VIE
and VIE’s
Subsidiary | | |
Elimination
Entries
and Reclassification
Entries
(1) | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Cash and cash equivalents | |
| 4,472 | | |
| 8,075,355 | | |
| 11,450,608 | | |
| 2,394,869 | | |
| (3,495,317 | ) | |
| 18,429,987 | |
Intercompany receivables (1) | |
| 14,333,994 | | |
| - | | |
| - | | |
| 27,139,795 | | |
| (41,473,789 | ) | |
| - | |
Total current assets | |
| 14,344,280 | | |
| 46,043,013 | | |
| 12,004,330 | | |
| 29,605,775 | | |
| (39,190,890 | ) | |
| 62,806,508 | |
Total Assets | |
| 14,344,280 | | |
| 46,043,013 | | |
| 12,005,875 | | |
| 29,659,663 | | |
| (39,246,323 | ) | |
| 62,806,508 | |
Intercompany payables (1) | |
| - | | |
| 42,054,570 | | |
| 4,074,729 | | |
| - | | |
| (46,129,299 | ) | |
| - | |
Total current liabilities | |
| 2,060,675 | | |
| 42,112,594 | | |
| 4,758,851 | | |
| 89,205 | | |
| 1,499,601 | | |
| 50,520,926 | |
Total Liabilities | |
| 2,060,675 | | |
| 42,112,594 | | |
| 4,758,851 | | |
| 89,205 | | |
| 1,499,601 | | |
| 50,520,926 | |
Total Shareholders’ Equity | |
| 12,283,605 | | |
| 3,928,443 | | |
| 7,247,024 | | |
| 29,570,458 | | |
| (40,745,924 | ) | |
| 12,283,606 | |
Non-controlling interests | |
| - | | |
| 1,976 | | |
| - | | |
| - | | |
| - | | |
| 1,976 | |
Total Liabilities and Equity | |
| 14,344,280 | | |
| 46,043,013 | | |
| 12,005,875 | | |
| 29,659,663 | | |
| (39,246,323 | ) | |
| 62,806,508 | |
| (1) | Elimination
of intercompany balances among parent company, other subsidiaries, WOFE and VIEs and their
subsidiaries that we consolidate and reclassification of retroactive adjustment for discontinued
operations. |
Selected Condensed Consolidated Statements
of Operations Data
| |
For the year ended March 31,
2024 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE
and VIE’s
Subsidiary | | |
Elimination
Entries and
Reclassification
Entries (2) | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Total revenue, net | |
| - | | |
| - | | |
| 2,414,338 | | |
| 694 | | |
| (694 | ) | |
| 2,414,338 | |
Total costs and expenses (benefits) | |
| 2,122,139 | | |
| 7,391,678 | | |
| 2,532,589 | | |
| (11,798 | ) | |
| (982,230 | ) | |
| 11,052,378 | |
Loss from subsidiaries and VIEs | |
| 7,394,438 | | |
| - | | |
| - | | |
| - | | |
| (7,394,438 | ) | |
| - | |
Total other income, net | |
| - | | |
| 128,983 | | |
| 18,809 | | |
| 5 | | |
| (601,548 | ) | |
| (453,751 | ) |
(Loss) income from continuing operations before income tax
expenses | |
| (9,116,779 | ) | |
| (7,262,066 | ) | |
| (99,443 | ) | |
| 12,497 | | |
| 7,374,000 | | |
| (9,091,791 | ) |
Less: income tax expense | |
| - | | |
| - | | |
| 24,988 | | |
| - | | |
| - | | |
| 24,988 | |
Net (loss) income from continuing operations | |
| (9,116,779 | ) | |
| (7,262,066 | ) | |
| (124,431 | ) | |
| 12,497 | | |
| 7,374,000 | | |
| (9,116,779 | ) |
Total gain (loss) from discontinued operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| (399,798 | ) | |
| (399,798 | ) |
Net (loss) income | |
| (9,116,779 | ) | |
| (7,262,066 | ) | |
| (124,431 | ) | |
| 12,497 | | |
| 6,974,202 | | |
| (9,516,577 | ) |
| |
For the year ended March 31,
2023 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE
and VIE’s
Subsidiary | | |
Elimination
Entries and
Reclassification
Entries (2) | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Total revenue, net | |
| - | | |
| 9,181,274 | | |
| 4,000,288 | | |
| 24,995 | | |
| (24,996 | ) | |
| 13,181,561 | |
Total costs and expenses | |
| 160,427 | | |
| 17,414,712 | | |
| 10,570,774 | | |
| 376,019 | | |
| (1,073,518 | ) | |
| 27,448,414 | |
Loss from subsidiaries and VIEs | |
| 1,086,999 | | |
| - | | |
| - | | |
| | | |
| (1,086,999 | ) | |
| - | |
Total other income, net | |
| - | | |
| 14,049,229 | | |
| 34,051 | | |
| 2,218 | | |
| (12,885,134 | ) | |
| 1,200,364 | |
(Loss) income from continuing operations before income tax
expenses | |
| (1,247,426 | ) | |
| 5,815,791 | | |
| (6,536,435 | ) | |
| (348,806 | ) | |
| (10,749,613 | ) | |
| (13,066,489 | ) |
Less: income tax expense | |
| - | | |
| 50 | | |
| 17,499 | | |
| - | | |
| - | | |
| 17,549 | |
Net (loss) income from continuing operations | |
| (1,247,426 | ) | |
| 5,815,741 | | |
| (6,553,934 | ) | |
| (348,806 | ) | |
| (10,749,613 | ) | |
| (13,084,038 | ) |
Total gain (loss) from discontinued operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| 11,836,612 | | |
| 11,836,612 | |
Net (loss) income | |
| (1,247,426 | ) | |
| 5,815,741 | | |
| (6,553,934 | ) | |
| (348,806 | ) | |
| 1,086,999 | | |
| (1,247,426 | ) |
| |
For the year ended March 31,
2022 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE
and VIE’s Subsidiary | | |
Elimination
Entries and
Reclassification
Entries(2) | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Total revenue, net | |
| - | | |
| 6,000,000 | | |
| - | | |
| 311,092 | | |
| (311,092 | ) | |
| 6,000,000 | |
Total costs and expenses | |
| 3,129,090 | | |
| 6,134,383 | | |
| 1,158,637 | | |
| 11,826,736 | | |
| (12,988,383 | ) | |
| 9,260,463 | |
Loss from subsidiaries and VIEs | |
| 13,720,643 | | |
| - | | |
| - | | |
| - | | |
| (13,720,643 | ) | |
| - | |
Total other income (loss), net | |
| - | | |
| (750,744 | ) | |
| (56,471 | ) | |
| 26,669 | | |
| 32,728 | | |
| (747,818 | ) |
Loss from continuing operations before income tax expenses | |
| (16,849,733 | ) | |
| (885,127 | ) | |
| (1,215,108 | ) | |
| (11,488,975 | ) | |
| 26,430,662 | | |
| (4,008,281 | ) |
Less: income tax (benefit) expense | |
| | | |
| 54,199 | | |
| 4 | | |
| 38,613 | | |
| | | |
| 92,816 | |
Net (loss) income from continuing operations | |
| (16,849,733 | ) | |
| (939,326 | ) | |
| (1,215,112 | ) | |
| (11,527,588 | ) | |
| 26,430,662 | | |
| (4,101,097 | ) |
Total gain (loss) from discontinued operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| (12,748,636 | ) | |
| (12,748,636 | ) |
Net (loss) | |
| (16,849,733 | ) | |
| (939,326 | ) | |
| (1,215,112 | ) | |
| (11,527,588 | ) | |
| 13,682,026 | | |
| (16,849,733 | ) |
| |
For the year ended March 31,
2021 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE
and VIE’s
Subsidiary | | |
Elimination
Entries
and
Reclassification Entries(2) | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Total revenue, net | |
| - | | |
| - | | |
| - | | |
| 2,300,653 | | |
| (2,300,653 | ) | |
| - | |
Total costs and expenses | |
| 4,293,327 | | |
| - | | |
| 1,143,272 | | |
| 35,304,848 | | |
| (36,500,198 | ) | |
| 4,241,249.00 | |
Loss from subsidiaries and VIEs | |
| 30,533,662 | | |
| - | | |
| - | | |
| - | | |
| (30,533,662 | ) | |
| - | |
Total other income (expense), net | |
| - | | |
| - | | |
| 533,510 | | |
| 398,836 | | |
| (984,424 | ) | |
| (52,078 | ) |
Loss from continuing operations before income tax expenses | |
| (34,826,989 | ) | |
| - | | |
| (609,762 | ) | |
| (32,605,359 | ) | |
| 63,748,783 | | |
| (4,293,327 | ) |
Less: income tax (benefit) expense | |
| - | | |
| | | |
| 1,929 | | |
| 481,413 | | |
| (483,342 | ) | |
| - | |
Net (loss) income from continuing operations | |
| (34,826,989 | ) | |
| - | | |
| (611,691 | ) | |
| (33,086,772 | ) | |
| 64,232,125 | | |
| (4,293,327 | ) |
Total (loss) from discontinued operations | |
| - | | |
| | | |
| - | | |
| - | | |
| (30,533,662 | ) | |
| (30,533,662 | ) |
Net (loss) | |
| (34,826,989 | ) | |
| - | | |
| (611,691 | ) | |
| (33,086,772 | ) | |
| 33,698,463 | | |
| (34,826,989 | ) |
(2) | Reclassification
of retroactive adjustment for discontinued operations |
Selected Condensed Consolidation Schedule
of Cash Flows
| |
For the year ended March 31,
2024 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE and
WOFE’s Subsidiary | | |
VIE
and
VIE’s Subsidiary | | |
Elimination
Entries and
Reclassification
Entries | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Net cash provided by (used in) operating activities | |
| (1,614,326 | ) | |
| 260,838 | | |
| 2,692,231 | | |
| 12,497 | | |
| - | | |
| 1,351,240 | |
Net cash provided by (used in) investing activities | |
| - | | |
| 1,528,918 | | |
| (56,250,000 | ) | |
| - | | |
| - | | |
| (54,721,082 | ) |
Net cash provided by (used in) financing activities | |
| 1,612,133 | | |
| 74,230,195 | | |
| 55,622,485 | | |
| 188,884 | | |
| - | | |
| 131,653,697 | |
Intercompany receive | |
| - | | |
| - | | |
| - | | |
| - | | |
| 138,042,067 | | |
| - | |
Intercompany payment | |
| - | | |
| - | | |
| - | | |
| - | | |
| (138,042,067 | ) | |
| - | |
| |
For the year ended March 31,
2023 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE
and
VIE’s Subsidiary | | |
Elimination
Entries and
Reclassification
Entries | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Net cash provided by (used in) operating activities | |
| 427,843 | | |
| (518,186 | ) | |
| (2,603,024 | ) | |
| (559,973 | ) | |
| - | | |
| (3,253,340 | ) |
Net cash provided by (used in) investing activities | |
| - | | |
| 20,000,000 | | |
| (1,528,918 | ) | |
| - | | |
| - | | |
| 18,471,082 | |
Net cash provided (used in) financing activities | |
| (427,857 | ) | |
| (27,513,848 | ) | |
| 1,584,805 | | |
| (1,156,948 | ) | |
| - | | |
| (27,513,848 | ) |
Intercompany receive | |
| - | | |
| - | | |
| - | | |
| - | | |
| 427,857 | | |
| - | |
Intercompany payment | |
| - | | |
| - | | |
| - | | |
| - | | |
| (427,857 | ) | |
| - | |
| |
For the year ended March 31,
2022 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE and
VIE’s Subsidiary | | |
Elimination
Entries and
Reclassification
Entries | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Net cash provided by (used in) operating activities | |
| (3,158,498 | ) | |
| (7,125,619 | ) | |
| (3,957,655 | ) | |
| 5,613,401 | | |
| - | | |
| (8,628,371 | ) |
Net cash provided by (used in) investing activities | |
| - | | |
| (20,000,000 | ) | |
| 1,491,687 | | |
| (1,455,547 | ) | |
| - | | |
| (19,963,860 | ) |
Net cash provided by (used in) financing activities | |
| 1,679,505 | | |
| 35,200,000 | | |
| 11,105,170 | | |
| (13,203,558 | ) | |
| - | | |
| 34,781,117 | |
Intercompany receive | |
| - | | |
| - | | |
| - | | |
| - | | |
| 337,695 | | |
| - | |
Intercompany payment | |
| - | | |
| - | | |
| - | | |
| - | | |
| (337,695 | ) | |
| - | |
| |
For the year ended March 31,
2021 | |
| |
Parent
Company | | |
Other
Subsidiaries | | |
WOFE
and
WOFE’s Subsidiary | | |
VIE
and
VIE’s Subsidiary | | |
Elimination
Entries and Reclassiication
Entries | | |
Consolidated
Total | |
| |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | | |
(US$) | |
Net cash (used in) provided by operating activities | |
| (6,547,518 | ) | |
| (10,184 | ) | |
| (4,785,527 | ) | |
| 21,401,699 | | |
| - | | |
| 10,058,470 | |
Net cash (used in) provided by investing activities | |
| - | | |
| | | |
| (408,081 | ) | |
| 407,419 | | |
| - | | |
| (662 | ) |
Net cash provided by (used in) financing activities | |
| 6,321,854 | | |
| 10,184 | | |
| (2,241,562 | ) | |
| (13,127,699 | ) | |
| - | | |
| (9,037,223 | ) |
Intercompany receive | |
| - | | |
| - | | |
| - | | |
| - | | |
| 11,327,745 | | |
| - | |
Intercompany payment | |
| - | | |
| - | | |
| - | | |
| - | | |
| (11,327,745 | ) | |
| - | |
The consolidated financial
statements of Akso Health Group, its subsidiaries and its consolidated former variable interest entities are included at the end of this
prospectus.
RISK FACTORS
Investing in our securities
involves a high degree of risk. You should carefully consider the risk factors set forth under “Risk Factors” described in
our most recent annual report on Form 20-F, as amended, filed on July 30, 2024, as supplemented and updated by subsequent reports on
Form 6-K that we have filed with the SEC, together with all other information contained or incorporated by reference in this prospectus
and any applicable prospectus supplement and in any related free writing prospectus in connection with a specific offering, before making
an investment decision. Each of the risk factors could materially and adversely affect our business, operating results, financial condition
and prospects, as well as the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose
all or part of your investment.
Summary of Risk Factors
Investing
in our ADSs involves significant risks. You should carefully consider all of the information in this prospectus before making an investment
in our ADSs. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed
more fully in the section titled “Item 3. Key Information — D. Risk Factors” in this prospectus.
RISKS RELATED
TO OUR BUSINESS AND INDUSTRY
| ● | We are no longer
engaged in the online microlending business, but we cannot assure you that we would not be
penalized under relevant regulations for the previous microlending business. (see “We
are no longer engaged in the online microlending business, but we cannot assure you that
we would not be penalized under relevant regulations for the previous microlending business”
on page 33 of this prospectus); |
| ● | Any harm to
our brand or reputation may materially and adversely affect our business and results of operations.
(see “Any harm to our brand or reputation may materially and adversely affect our business
and results of operations” on page 33 of this prospectus); |
| ● | If our social
e-commerce platform is unable to provide good customer experience, our business and reputation
may be materially and adversely affected. (see “If our social e-commerce platform is
unable to provide good customer experience, our business and reputation may be materially
and adversely affected” on page 33 of this prospectus); |
| ● | We may incur
liability or become subject to administrative penalties for counterfeit or unauthorized merchandise
displayed on our platform, or for merchandise displayed on our platform that infringe on
third-party intellectual property rights, or for other misconduct. (see “We may incur
liability or become subject to administrative penalties for counterfeit or unauthorized merchandise
displayed on our platform, or for merchandise displayed on our platform that infringe on
third-party intellectual property rights, or for other misconduct” on page 34 of this
prospectus); |
| ● | We plan to establish
and operate cancer therapy and radiation oncology centers that will be majority-owned by
us and are subject to significant risks. (see “We plan to establish and operate cancer
therapy and radiation oncology centers that will be majority-owned by us and are subject
to significant risks” on page 35 of this prospectus); |
| ● | We may encounter
difficulties in successfully introducing new services in a timely and cost-effective manner,
which could materially and adversely affect our business and operations. (see “We may
encounter difficulties in successfully introducing new services in a timely and cost-effective
manner, which could materially and adversely affect our business and operations” on
page 35 of this prospectus); |
| ● | Our development
of new cancer therapy and radiation oncology centers could result in fluctuations in our
short-term financial performance, and newly opened cancer therapy and radiation oncology
centers and clinics may not achieve timely profitability, or at all. (see “Our development
of new cancer therapy and radiation oncology centers could result in fluctuations in our
short-term financial performance, and newly opened cancer therapy and radiation oncology
centers and clinics may not achieve timely profitability, or at all” on page 35 of
this prospectus); |
| ● | Our growth plan
includes the construction of cancer therapy and radiation oncology centers. If we cannot
identify and seize growth opportunities in fast-changing markets, our future growth will
face uncertainties. (see “Our growth plan includes the construction of cancer therapy
and radiation oncology centers. If we cannot identify and seize growth opportunities in fast-changing
markets, our future growth will face uncertainties” on page 36 of this prospectus); |
| ● | We conduct our
business in a heavily regulated industry. (see “We conduct our business in a heavily
regulated industry” on page 36 of this prospectus); |
| ● | We are reliant
on our core senior management team. If one or more key executives were unable or unwilling
to continue in their present positions, our business and results of operations may be adversely
affected. (see “We are reliant on our core senior management team. If one or more key
executives were unable or unwilling to continue in their present positions, our business
and results of operations may be adversely affected” on page 36 of this prospectus); |
| ● | We compete for
skilled and quality employees, and failure to attract and retain them may adversely affect
our business and prevent us from achieving our intended level of growth. (see “We
compete for skilled and quality employees, and failure to attract and retain them may adversely
affect our business and prevent us from achieving our intended level of growth”
on page 37 of this prospectus); |
| ● | If labor costs
in the PRC increase substantially, our business and costs of operations may be adversely affected.
(see “If labor costs in the PRC increase substantially, our business and costs of operations
may be adversely affected” on page 37 of this prospectus); |
| ● | Our innovative
corporate culture is important to our business, if our culture changes our business and corporate
objectives may be adversely affected. (see “Our innovative corporate culture is important
to our business, if our culture changes our business and corporate objectives may be adversely
affected” on page 37 of this prospectus); |
| ● | We do not have
business insurance coverage. (see “We do not have business insurance coverage”
on page 37 of this prospectus); |
| ● | If we do not
find available sources of liquidity for capital and financing needs, our business and operations
may be materially and adversely affected. (see “If we do not find available sources
of liquidity for capital and financing needs, our business and operations may be materially
and adversely affected” on page 38 of this prospectus); |
| ● | Our business,
financial performance and results of operations could be adversely affected by deterioration
of the relation between China and the United States. (see “Our business, financial
performance and results of operations could be adversely affected by deterioration of the
relation between China and the United States” on page 39 of this prospectus); |
RISKS RELATED
TO OUR CORPORATE STRUCTURE
| ● | PRC regulation
of loans to and direct investment in PRC entities by offshore holding companies and governmental
control of currency conversion may delay or prevent us from using the proceeds of our initial
public offering and the concurrent private placement to make loans to or make additional
capital contributions to our PRC subsidiary, which could materially and adversely affect
our liquidity and our ability to fund and expand our business. (see “PRC regulation
of loans to and direct investment in PRC entities by offshore holding companies and governmental
control of currency conversion may delay or prevent us from using the proceeds of our initial
public offering and the concurrent private placement to make loans to or make additional
capital contributions to our PRC subsidiary, which could materially and adversely affect
our liquidity and our ability to fund and expand our business” on page 39 of this
prospectus); |
RISKS RELATED
TO DOING BUSINESS IN THE PEOPLE’S REPUBLIC OF CHINA
| ● | There are uncertainties
regarding the enforcement of laws and rules and regulations in China, which can change quickly
with little advance notice, and there is a risk that the Chinese government may intervene
or influence our operations at any time, exert more oversight and control over offerings
that are conducted overseas and/or foreign investment in China-based issuers, which could
materially and adversely affect our business and hinder our ability to offer or continue
our operations, and cause the value of our securities to significantly decline or become
worthless. |
| ● | Although the
audit report included in this prospectus is prepared by an auditor who are currently inspected
by the Public Company Accounting Oversight Board (the “PCAOB”), there is no guarantee
that future audit reports will be prepared by auditors inspected by the PCAOB and, as such,
in the future investors may be deprived of the benefits of such inspection. Furthermore,
trading in our securities may be prohibited under the Holding Foreign Companies Accountable
Act (the “HFCA Act”) if the SEC subsequently determines our audit work is performed
by auditors that the PCAOB is unable to inspect or investigate completely, and as a result,
U.S. national securities exchanges, such as Nasdaq, may determine to delist our securities.
Furthermore, on December 29, 2022, the Consolidated Appropriations Act, was signed into law
by President Biden. The Consolidated Appropriations Act contained, among other things, an
identical provision to AHFCAA, which reduce the number of consecutive non-inspection years
required for triggering the prohibitions under the HFCA Act from three years to two. (see
“Although the audit report included in this prospectus is prepared by an auditor who
are currently inspected by the Public Company Accounting Oversight Board (the “PCAOB”),
there is no guarantee that future audit reports will be prepared by auditors inspected by
the PCAOB and, as such, in the future investors may be deprived of the benefits of such inspection.
Furthermore, trading in our securities may be prohibited under the Holding Foreign Companies
Accountable Act (the “HFCA Act”) if the SEC subsequently determines our audit
work is performed by auditors that the PCAOB is unable to inspect or investigate completely,
and as a result, U.S. national securities exchanges, such as Nasdaq, may determine to delist
our securities. Furthermore, on December 29, 2022, the Consolidated Appropriations Act, was
signed into law by President Biden. The Consolidated Appropriations Act contained, among
other things, an identical provision to AHFCAA, which reduce the number of consecutive non-inspection
years required for triggering the prohibitions under the HFCA Act from three years to two”
on page 41 of this prospectus); |
| ● | The recent joint
statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the
U.S. Senate and the U.S. House of Representatives, all call for additional and more stringent
criteria to be applied to emerging market companies. These developments could add uncertainties
to our business operations, share price and reputation. (see “The recent joint statement
by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate
and the U.S. House of Representatives, all call for additional and more stringent criteria
to be applied to emerging market companies. These developments could add uncertainties to
our business operations, share price and reputation” on page 43 of this prospectus); |
| ● | There may be
changes in the regulations of PRC government bodies and agencies relating to VAT collection
procedure and ACTCS business. (see “There may be changes in the regulations of PRC
government bodies and agencies relating to VAT collection procedure and ACTCS business”
on page 44 of this prospectus); |
| ● | Failure to comply
with laws and regulations applicable to our business could subject us to fines and penalties
and could also cause us to lose customers or otherwise harm our business. (see “Failure
to comply with laws and regulations applicable to our business could subject us to fines
and penalties and could also cause us to lose customers or otherwise harm our business”
on page 45 of this prospectus); |
| ● | In light of
recent events indicating greater oversight by the Cyberspace Administration of China, or
CAC, over data security, particularly for companies seeking to list on a foreign exchange,
we are subject to a variety of laws and other obligations regarding cybersecurity and data
protection, and any failure to comply with applicable laws and obligations could have a material
and adverse effect on our business, our listing on NASDAQ, financial condition, and results
of operations. (see “In light of recent events indicating greater oversight by the
Cyberspace Administration of China, or CAC, over data security, particularly for companies
seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations
regarding cybersecurity and data protection, and any failure to comply with applicable laws
and obligations could have a material and adverse effect on our business, our listing on
NASDAQ, financial condition, and results of operations” on page 45 of this prospectus); |
| ● | The approval
of the China Securities Regulatory Commission, or the CSRC, may be required in connection
with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict
whether or how soon we will be able to obtain such approval. As a result, both you and us
fact uncertainty about future actions by the PRC government that could significantly affect
our business, our listing on Nasdaq, financial condition and results of operations. (see
“The approval of the China Securities Regulatory Commission, or the CSRC, may be required
in connection with an offering under PRC rules, regulations, or policies, and, if required,
we cannot predict whether or how soon we will be able to obtain such approval. As a result,
both you and us fact uncertainty about future actions by the PRC government that could significantly
affect our business, our listing on Nasdaq, financial condition and results of operations”
on page 47 of this prospectus); |
| ● | Changes in the
policies of the PRC government could have a significant impact upon our ability to operate
profitably in the PRC. (see “Changes in the policies of the PRC government could have
a significant impact upon our ability to operate profitably in the PRC” on page 49
of this prospectus); |
| ● | Because our
business is dependent upon government policies that encourage a market-based economy, change
in the political or economic climate in the PRC may impair our ability to operate profitably,
if at all. (see “Because our business is dependent upon government policies that encourage
a market-based economy, change in the political or economic climate in the PRC may impair
our ability to operate profitably, if at all” on page 49 of this prospectus); |
| ● | PRC laws and
regulations governing our current business operations are sometimes vague and uncertain and
any changes in such laws and regulations may impair our ability to operate profitable. (see
“PRC laws and regulations governing our current business operations are sometimes vague
and uncertain and any changes in such laws and regulations may impair our ability to operate
profitable” on page 49 of this prospectus); |
| ● | Changes in China’s
macroeconomic, socio-political conditions or government policies could have a material adverse
effect on our business and results of operations. (see “Changes in China’s macroeconomic,
socio-political conditions or government policies could have a material adverse effect on
our business and results of operations” on page 50 of this prospectus); |
| ● | Substantial
uncertainties exist with respect to the interpretation and implementation of the newly enacted
PRC Foreign Investment Law and how it may impact the viability of our current corporate structure,
corporate governance and business operations. (see “Substantial uncertainties exist
with respect to the interpretation and implementation of the newly enacted PRC Foreign Investment
Law and how it may impact the viability of our current corporate structure, corporate governance
and business operations” on page 51 of this prospectus); |
| ● | We may be adversely
affected by the complexity, uncertainties and changes in PRC regulation of Internet-related
businesses and companies, and any lack of requisite approvals, licenses or permits applicable
to our business may have a material adverse effect on our business and results of operations.
(see “We may be adversely affected by the complexity, uncertainties and changes in
PRC regulation of Internet-related businesses and companies, and any lack of requisite approvals,
licenses or permits applicable to our business may have a material adverse effect on our
business and results of operations” on page 51 of this prospectus); |
| ● | Fluctuations
in exchange rates could have a material adverse effect on our results of operations and the
value of your investment. (see “Fluctuations in exchange rates could have a material
adverse effect on our results of operations and the value of your investment” on page
51 of this prospectus); |
| ● | Governmental control
of currency conversion may limit our ability to utilize our net revenues effectively and
affect the value of your investment. (see “Governmental control of currency conversion
may limit our ability to utilize our net revenues effectively and affect the value of your
investment” on page 52 of this prospectus); |
| ● | Failure to make
adequate contributions to various employee benefit plans as required by PRC regulations may
subject us to penalties. (see “Failure to make adequate contributions to various
employee benefit plans as required by PRC regulations may subject us to penalties”
on page 52 of this prospectus); |
| ● | The M&A Rules and
certain other PRC regulations establish complex procedures for some acquisitions of Chinese
companies by foreign investors, which could make it more difficult for us to pursue growth
through acquisitions in China. (see “The M&A Rules and certain other
PRC regulations establish complex procedures for some acquisitions of Chinese companies by
foreign investors, which could make it more difficult for us to pursue growth through acquisitions
in China” on page 53 of this prospectus); |
| ● | PRC regulations
relating to offshore investment activities by PRC residents may limit our PRC subsidiary’s
ability to increase its registered capital or distribute profits to us or otherwise expose
us or our PRC resident beneficial owners to liability and penalties under PRC law. (see
“PRC regulations relating to offshore investment activities by PRC residents may limit
our PRC subsidiary’s ability to increase its registered capital or distribute profits
to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties
under PRC law” on page 53 of this prospectus); |
| ● | Any failure
to comply with PRC regulations regarding the registration requirements for employee stock incentive
plans may subject the PRC plan participants or us to fines and other legal or administrative
sanctions. (see “Any failure to comply with PRC regulations regarding the registration
requirements for employee stock incentive plans may subject the PRC plan participants
or us to fines and other legal or administrative sanctions” on page 54 of this prospectus); |
| ● | If we are classified
as a PRC resident enterprise for PRC income tax purposes, such classification could result
in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders. (see
“If we are classified as a PRC resident enterprise for PRC income tax purposes, such
classification could result in unfavorable tax consequences to us and our non-PRC shareholders
or ADS holders” on page 54 of this prospectus); |
| ● | We may not be
able to obtain certain benefits under relevant tax treaty on dividends paid by our PRC subsidiary to
us through our Hong Kong subsidiary. (see “We may not be able to obtain certain benefits
under relevant tax treaty on dividends paid by our PRC subsidiary to us through our
Hong Kong subsidiary” on page 54 of this prospectus); |
| ● | Enhanced scrutiny
over acquisition transactions by the PRC tax authorities may have a negative impact on potential
acquisitions we may pursue in the future. (see “Enhanced scrutiny over acquisition
transactions by the PRC tax authorities may have a negative impact on potential acquisitions
we may pursue in the future” on page 55 of this prospectus); |
| ● | Any actions
by the Chinese government, including any decision to intervene or influence the operations
of the operating entities or to exert control over any offering of securities conducted overseas
and/or foreign investment in China-based issuers, may cause us to make material changes to
the operations of the PRC operating entities, may limit or completely hinder our ability
to offer or continue to offer securities to investors, and may cause the value of such securities
to significantly decline or be worthless. (see “Any actions by the Chinese government,
including any decision to intervene or influence the operations of the operating entities
or to exert control over any offering of securities conducted overseas and/or foreign investment
in China-based issuers, may cause us to make material changes to the operations of the PRC
operating entities, may limit or completely hinder our ability to offer or continue to offer
securities to investors, and may cause the value of such securities to significantly decline
or be worthless” on page 56 of this prospectus); |
| ● | To the extent cash or assets of
our business, or of our PRC or Hong Kong subsidiaries, is in PRC or Hong Kong, such cash
or assets may not be available to fund operations or for other use outside of the PRC or
Hong Kong, due to interventions in or the imposition of restrictions and limitations by the
PRC government to the transfer of cash or assets. (see “To the extent cash or assets
of our business, or of our PRC or Hong Kong subsidiaries, is in PRC or Hong Kong, such cash
or assets may not be available to fund operations or for other use outside of the PRC or
Hong Kong, due to interventions in or the imposition of restrictions and limitations by the
PRC government to the transfer of cash or assets” on page 57 of this prospectus); |
RISKS RELATED
TO OUR ADSs
| ● | The trading price of our ADSs
may be volatile, which could result in substantial losses to investors. (see “The
trading price of our ADSs may be volatile, which could result in substantial losses to investors”
on page 58 of this prospectus); |
| ● | Techniques employed by short sellers
may drive down the market price of our ADSs. (see “Techniques employed by short sellers
may drive down the market price of our ADSs” on page 59 of this prospectus); |
| ● | If securities or industry
analysts do not publish research or publish inaccurate or unfavorable research about our
business, the market price for our ADSs and trading volume could decline. (see “If securities
or industry analysts do not publish research or publish inaccurate or unfavorable research
about our business, the market price for our ADSs and trading volume could decline”
on page 59 of this prospectus); |
| ● | We cannot assure you that
our existing dividend policy will not change in the future or the amount the dividends that
you may receive, and as such, you must rely on price appreciation of our ADSs for return
on your investment. (see “We cannot assure you that our existing dividend policy
will not change in the future or the amount the dividends that you may receive, and as such,
you must rely on price appreciation of our ADSs for return on your investment” on page
59 of this prospectus); |
| ● | Substantial future sales
or perceived potential sales of our ADSs in the public market could cause the price of our
ADSs to decline. (see “Substantial future sales or perceived potential sales of
our ADSs in the public market could cause the price of our ADSs to decline” on page
60 of this prospectus); |
| ● | We may be classified as a passive
foreign investment company for U.S. federal income tax purposes, which could result
in adverse U.S. federal income tax consequences to U.S. Holders of our ADSs or
ordinary shares. (see “We may be classified as a passive foreign investment company
for U.S. federal income tax purposes, which could result in adverse U.S. federal
income tax consequences to U.S. Holders of our ADSs or ordinary shares” on page
60 of this prospectus); |
| ● | The second amended and restated
memorandum and articles of association contain anti-takeover provisions that could have a
material adverse effect on the rights of holders of our ordinary shares and ADSs. (see
“The second amended and restated memorandum and articles of association contain anti-takeover
provisions that could have a material adverse effect on the rights of holders of our ordinary
shares and ADSs” on page 61 of this prospectus); |
| ● | You may face difficulties in protecting
your interests, and your ability to protect your rights through U.S. courts may
be limited, because we are incorporated under Cayman Islands law. (see “You may
face difficulties in protecting your interests, and your ability to protect your rights through
U.S. courts may be limited, because we are incorporated under Cayman Islands law”
on page 61 of this prospectus); |
| ● | Certain judgments obtained
against us by our shareholders may not be enforceable. (see “Certain judgments
obtained against us by our shareholders may not be enforceable” on page 62 of
this prospectus); |
| ● | We are a foreign private issuer
within the meaning of the rules under the Exchange Act, and as such we are exempt from
certain provisions applicable to United States domestic public companies. (see “We
are a foreign private issuer within the meaning of the rules under the Exchange Act,
and as such we are exempt from certain provisions applicable to United States domestic
public companies” on page 62 of this prospectus); |
| ● | The voting rights of holders of
ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise
any right to vote the ordinary shares which are represented by your ADSs. (see “The
voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you
may not be able to exercise any right to vote the ordinary shares which are represented by
your ADSs” on page 63 of this prospectus); |
| ● | The depositary for our ADSs will
give us a discretionary proxy to vote the ordinary shares represented by your ADSs if you
do not give proper or timely voting instructions to the depositary, except in limited circumstances,
which could adversely affect your interests. (see “The depositary for our ADSs
will give us a discretionary proxy to vote the ordinary shares represented by your ADSs if
you do not give proper or timely voting instructions to the depositary, except in limited
circumstances, which could adversely affect your interests” on page 63 of this
prospectus); |
| ● | You may not receive dividends
or other distributions on our ordinary shares and you may not receive any value for them
if it is illegal or impracticable to make them available to you. (see “You may
not receive dividends or other distributions on our ordinary shares and you may not receive
any value for them if it is illegal or impracticable to make them available to you”
on page 63 of this prospectus); |
| ● | You may experience dilution of
your holdings due to inability to participate in rights offerings. (see “You may experience
dilution of your holdings due to inability to participate in rights offerings” on page
64 of this prospectus); |
| ● | You may be subject to limitations
on transfer of your ADSs. (see “You may be subject to limitations on transfer of your
ADSs” on page 64 of this prospectus); |
| ● | We will incur significantly increased
costs and devote substantial management time as a result of being a public company. (see
“We will incur significantly increased costs and devote substantial management time
as a result of being a public company” on page 64 of this prospectus). |
RISKS RELATED
TO OUR BUSINESS AND INDUSTRY
We
are no longer engaged in the online microlending business, but we cannot assure you that we would not be penalized under relevant regulations
for the previous microlending business.
In
August 2017, we established Wusu Company, through which we started to conduct our online microlending business. We have engaged in online
microlending business since then and have been continuing to contribute resources to our microlending business up to September 30, 2019,
since when the principal business scope of Wusu Company has been changed to trading, provision of technological promotion services and
import and export. Since May 2019, we have ceased to issue new loans through microlending businesses. The microlending industry is rapidly
evolving with significant regulatory uncertainties, and our microlending business may be subject to a variety of laws and regulations
in the PRC with ambiguous and inconsistent application and interpretation. As a result, we cannot assure you that our investment and
exploration in microlending would not be subject to legal risks. Since the change of Wusu Company’s business scope, we cannot carry
out any new microlending business without the proper business registration. However, for the loans which were issued prior to the change
of the business scope, we are entitled to the credit right over such loans until their maturity. If, however, the authorities were to
determine that our historical microlending business was in violation of the relevant PRC laws and regulations, we may be subject to fines
and other administrative penalties imposed by the authorities and our business and reputation could be adversely affected.
Any
harm to our brand or reputation may materially and adversely affect our business and results of operations.
We
believe that the recognition and reputation of our brand, Xiaobai Maimai, among our members, users, third-party merchants and service
providers have contributed significantly to the growth and success of our business. Maintaining and enhancing the recognition and reputation
of our brand are critical to our business and competitiveness. Many factors, some of which are beyond our control, are important to maintaining
and enhancing our brand. These factors include our ability to:
|
● |
provide a superior shopping experience to our members
and users; |
|
● |
maintain the popularity, attractiveness, diversity, quality and
authenticity of product offerings on our platform; |
|
● |
maintain the efficiency, reliability and quality of the fulfillment
and delivery services to our buyers; |
|
● |
maintain or improve user satisfaction with our services; |
|
● |
increase brand awareness through marketing and brand promotion activities;
and |
|
● |
preserve our reputation and goodwill in the event of any negative
publicity on consumer experience or merchant service, Internet and data security, product quality, price or authenticity, or
other issues affecting us or other social e-commerce businesses in China. |
Public
perception that non-authentic, counterfeit or defective goods are displayed on our platform or that we or third-party service providers
do not provide satisfactory customer service, even if factually incorrect or based on isolated incidents, could damage our reputation,
diminish the value of our brand, undermine the trust and credibility we have established and have a negative impact on our ability to
attract new users or retain our current users. If we are unable to maintain our reputation, enhance our brand recognition or increase
positive awareness of our platform, products and services, it may be difficult to maintain and grow our member and user base, and our
business and growth prospects may be materially and adversely affected.
If
our social e-commerce platform is unable to provide good customer experience, our business and reputation may be materially and adversely
affected.
If
our social e-commerce platform does not provide good consumer experience, it could damage our reputation, diminish the value of our brand,
undermine the trust and credibility we have established, have a negative impact on our ability to attract new consumers or retain our
current consumers, and our business and growth prospects may be materially and adversely affected. Our ability to provide good customer
experience depends on a variety of factors. These factors include, among others, our ability to continue to offer authentic products
at competitive prices, to source products in response to evolving customer tastes and demands, to ensure the quality of our products
and services and to provide flexible payment options. For example, If we are unable to develop and maintain good relationships with
third-party merchants that would allow us to obtain a sufficient amount and variety of authentic and quality products on acceptable commercial
terms, we may be unable to meet customer demands for these products or to offer these products at attractive prices.
The
third-party merchants in our marketplace business rely on a number of contracted third-party delivery logistics service providers to
deliver the products to the customers. The products on our platform are supplied by the merchants, who are separately responsible for
sourcing and coordinating the delivery of the products with the third-party delivery logistics service providers. As we do not directly
control or manage the operations of these third-party logistics service providers, we may not be able to guarantee their performance.
Interruptions to or failures in the delivery services could prevent the timely or proper delivery of our products. These interruptions
or failures may be due to unforeseen events that are beyond our control or the control of our third-party logistics and delivery service
providers, such as inclement weather, health epidemics, natural disasters, transportation disruptions or labor unrest. Delivery of the
products could also be affected or interrupted by the merger, acquisition, insolvency or shut-down of the delivery companies the third-party
merchants engage to make deliveries, especially those local companies with relatively small business scales. If the products are not
delivered on a timely basis or are delivered in a damaged state, customers may refuse to accept the products purchased and have less
confidence in our platform, and our business and reputation could suffer. We cannot assure you that our third-party merchants will be
able to find alternative cost-effective logistics service providers to offer satisfactory delivery services in a timely manner, or at
all, which could cause our business and reputation to suffer or cause third-party merchants to move to other platforms and have a negative
impact on our financial conditions. In addition, if our third-party logistics service providers fail to comply with applicable rules
and regulations in China, our delivery services may be materially and adversely affected. Furthermore, the delivery personnel of contracted
third-party delivery service providers directly interact with our customers on our behalf. We need to effectively manage these third-party
logistics service providers to ensure the quality of customer services. Any failure to provide high-quality delivery services to our
customers may negatively impact the shopping experience of our customers, damage our reputation, and cause us to lose customers.
If
our customer service representatives, sales representatives or maintenance engineers and technicians fail to provide satisfactory service,
it may compromise our ability to provide effective customer service and enjoyable user engagement, which may in turn cause damage to
our reputation, loss of customers or direct economic loss. In addition, any negative publicity or poor feedback regarding our customer
service may diminish customer confidence in us and the value of our brand, and in turn cause us to lose customers and market share.
In
addition, we rely on our technology infrastructure to offer a good customer experience and to attract and retain customers on our platform.
Any failure to properly upgrade our technology infrastructure to serve the growing number of customers, maintain the satisfactory performance,
security and integrity of our social e-commerce platform and systems, may materially and adversely affect our business and reputation.
We
may incur liability or become subject to administrative penalties for counterfeit or unauthorized merchandise displayed on our platform,
or for merchandise displayed on our platform that infringe on third-party intellectual property rights, or for other misconduct.
Our
platform sources merchandise from third-party merchants. Although we have adopted measures to verify the authenticity and authorization
of merchandise displayed on our platform and to avoid potential infringement on third-party intellectual property rights in the course
of sourcing and selling merchandise, we may not always be successful in these efforts. In the event that any counterfeit, unauthorized
or infringing merchandise is displayed on our platform, we could face claims for which we may be held liable. We have not in the past
received claims alleging our infringement on third parties’ rights, and if we receive such claims in the future irrespective of
their validity, we could incur significant costs and efforts in either defending against or settling such claims. If there is a successful
claim against us, we might be required to pay substantial damages or refrain from further sale of the relevant merchandise. If we negligently
participate or assist in infringement activities associated with counterfeit goods, we may be subject to potential liability under PRC
law including injunctions to cease infringing activities, rectification, compensation, administrative penalties, and even criminal liability.
Moreover, such third-party claims or administrative penalties could result in negative publicity and our reputation could be severely
damaged. Any of these events could have a material and adverse effect on our business, results of operations or financial condition.
We
plan to establish and operate cancer therapy and radiation oncology centers that will be majority-owned by us and are subject to significant
risks.
As
part of our growth strategy, we plan to establish and operate cancer therapy and radiation oncology centers that will focus on providing
a variety of radiotherapy services as well as catering to cancer patients at varying stages of treatment. This will include specialized
radiation therapy centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other related services
for a wide variety of cancer therapy treatments.
Since
we have limited experience in operating our own centers and clinics, or in providing many of the services that we plan to offer in such
centers and clinics, we may not be able to provide as high a level of service quality for those treatment options as compared to the
other treatments that we offer at our network of centers, which may result in damage to our reputation and growth prospects.
In
addition, we may not be successful in recruiting qualified medical professionals to effectively provide the services that we intend to
offer in our own centers and clinics. When we establish our own centers and hospitals under our brand name, we may not be able to immediately
gain wide acceptance among patients and, thus, may be unable to attract a sufficient number of patients to our new centers and clinics.
We
may encounter difficulties in successfully introducing new services in a timely and cost-effective manner, which could materially and
adversely affect our business and operations.
Our
new cancer therapy and radiation oncology services may not be well received by our clients, and newly introduced services may not achieve
expected results. Furthermore, our services will require specialized knowledge of the industry and comprehensive understanding of the
market of medical equipment and consumables. We may misjudge the trend of the industry and the market, and may not be able to develop
the appropriate solutions for our clients. The efforts to introduce new services may require substantial investments of additional human
capital and financial resources. If we fail to improve our existing services or introduce new ones in a timely or cost-effective manner,
our ability to attract and retain clients may be impaired, and our results of operations and prospects may be adversely affected.
Our
development of new cancer therapy and radiation oncology centers could result in fluctuations in our short-term financial performance,
and newly opened cancer therapy and radiation oncology centers and clinics may not achieve timely profitability, or at all.
New
cancer therapy and radiation oncology centers generally have lower income and higher operating costs during the initial stages of their
operations. We will also incur substantial expenses before opening new cancer therapy and radiation oncology centers such as labor costs,
construction expenditures, renovation costs, rental expenses and equipment costs. Based on our research, it generally takes years for
new cancer therapy and radiation oncology centers to achieve monthly breakeven and much longer to recover the initial investment. Accordingly,
the timing of new cancer therapy and radiation oncology centers openings may have a significant impact on our future profitability. As
a result, our results of operations may fluctuate significantly from period to period, which renders the period-to-period comparisons
of our results of operations to be not meaningful in predicting our future performance.
Moreover,
we may not be successful in recruiting qualified medical professionals to effectively provide the services that we intend to offer in
our new cancer therapy and radiation oncology centers. It could also take significant lead time for newly opened cancer hospitals and
clinics to achieve a utilization rate that is profitable, due to factors such as time needed to build patient awareness in the local
community. In addition, the opening of new cancer therapy and radiation oncology centers involve regulatory approvals and reviews by
various authorities in the U.S., including health authorities. We may not be able to obtain all the required approvals, permits, licenses
or certificates in a timely manner or at all. Therefore, we may not be able to immediately utilize or derive revenue from new cancer
therapy and radiation oncology centers as anticipated. In addition, the operating results generated from newly opened cancer therapy
and radiation oncology centers may not be comparable to the operating results generated from any of our existing businesses. Newly opened
cancer therapy and radiation oncology centers may even operate at a loss, which could adversely affect our results of operations.
Our
growth plan includes the construction of cancer therapy and radiation oncology centers. If we cannot identify and seize growth opportunities
in fast-changing markets, our future growth will face uncertainties.
We
plan to build cancer therapy and radiation oncology centers on the east coast of the United States, the implementation process of which
will be complex, time-consuming and subject to uncertainty.
We
are identifying suitable regions for self-operated cancer therapy and radiation oncology centers by considering a number of factors,
including regional market size, existing competition and potential strategic partners. There are uncertainties regarding how successfully
we can identify the suitable market, acquire required government approvals in a timely manner and control planned investments. In addition,
we may face competition from our existing cancer therapy and radiation oncology centers.
We
conduct our business in a heavily regulated industry.
The
operation of our cancer therapy and radiation oncology centers is subject to laws and regulations issued by a number of government agencies
at the national and local levels. These rules and regulations relate mainly to the procurement of large medical equipment, the pricing
of medical services, the operation of radiotherapy and diagnostic imaging equipment, the licensing and operation of medical institutions,
the licensing of medical staff and the prohibition on non-profit medical institutions from entering into cooperation agreements with
third parties to set up for-profit centers that are not independent legal entities. In addition, our cancer therapy and radiation oncology
centers will be subject to periodic license or permit renewal requirements and inspections by various government authorities at the provincial
and municipal levels. We are also exposed to potential legal liabilities arising from claims relating to medical incidents, patient privacy,
anti-corruption and anti-bribery, and environmental protection. Our growth prospects may be constrained by such rules and regulations,
particularly those relating to the procurement of large medical equipment. Moreover, new laws and regulations applicable to our operations
may be introduced in the future, or the current applicable ones may otherwise be amended or replaced to impose additional supervision
and management requirements. Any changes in laws and regulations could require us to obtain additional licenses, permits or approvals,
broaden the scope of our potential liabilities, increase our operating costs and expenses, or even result in the invalidation of our
existing licenses.
If
we or our future partners fail to comply with such applicable laws and regulations, we could be required to make significant changes
to our business or suffer fines or penalties, including the potential loss of our business licenses, the suspension from use of our medical
equipment, and the suspension or cessation of operations at cancer therapy and radiation oncology centers in our network.
We
are reliant on our core senior management team. If one or more key executives were unable or unwilling to continue in their present positions,
our business and results of operations may be adversely affected.
Our
business, corporate strategies and future performance depends on our core senior management team comprising our directors, executive
officers and other key personnel. If we fail to attract and retain any of our key personnel, or if they are unable or unwilling to continue
in their present position due to any reason, we will have to go through a difficult process of replacement. The replacement process will
necessarily involve significant time and expenses and may adversely affect our business and results of operations and our business objectives
may not be achieved at the pace we expected, or at all.
We
compete for skilled and quality employees, and failure to attract and retain them may adversely affect our business and prevent us from
achieving our intended level of growth.
Competition
for our employees including systems engineers, financial officers and marketing professionals is intense. Our business and success relies
on the efforts and standard of work of our employees. If we are unable to attract, motivate and retain skilled and trained employees,
or if we are unable to continue to provide attractive compensation packages, our business and operations may be adversely affected and
our intended levels and rates of growth may be impended.
We
invest significant time and expense in the training and development of our employees. Failure to retain our existing employees will incur
further significant costs to find suitable replacements and a duplication of effort for their training, which may affect our operations
and our quality of service to customers and third-party merchants may be compromised, resulting in a material adverse effect on our business
and results of operations.
If
labor costs in the PRC increase substantially, our business and costs of operations may be adversely affected.
In
recent years, the Chinese economy has experienced inflationary and labor costs increases. Average wages are projected to continue to
increase. Further, under PRC law we are required to pay various statutory employee benefits, including pension, housing fund, medical
insurance, work-related injury insurance, unemployment insurance and maternity insurance to designated government agencies for the benefit
of our employees. The relevant government agencies may examine whether an employer has made adequate payments to the statutory employee
benefits, and those employers who fail to make adequate payments may be subject to late payment fees, fines and/or other penalties. We
expect that our labor costs, including wages and employee benefits, will continue to increase. If we are unable to control our labor
costs or pass such increased labor costs on to our users by increasing the fees of our services, our financial condition and results
of operations may be adversely affected.
Our
innovative corporate culture is important to our business, if our culture changes our business and corporate objectives may be adversely
affected.
Our
corporate culture fosters innovation, a collegiate environment of team effort and encourages creativity, which is important to our business
and development of our product pipeline and service upgrades. If we fail to maintain these valuable aspects of our culture during the
course of our adaptation into a public company and building the relevant infrastructure, our future success and strategic goals may be
affected. Furthermore, we may be unable to retain and attract talent, leading to a negative impact on our business and corporate objectives.
We
do not have business insurance coverage.
Insurance
companies in China currently do not offer as extensive an array of insurance products as insurance companies in more developed economies.
Currently, we do not have any business liability or disruption insurance to cover our operations. We have determined that the costs of
insuring for these risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical
for us to have such insurance. Any uninsured business disruptions may result in our incurring substantial costs and the diversion of
resources, which could have an adverse effect on our results of operations and financial condition.
If
we do not find available sources of liquidity for capital and financing needs, our business and operations may be materially and adversely
affected.
We
may experience unexpected changes in business conditions, creating additional capital and financing needs. We believe that our current
cash and cash equivalents, anticipated cash flows from operating activities, and the loans from third parties or our related parties
will be sufficient to meet our anticipated working capital requirements and capital expenditures in the ordinary course of business for
the next 12 months. However, we may need additional sources of liquidity if we find and wish to pursue opportunities for investment,
acquisition, capital expenditure or otherwise. If our available cash and cash equivalents on hand are insufficient to cover our expected
cash requirements, we may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity
would result in dilution to our shareholders. We cannot guarantee that financing will be available to us under terms acceptable to us,
or at all.
|
● |
The incurrence of indebtedness would result in increased fixed obligations
and could result in covenants restricting our operations. It could further lead to a number of risks that could adversely affect
our operations or financial conditions; |
|
● |
default and foreclosure on our assets if our operating revenue is
insufficient to repay debt obligations; |
|
● |
acceleration of obligations to repay the indebtedness (or other
outstanding indebtedness), even if we make all principal and interest payments when due, if we breach any covenants that require
the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
|
● |
our inability to obtain necessary additional financing if the debt
security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
|
● |
diverting a substantial portion of cash flow to pay principal and
interest on such debt, which would reduce the funds available for expenses, capital expenditures, acquisitions, and other general
corporate purposes; |
|
● |
creating potential limitations on our flexibility in planning for
and reacting to changes in our business and in the industry in which we operate; and |
|
● |
loss that might be incurred due to our overseas investment activities. |
If
our internal controls over financial reporting are insufficient or ineffective, we may not be able to accurately report our financial
results or prevent fraud.
We
are subject to reporting obligations under the U.S. securities laws. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we include
a management report on such company’s internal control over financial reporting in our annual report on Form 20-F. Our management
has concluded that our internal control over financial reporting was effective as of March 31, 2024. See “Item 15. Controls and
Procedures.”
During
the course of documenting and testing our internal control procedures, in order to satisfy the requirements of Section 404, we may
identify weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy
of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may
not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404.
If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial
statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial
information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading
price of our ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or
misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations
and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods.
Our
business, financial performance and results of operations could be adversely affected by deterioration of the relation between China
and the United States.
The
relation between China and the United States is constantly changing. There was a “trade war” between the two countries in
2019 and tensions exist in other areas such as political, social and health issues, particularly recent disagreements in relation to
the COVID-19 pandemic. In light of the recent tensions between China and the United States, there is a risk that our business, the offering
and our listing status may be adversely affected by trade restrictions, sanctions and other policies that may be implemented. As we operate
in China, any deterioration in political or trade relations might cause a public perception in the United States or elsewhere that might
cause our services to become less attractive. The United States lawmakers have introduced several bills intended to protect American
investments in Chinese companies. On June 4, 2020, the U.S. President Donald Trump issued PWG, criticizing China’s failure
to uphold international commitment to transparency and calling for recommendations to protect U.S. investors from China’s failure
to allow audits of U.S.-listed Chinese companies. PWG may impact U.S.-listed Chinese companies if strict compliance with audit requirements
and U.S. law or new listing rules or governance standards were imposed. Changes in political conditions and changes in the state
of China-U.S. relations are difficult to predict and could adversely affect our business, operating results and financial condition.
We cannot predict what effect any changes in China-U.S. relations may have on our ability to access capital or effectively operate our
business in China. Moreover, any political or trade controversies between the United States and China, whether or not directly related
to our business, could cause investors to be unwilling to hold or buy our ADSs and consequently cause the trading price of our ADSs to
decline.
RISKS RELATED
TO OUR CORPORATE STRUCTURE
PRC
regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion
may delay or prevent us from using the proceeds of our initial public offering and the concurrent private placement to make loans to
or make additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability
to fund and expand our business.
Under
PRC laws and regulations, we are permitted to utilize the proceeds from our initial public offering and the concurrent private placement
to fund our PRC subsidiary by making loans to or additional capital contributions to our PRC subsidiary, subject to applicable government
registration and approval requirements.
Any
loans to our PRC subsidiary, which are treated as foreign-invested enterprises under PRC laws, are subject to PRC regulations and foreign
exchange loan registrations. For example, loans by us to our PRC subsidiary to finance their activities cannot exceed statutory limits
and must be registered with the local counterpart of the State Administration of Foreign Exchange, or SAFE. According to the Interim
Measures on the Management of Foreign Debts promulgated by SAFE, the Ministry of Finance and the National Development and Reform Commission,
or the NDRC, on January 8, 2003, the statutory limit for the total amount of foreign debts of a foreign-invested company is
the difference between the amount of total investment as approved by the MOC or its local counterpart and the amount of registered capital
of such foreign-invested company, or two times of the net assets provided in the latest audited financial report of such PRC subsidiary,
as applicable. According to the Circular of the People’s Bank of China on Matters relating to the Comprehensive Macro-prudential
Management of Cross-border Financing issued by the People’s Bank of China in January 2017, or Circular 9, and Circular
of the People’s Bank of China and the State Administration of Foreign Exchange on Adjusting the Macro-prudential Regulation Parameter
for Full-covered Cross-border Financing in March 2020, or Circular 64, the maximum amounts of foreign debt that each company
may borrow is determined by reference to its so-called risk-weighted balance of cross-border financing, which may not exceed two times
its net assets as indicated in its latest audited financial report. The risk-weighted balance of cross-border financing of a company
is calculated based on its outstanding amounts of Renminbi and foreign currency cross-border debt, multiplied by risk conversion factors
corresponding to their respective remaining terms, loan categories and currency. However, for a one-year grace period starting from January 11, 2017,
a foreign-invested company such as our PRC subsidiaries may elect to determine the maximum amount of its foreign debt in according with
the rules in effect prior to Circular 9, or to comply with Circular 9. On the other hand, PRC domestic companies such
as our consolidated variable interest entities must comply with Circular 9. Moreover, according to Notice of the National Development
and Reform Commission on Promoting the Administrative Reform of the Recordation and Registration System for Enterprises’ Issuance
of Foreign Debts issued by the NDRC in September 2015, any loans we extend to our consolidated variable interest entities or other
PRC operating companies that are domestic PRC entities for more than one year must be filed with the NDRC or its local counterpart and
must also be registered with SAFE or its local branches.
We
may also decide to finance our PRC subsidiary by means of capital contributions. These capital contributions must be approved by the
MOC or its local counterpart. In addition, SAFE issued a circular in September 2008, SAFE Circular 142, regulating the conversion
by a foreign-invested enterprise of foreign currency registered capital into RMB by restricting how the converted RMB may be used. SAFE
Circular 142 provides that the RMB capital converted from foreign currency registered capital of a foreign-invested enterprise may
only be used for purposes within the business scope approved by the applicable government authority and unless otherwise provided by
law, may not be used for equity investments within the PRC. Although on July 4, 2014, the SAFE issued the Circular of the SAFE
on Relevant Issues Concerning the Pilot Reform in Certain Areas of the Administrative Method of the Conversion of Foreign Exchange Funds
by Foreign-invested Enterprises, or SAFE Circular 36, which launched a pilot reform of the administration of the settlement of the
foreign exchange capitals of foreign-invested enterprises in certain designated areas from August 4, 2014 and some of the restrictions
under SAFE Circular 142 will not apply to the settlement of the foreign exchange capitals of the foreign-invested enterprises established
within the designate areas and such enterprises mainly engaging in investment are allowed to use its RMB capital converted from foreign
exchange capitals to make equity investment, our PRC subsidiary is not established within the designated areas. On March 30, 2015,
SAFE promulgated Circular 19, to expand the reform nationwide. Circular 19 came into force and replaced both Circular 142
and Circular 36 on June 1, 2015. Circular 19 allows foreign-invested enterprises to make equity investments by using
RMB fund converted from foreign exchange capital. However, Circular 19 continues to prohibit foreign-invested enterprises from,
among other things, using RMB fund converted from its foreign exchange capitals for expenditure beyond its business scope, providing
entrusted loans or repaying loans between non-financial enterprises. On June 9, 2016, the SAFE promulgated Circular 16,
which expands the application scope from only the capital of the foreign-invested enterprises to the capital, the foreign debt funds
and the funds from oversea public offerings. Also, Circular 16 allows enterprises to use their foreign exchange capitals under their
capital account as stipulated by the relevant laws and regulations. On October 23, 2019, the SAFE issued the Notice of the
State Administration of Foreign Exchange on Further Facilitating Cross-border Trade and Investment, which, among other things, expanded
the use of foreign exchange capital to domestic equity investments. Non-investment foreign-funded enterprises are allowed to lawfully
make domestic equity investments by using capital funds, subject to the authenticity and compliance with the regulations of such domestic
investment projects (including, among others, the compliance of special administrative measures for access of foreign investments (negative
list)). If our consolidated variable interest entities need financial support from us or our wholly owned subsidiaries in the future
and we find it necessary to use foreign currency-denominated capital to provide such financial support, our ability to fund our consolidated
variable interest entities’ operations will be subject to statutory limits and restrictions, including those described above.
In
light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies,
we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals
on a timely basis, if at all, with respect to future loans to our PRC subsidiary or future capital contributions by us to our PRC subsidiary.
If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds we expect to receive from our initial
public offering and the concurrent private placement and to capitalize or otherwise fund our PRC operations may be negatively affected,
which could materially and adversely affect our liquidity and our ability to fund and expand our business.
RISKS RELATED TO DOING BUSINESS IN
THE PEOPLE’S REPUBLIC OF CHINA
There
are uncertainties regarding the enforcement of laws and rules and regulations in China, which can change quickly with little advance
notice, and there is a risk that the Chinese government may intervene or influence our operations at any time, exert more oversight and
control over offerings that are conducted overseas and/or foreign investment in China-based issuers, which could materially and adversely
affect our business and hinder our ability to offer or continue our operations, and cause the value of our securities to significantly
decline or become worthless.
Although
the audit report included in this prospectus is prepared by an auditor who are currently inspected by the Public Company Accounting Oversight
Board (the “PCAOB”), there is no guarantee that future audit reports will be prepared by auditors inspected by the PCAOB
and, as such, in the future investors may be deprived of the benefits of such inspection. Furthermore, trading in our securities may
be prohibited under the Holding Foreign Companies Accountable Act (the “HFCA Act”) if the SEC subsequently determines our
audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely, and as a result, U.S. national securities
exchanges, such as Nasdaq, may determine to delist our securities. Furthermore, on December 29, 2022, the Consolidated Appropriations
Act, was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision
to AHFCAA, which reduce the number of consecutive non-inspection years required for triggering the prohibitions under the HFCA Act from
three years to two.
There
are substantial uncertainties regarding the interpretation and application of PRC laws and regulations including, but not limited to,
the laws and regulations related to our business and the enforcement and performance of our arrangements with customers in certain circumstances.
The laws and regulations are sometimes vague and may be subject to future changes, and their official interpretation and enforcement
may involve substantial uncertainty. The effectiveness and interpretation of newly enacted laws or regulations, including amendments
to existing laws and regulations, may be delayed, and our business may be affected if we rely on laws and regulations which are subsequently
adopted or interpreted in a manner different from our understanding of these laws and regulations. New laws and regulations that affect
existing and proposed future businesses may also be applied retroactively. We cannot predict what effect the interpretation of existing
or new PRC laws or regulations may have on our business. The uncertainties regarding the enforcement of laws and the fact that rules
and regulations in mainland China can change quickly with little advance notice could result in a material change in our operations,
financial performance and/or cause the value of our securities to significantly decline or become worthless and/or impair our ability
to raise money.
The
Chinese government may exercise significant oversight and discretion over the conduct of business in the PRC and may intervene in or
influence our operations at any time, which could result in a material change in our operations and/or the value of our securities. We
are also currently not required to obtain approval from Chinese authorities to list on U.S. exchanges, however, if we are required to
obtain approval in the future and are denied permission from Chinese authorities to list on U.S. exchanges, we will not be able to continue
listing on U.S. exchange, which would materially affect the interest of the investors. The PRC government may intervene or influence
our business operations at any time or may exert more control over offerings conducted overseas and foreign investment in China-based
issuers, which could result in a material change in our business operations or the value of our securities. Additionally, the governmental
and regulatory interference could significantly limit or completely hinder our ability to offer or continue to offer securities to investors
and cause the value of such securities to significantly decline or be worthless.
As
an auditor of companies that are registered with the SEC and publicly traded in the United States and a firm registered with the PCAOB,
our auditor is required under the laws of the United States to undergo regular inspections by the PCAOB to assess their compliance with
the laws of the United States and professional standards.
Although
we operate part of our business in mainland China, a jurisdiction where the PCAOB is currently unable to conduct inspections without
the approval of the Chinese government authorities, our auditor, OneStop Assurance PAC, the independent registered public accounting
firm that issues the audit report included elsewhere in this prospectus, is subject to laws in the United States pursuant to which the
PCAOB conducts regular inspections to assess our auditor’s compliance with the applicable professional standards. Inspections of
other auditors conducted by the PCAOB outside mainland China have at times identified deficiencies in those auditors’ audit procedures
and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The lack of
PCAOB inspections of audit work undertaken in mainland China prevents the PCAOB from regularly evaluating auditors’ audits and
their quality control procedures. As a result, if there is any component of our auditor’s work papers become located in mainland
China in the future, such work papers will not be subject to inspection by the PCAOB. As a result, investors would be deprived of such
PCAOB inspections, which could result in limitations or restrictions to our access of the U.S. capital markets.
As
part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law,
in particular mainland China’s, in June 2019, a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress
which, if passed, would require the SEC to maintain a list of issuers for which PCAOB is not able to inspect or investigate the audit
work performed by a foreign public accounting firm completely. The proposed Ensuring Quality Information and Transparency for Abroad-Based
Listings on our Exchanges (“EQUITABLE”) Act prescribes increased disclosure requirements for these issuers and, beginning
in 2025, the delisting from U.S. national securities exchanges such as Nasdaq of issuers included on the SEC’s list for three consecutive
years. It is unclear if this proposed legislation will be enacted. Furthermore, there have been recent deliberations within the U.S.
government regarding potentially limiting or restricting China-based companies from accessing U.S. capital markets. On May 20, 2020,
the U.S. Senate passed the Holding Foreign Companies Accountable Act (the “HFCA Act”), which includes requirements for the
SEC to identify issuers whose audit work is performed by auditors that the PCAOB is unable to inspect or investigate completely because
of a restriction imposed by a non-U.S. authority in the auditor’s local jurisdiction. The U.S. House of Representatives passed
the HFCA Act on December 2, 2020, and the HFCA Act was signed into law on December 18, 2020. Additionally, in July 2020, the U.S. President’s
Working Group on Financial Markets issued recommendations for actions that can be taken by the executive branch, the SEC, the PCAOB or
other federal agencies and department with respect to Chinese companies listed on U.S. stock exchanges and their audit firms, in an effort
to protect investors in the United States. In response, on November 23, 2020, the SEC issued guidance highlighting certain risks (and
their implications to U.S. investors) associated with investments in China-based issuers and summarizing enhanced disclosures the SEC
recommends China-based issuers make regarding such risks. On March 24, 2021, the SEC adopted interim final rules relating to the implementation
of certain disclosure and documentation requirements of the HFCA Act. We will be required to comply with these rules if the SEC identifies
us as having a “non-inspection” year (as defined in the interim final rules) under a process to be subsequently established
by the SEC. The SEC is assessing how to implement other requirements of the HFCA Act, including the listing and trading prohibition requirements
described above. Under the HFCA Act, our securities may be prohibited from trading on Nasdaq or other U.S. stock exchanges if our auditor
is not inspected by the PCAOB for three consecutive years, and this ultimately could result in our Ordinary Shares being delisted.
Furthermore,
on June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act (“AHFCAA”), which, if
enacted, would amend the HFCA Act and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges
if its auditor is not subject to PCAOB inspections for two consecutive years instead of three and would reduce the time before our securities
may be prohibited from trading or delisted. On September 22, 2021, the PCAOB adopted a final rule implementing the AHFCAA, which provides
a framework for the PCAOB to use when determining, as contemplated under the AHFCAA, whether the Board is unable to inspect or investigate
completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities
in that jurisdiction. On November 5, 2021, the SEC approved the PCAOB’s Rule 6100, Board Determinations Under the HFCA Act. On
December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the HFCA Act.
The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public
accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because of a
position taken by an authority in foreign jurisdictions. On December 16, 2021, the PCAOB issued a Determination Report which found that
the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in: (1) mainland China of the
PRC, and (2) Hong Kong. In addition, the PCAOB’s report identified the specific registered public accounting firms which are subject
to these determinations. On December 29, 2022, the Consolidated Appropriations Act, was signed into law by President Biden. The Consolidated
Appropriations Act contained, among other things, an identical provision to AHFCAA, which reduce the number of consecutive non-inspection
years required for triggering the prohibitions under the HFCA Act from three years to two. Our auditor, OneStop Assurance PAC, is headquartered
in Singapore, not mainland China or Hong Kong and was not identified in this report as a firm subject to the PCAOB’s determination.
Therefore, our auditor is not currently subject to the determinations announced by the PCAOB on December 16, 2021, and it is currently
subject to the PCAOB inspections.
While
our auditor is based in the Singapore and is registered with the PCAOB and has been inspected by the PCAOB on a regular basis, in the
event it is later determined that the PCAOB is unable to inspect or investigate completely our auditor because of a position taken by
an authority in a foreign jurisdiction, then such lack of inspection could cause trading in the our securities to be prohibited under
the HFCA Act, and ultimately result in a determination by a securities exchange to delist our securities. In addition, the recent developments
would add uncertainties to the listing and trading of our Class A ordinary shares and we cannot assure you whether Nasdaq or regulatory
authorities would apply additional and more stringent criteria to us after considering the effectiveness of our auditor’s audit
procedures and quality control procedures, adequacy of personnel and training, or sufficiency of resources, geographic reach or experience
as it relates to the audit of our financial statements. It remains unclear what the SEC’s implementation process related to the
above rules will entail or what further actions the SEC, the PCAOB or Nasdaq will take to address these issues and what impact those
actions will have on U.S. companies that have significant operations in the PRC and have securities listed on a U.S. stock exchange (including
a national securities exchange or over-the-counter stock market). In addition, the above amendments and any additional actions, proceedings,
or new rules resulting from these efforts to increase U.S. regulatory access to audit information could create some uncertainty for investors,
the market price of our ADSs could be adversely affected, and we could be delisted if we and our auditor are unable to meet the PCAOB
inspection requirement or being required to engage a new audit firm, which would require significant expense and management time.
On
August 26, 2022, the PCAOB signed a Statement of Protocol (the “SOP”) Agreements with the CSRC and China’s Ministry
of Finance. The SOP Agreement, together with two protocol agreements (collectively, “SOP Agreements”), governs inspections
and investigations of audit firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to
inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet
with respect to the Protocol disclosed by the SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection
or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined
that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland
China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise
fail to facilitate the PCAOB’s access in the future, the PCAOB Board will consider the need to issue a new determination. Delisting
of our ADSs would force holders of our ADSs to sell their ADSs. The market price of our ADSs could be adversely affected as a result
of anticipated negative impacts of these executive or legislative actions upon, as well as negative investor sentiment towards, companies
with significant operations in China that are listed in the United States, regardless of whether these executive or legislative actions
are implemented and regardless of our actual operating performance.
The
recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and an act passed by the U.S. Senate and the U.S. House
of Representatives, all call for additional and more stringent criteria to be applied to emerging market companies. These developments
could add uncertainties to our business operations, share price and reputation.
U.S.
public companies that have substantially all of their operations in China have been the subject of intense scrutiny, criticism and negative
publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative
publicity has centered on financial and accounting irregularities and mistakes, a lack of effective internal controls over financial
accounting, inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud.
On
December 7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators
in their oversight of financial statement audits of U.S.-listed companies with significant operations in China. On April 21, 2020,
SEC Chairman Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting
the risks associated with investing in companies based in or have substantial operations in emerging markets including China, reiterating
past SEC and PCAOB statements on matters including the difficulty associated with inspecting accounting firms and audit work papers in
China and higher risks of fraud in emerging markets and the difficulty of bringing and enforcing SEC, Department of Justice and other
U.S. regulatory actions, including in instances of fraud, in emerging markets generally.
On
May 18, 2020, Nasdaq filed three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily
operating in a “Restrictive Market”, (ii) adopt a new requirement relating to the qualification of management or board
of director for Restrictive Market companies, and (iii) apply additional and more stringent criteria to an applicant or listed company
based on the qualifications of the company’s auditors.
On
May 20, 2020, the U.S. Senate passed the Holding Foreign Companies Accountable Act requiring a foreign
company to certify it is not owned or controlled by a foreign government if the PCAOB is unable to audit specified reports because the
company uses a foreign auditor not subject to PCAOB inspection. If the PCAOB is unable to inspect the company’s auditors for three
consecutive years, the issuer’s securities are prohibited to trade on a national exchange. On December 2, 2020, the U.S. House
of Representatives approved the Holding Foreign Companies Accountable Act.
On
May 21, 2021, Nasdaq filed three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily operating
in a “Restrictive Market”, (ii) prohibit Restrictive Market companies from directly listing on Nasdaq Capital Market, and
only permit them to list on Nasdaq Global Select or Nasdaq Global Market in connection with a direct listing and (iii) apply additional
and more stringent criteria to an applicant or listed company based on the qualifications of the company’s auditors.
As
a result of these scrutiny, criticism and negative publicity, the publicly traded stock of many U.S. listed Chinese companies sharply
decreased in value and, in some cases, has become virtually worthless. Many of these companies are now subject to shareholder lawsuits
and SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what effect
this sector-wide scrutiny, criticism and negative publicity will have on us, our business and our share price. If we become the subject
of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources
to investigate such allegations and/or defend our company. This situation will be costly and time consuming and distract our management
from developing our growth. If such allegations are not proven to be groundless, we and our business operations will be severely affected
and you could sustain a significant decline in the value of our share.
There
may be changes in the regulations of PRC government bodies and agencies relating to VAT collection procedure and ACTCS business
PRC
laws, regulations and policies concerning VAT collection procedures and ACTCS business are evolving and the PRC government authorities
may promulgate new laws, regulations and policies in the future. We cannot assure you that our practices would not be deemed to violate
any PRC laws, regulations or policies either now or in the future.
Moreover,
developments in the ACTCS service industry may lead to changes in PRC laws, regulations and policies or in the interpretation and application
of existing laws, regulations and policies, which may limit or restrict the ACTCS hardware and services we offer. Furthermore, we cannot
rule out the possibility that the PRC government will institute a new licensing regime covering services we provide in the future.
If such a licensing regime were introduced, we cannot assure you that we would be able to obtain any newly required license in a timely
manner, or at all, which could materially and adversely affect our business and impede our ability to continue our operations.
Failure
to comply with laws and regulations applicable to our business could subject us to fines and penalties and could also cause us to lose
customers or otherwise harm our business.
Our
business is subject to regulation by various governmental agencies in China, including agencies responsible for monitoring and enforcing
compliance with various legal obligations, such as value-added telecommunication laws and regulations, privacy and data protection-related
laws and regulations, intellectual property laws, employment and labor laws, workplace safety, environmental laws, consumer protection
laws, governmental trade laws, import and export controls, anti-corruption and anti-bribery laws, and tax laws and regulations. In certain
jurisdictions, these regulatory requirements may be more stringent than in China. These laws and regulations impose added costs on our
business. Noncompliance with applicable regulations or requirements could subject us to:
|
● |
investigations, enforcement actions, and sanctions; |
|
● |
mandatory changes to our network and products; |
|
● |
disgorgement of profits, fines, and damages; |
|
● |
civil and criminal penalties or injunctions; |
|
● |
claims for damages by our customers or channel partners; |
|
● |
termination of contracts; |
|
● |
loss of intellectual property rights; |
|
● |
failure to obtain, maintain or renew certain licenses, approvals,
permits, registrations or filings necessary to conduct our operations; and |
|
● |
temporary or permanent debarment from sales to public service organizations. |
If
any governmental sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of
operations, and financial condition could be adversely affected. In addition, responding to any action will likely result in a significant
diversion of our management’s attention and resources and an increase in professional fees. Enforcement actions and sanctions could
materially harm our business, results of operations, and financial condition.
Additionally,
companies in the technology industry have recently experienced increased regulatory scrutiny. Any reviews by regulatory agencies or legislatures
may result in substantial regulatory fines, changes to our business practices, and other penalties, which could negatively affect our
business and results of operations. Changes in social, political, and regulatory conditions or in laws and policies governing a wide
range of topics may cause us to change our business practices. Further, our expansion into a variety of new fields also could raise a
number of new regulatory issues. These factors could negatively affect our business and results of operations in material ways.
Moreover,
we are exposed to the risk of misconduct, errors and failure to functions by our management, employees and parties that we collaborate
with, who may from time to time be subject to litigation and regulatory investigations and proceedings or otherwise face potential liability
and penalties in relation to noncompliance with applicable laws and regulations, which could harm our reputation and business.
In
light of recent events indicating greater oversight by the Cyberspace Administration of China, or CAC, over data security, particularly
for companies seeking to list on a foreign exchange, we are subject to a variety of laws and other obligations regarding cybersecurity
and data protection, and any failure to comply with applicable laws and obligations could have a material and adverse effect on our business,
our listing on NASDAQ, financial condition, and results of operations.
We
are subject relating various risks and costs associated with to the collection, use, sharing, retention, security, and transfer of confidential
and private information, such as personal information and other data. This data is wide ranging and relates to our customers and any
other third parties. Our compliance obligations include those relating to the Data Protection Act (As Revised) of the Cayman Islands
and the relevant PRC laws in this regard. These PRC laws apply not only to third-party transactions, but also to transfers of information
among us and our PRC subsidiaries, and other parties with which we have commercial relations. These laws continue to develop, and the
PRC government may adopt other rules and restrictions in the future. Non-compliance could result in penalties or other significant legal
liabilities.
Pursuant
to the PRC Cybersecurity Law, which was promulgated by the Standing Committee of the National People’s Congress on November 7,
2016 and took effect on June 1, 2017, personal information and important data collected and generated by a critical information infrastructure
operator in the course of its operations in China must be stored in China, and if a critical information infrastructure operator purchases
internet products and services that affects or may affect national security, it should be subject to cybersecurity review by the CAC.
Due to the lack of further interpretations, the exact scope of “critical information infrastructure operator” remains unclear.
On December 28, 2021, the CAC and other relevant PRC governmental authorities jointly promulgated the Cybersecurity Review Measures (the
“new Cybersecurity Review Measures”) to replace the original Cybersecurity Review Measures. The new Cybersecurity Review
Measures took effect on February 15, 2022. Pursuant to the new Cybersecurity Review Measures, if critical information infrastructure
operators purchase network products and services, or network platform operators conduct data processing activities that affect or may
affect national security, they will be subject to cybersecurity review. A network platform operator holding more than one million users/users’
individual information also shall be subject to cybersecurity review before listing abroad. The cybersecurity review will evaluate, among
others, the risk of critical information infrastructure, core data, important data, or a large amount of personal information being influenced,
controlled or maliciously used by foreign governments and risk of network data security after going public overseas. In the opinion of
our PRC counsel, Hebei Changjun Law Firm we are not subject to cybersecurity review, because: (i) we do not collect or maintain personal
information in our business operations and (ii) data processed in our business does not have a bearing on national security and thus
may not be classified as core or important data by the authorities. However, Hebei Changjun Law Firm has also advised us that since the
regulatory authorities have discretion in this regard, whether an entity is subject to cybersecurity review shall still subject to the
regulatory authorities’ view. In addition, we currently do not have over one million users’ personal information and do not
anticipate to collect over one million users’ personal information in the foreseeable future. If we ever became subject to the
cybersecurity review of CAC in the future as the applicable rules, regulations, policies or the interpretation thereof change, during
such review, we may be required to suspend our operation or experience other disruptions to our operations. Cybersecurity review could
also result in negative publicity with respect to our company and diversion of our managerial and financial resources.
Furthermore,
if we were found to be in violation of applicable laws and regulations in China during such review, we could be subject to administrative
penalties, such as warnings, fines, or service suspension. Therefore, cybersecurity review could materially and adversely affect our
business, financial condition, and results of operations.
In
addition, the PRC Data Security Law, which was promulgated by the Standing Committee of the National People’s Congress on June
10, 2021 and took effect on September 1, 2021, requires data collection to be conducted in a legitimate and proper manner, and stipulates
that, for the purpose of data protection, data processing activities must be conducted based on data classification and hierarchical
protection system for data security. As the Data Security Law was recently promulgated, we may be required to make further adjustments
to our business practices to comply with this law. If our data processing activities were found to be not in compliance with this law,
we could be ordered to make ‘corrections, and under certain serious circumstances, such as severe data divulgence, we could be
subject to penalties, including the revocation of our business licenses or other permits. Furthermore, the recently issued Opinions on
Strictly Cracking Down Illegal Securities Activities in Accordance with the Law require (i) speeding up the revision of the provisions
on strengthening the confidentiality and archives management relating to overseas issuance and listing of securities and (ii) improving
the laws and regulations relating to data security, cross-border data flow, and management of confidential information. As there remain
uncertainties regarding the further interpretation and implementation of those laws and regulations, we cannot assure you that we will
be compliant such new regulations in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal
by the regulatory authorities and become subject to fines and other sanctions. As a result, we may be required to suspend our relevant
businesses, shut down our website, take down our operating applications, or face other penalties, which may materially and adversely
affect our business, financial condition, and results of operations.
On
August 20, 2021, the Standing Committee of the National People’s Congress of China promulgated the PIPL, which took effect in November
2021. As the first systematic and comprehensive law specifically for the protection of personal information in the PRC, the PIPL provides,
among others, that (i) an individual’s consent shall be obtained to use sensitive personal information, such as biometric characteristics
and individual location tracking, (ii) personal information operators using sensitive personal information shall notify individuals of
the necessity of such use and impact on the individual’s rights, and (iii) where personal information operators reject an individual’s
request to exercise his or her rights, the individual may file a lawsuit with a People’s Court. As uncertainties remain regarding
the interpretation and implementation of the PIPL, we cannot assure you that we will comply with the PIPL in all respects, we may become
subject to fines and/or other penalties which may have material adverse effect on our business, operations and financial condition.
While
we take measures to comply with all applicable data privacy and protection laws and regulations, we cannot guarantee the effectiveness
of the measures undertaken by us. However, compliance with any additional laws could be expensive, and may place restrictions on our
business operations and the manner in which we interact with our users. In addition, any failure to comply with applicable cybersecurity,
privacy, and data protection laws and regulations could result in proceedings against us by government authorities or others, including
notification for rectification, confiscation of illegal earnings, fines, or other penalties and legal liabilities against us, which could
materially and adversely affect our business, financial condition, results of operations and the value of our ADSs. In addition, any
negative publicity on our website or platform’s safety or privacy protection mechanism and policy could harm our public image and
reputation and materially and adversely affect our business, financial condition, and results of operations.
The
approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules,
regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result,
both you and us fact uncertainty about future actions by the PRC government that could significantly affect our business, our listing
on Nasdaq, financial condition and results of operations.
On
August 8, 2006, six PRC regulatory agencies, including the MOFCOM, the State-Owned Assets Supervision and Administration Commission,
or the SASAC, the SAT, the State Administration for Industry and Commerce, or the SAIC, the CSRC, and the State Administration of Foreign
Exchange, or the SAFE, jointly adopted the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the
M&A Rules, which came into effect on September 8, 2006 and were amended on June 22, 2009. The M&A Rules include, among other
things, provisions that purport to require that an offshore special purpose vehicle that is controlled by PRC domestic companies or individuals
and that has been formed for the purpose of an overseas listing of securities through acquisitions of PRC domestic companies or assets
to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle’s securities on an overseas
stock exchange. On September 21, 2006, the CSRC published on its official website procedures regarding its approval of overseas listings
by special purpose vehicles. However, substantial uncertainty remains regarding the scope and applicability of the M&A Rules to offshore
special purpose vehicles.
While
the application of the M&A Rules remains unclear, we believe, based on the advice of our PRC legal counsel, Hebei Changjun Law Firm
that the CSRC approval is not required for the listing and trading our ADSs on the Nasdaq Capital Market because Qingdao Akso Health
Management Co., Ltd., or our WFOE was incorporated as a foreign-invested enterprise by means of foreign direct investments rather than
by merger with or acquisition of any PRC domestic companies as defined under the M&A Rules. There can be no assurance that the relevant
PRC government agencies, including the CSRC, would reach the same conclusion as our PRC legal counsel. If the CSRC or other PRC regulatory
body subsequently determines that we need to obtain the CSRC’s approval for our offering or if the CSRC or any other PRC government
authorities promulgates any interpretation or implements rules that would require us to obtain CSRC or other governmental approvals for
our offering, we may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies. In any such event, these regulatory
agencies may impose fines and penalties on our operations in China, limit our operating privileges in China, delay or restrict the repatriation
of the proceeds from our offerings into the PRC, restrictions on or prohibition of the payments or remittance of dividends by our subsidiaries
in China, or other actions that could have a material and adverse effect on our business, reputation, financial condition, results of
operations, prospects, as well as the trading price of the ADSs. The CSRC or other PRC regulatory agencies may also take actions requiring
us, or making it advisable for us, to halt our offering before settlement and delivery of the Ordinary Shares that we are offering. Consequently,
if you engage in market trading or other activities in anticipation of and prior to settlement and delivery, you would be doing so at
the risk that the settlement and delivery may not occur. In addition, if the CSRC or other regulatory agencies later promulgate new rules
or explanations requiring us to obtain their approvals for our offering, we may be unable to obtain waivers of such approval requirements.
Any uncertainties or negative publicity regarding such approval requirements could materially and adversely affect the trading price
of our ADSs.
As
of the date of this prospectus, as advised by our PRC counsel, Hebei Changjun Law Firm, we and our subsidiaries, (1) currently are not
required to obtain permissions from any PRC authorities to list or trade our ADSs in foreign stock exchanges, (2) are not subject to
permission requirements from the CSRC, CAC or any other entity that is required to approve of our PRC subsidiaries’ operations,
and (3) have not received or were denied such permissions by any PRC authorities. Nevertheless, the General Office of the Central Committee
of the Communist Party of China and the General Office of the State Council jointly issued the “Opinions on Severely Cracking Down
on Illegal Securities Activities According to Law,” or the Opinions, which were made available to the public on July 6, 2021. The
Opinions emphasized the need to strengthen the administration over illegal securities activities, and the need to strengthen the supervision
over overseas listings by Chinese companies. Given the current PRC regulatory environment, it is uncertain when and whether we or our
PRC subsidiaries, will be required to obtain permission from the PRC government to list on U.S. exchanges in the future, and even when
such permission is obtained, whether it will be denied or rescinded. We have been closely monitoring regulatory developments in China
regarding any necessary approvals from the CSRC or other PRC governmental authorities required for overseas listings. As of the date
of this prospectus, we have not received any inquiry, notice, warning, sanctions or regulatory objection to this offering from the CSRC
or other PRC governmental authorities. However, there remains significant uncertainty as to the enactment, interpretation and implementation
of regulatory requirements related to overseas securities offerings and other capital markets activities.
On
February 17, 2023, the CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies
(the “Trial Measures”), which took effect on March 31, 2023. The Trial Measures clarified and emphasized several aspects,
which include but are not limited to: (1) comprehensive determination of the “indirect overseas offering and listing by PRC domestic
companies” in compliance with the principle of “substance over form” and particularly, an issuer will be required to
go through the filing procedures under the Trial Measures if the following criteria are met at the same time: a) 50% or more of the issuer’s
operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most
recent accounting year is accounted for by PRC domestic companies, and b) the main parts of the issuer’s business activities are
conducted in mainland China, or its main places of business are located in mainland China, or the senior managers in charge of its business
operation and management are mostly Chinese citizens or domiciled in mainland China; (2) exemptions from immediate filing requirements
for issuers that a) have already been listed or registered but not yet listed in foreign securities markets, including U.S. markets,
prior to the effective date of the Trial Measures, and b) are not required to re-perform the regulatory procedures with the relevant
overseas regulatory authority or the overseas stock exchange, c) whose such overseas securities offering or listing shall be completed
before September 30, 2023, provided however that such issuers shall carry out filing procedures as required if they conduct refinancing
or are involved in other circumstances that require filing with the CSRC; (3) a negative list of types of issuers banned from listing
or offering overseas, such as (a) issuers whose listing or offering overseas have been recognized by the State Council of the PRC as
possible threats to national security, (b) issuers whose affiliates have been recently convicted of bribery and corruption, (c) issuers
under ongoing criminal investigations, and (d) issuers under major disputes regarding equity ownership; (4) issuers’ compliance
with web security, data security, and other national security laws and regulations; (5) issuers’ filing and reporting obligations,
such as obligation to file with the CSRC after it submits an application for initial public offering to overseas regulators, and obligation
after offering or listing overseas to report to the CSRC material events including change of control or voluntary or forced delisting
of the issuer; and (6) the CSRC’s authority to fine both issuers and their shareholders between 1 and 10 million RMB for failure
to comply with the Trial Measures, including failure to comply with filing obligations or committing fraud and misrepresentation.
Changes
in the policies of the PRC government could have a significant impact upon our ability to operate profitably in the PRC.
We
conduct all of our operations and all of our revenue is generated in the PRC. Accordingly, economic, political and legal developments
in the PRC will significantly affect our business, financial condition, results of operations and prospects. Policies of the PRC government
can have significant effects on economic conditions in the PRC and the ability of businesses to operate profitably. Our ability to operate
profitably in the PRC may be adversely affected by changes in policies by the PRC government, including changes in laws, regulations
or their interpretation, particularly those dealing with the Internet, including censorship and other restriction on material which can
be transmitted over the Internet, security, intellectual property, money laundering, taxation and other laws that affect our ability
to operate our website.
Because
our business is dependent upon government policies that encourage a market-based economy, change in the political or economic climate
in the PRC may impair our ability to operate profitably, if at all.
Although
the PRC government has been pursuing a number of economic reform policies for more than two decades, the PRC government continues to
exercise significant control over economic growth in the PRC. Because of the nature of our business, we are dependent upon the PRC government
pursuing policies that encourage private ownership of businesses. Restrictions on private ownership of businesses would affect the VAT
filing and collection in general and businesses using ACTCS in particular. We cannot assure you that the PRC government will pursue policies
favoring a market-oriented economy or that existing policies will not be significantly altered, especially in the event of a change in
leadership, social or political disruption, or other circumstances affecting political, economic and social life in the PRC.
PRC
laws and regulations governing our current business operations are sometimes vague and uncertain and any changes in such laws and regulations
may impair our ability to operate profitable.
There
are substantial uncertainties regarding the interpretation and application of PRC laws and regulations including, but not limited to,
the laws and regulations governing our business and the enforcement and performance of our arrangements with customers in certain circumstances.
The laws and regulations are sometimes vague and may be subject to future changes, and their official interpretation and enforcement
may involve substantial uncertainty. The effectiveness and interpretation of newly enacted laws or regulations, including amendments
to existing laws and regulations, may be delayed, and our business may be affected if we rely on laws and regulations which are subsequently
adopted or interpreted in a manner different from our understanding of these laws and regulations. New laws and regulations that affect
existing and proposed future businesses may also be applied retroactively. We have substantially operations conducted by our VIEs in
China, which are governed by PRC laws, rules and regulations. Our PRC subsidiaries and the VIEs are subject to laws and regulations applicable
to foreign investment in China. We cannot predict what effect the interpretation of existing or new PRC laws or regulations may have
on our business.
The
PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil
law system may be cited for reference but have limited precedential value. Since these laws and regulations are relatively new and the
PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and the
enforcement of these laws, regulations and rules involves uncertainties.
In
1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The
overall effect of legislation over the past three decades has significantly enhanced the protections afforded to various forms of foreign
investments in China. However, China has not developed a fully integrated legal system, and recently enacted laws and regulations may
not sufficiently cover all aspects of economic activities in China. In particular, the interpretation and enforcement of these laws and
regulations involve uncertainties. Since PRC administrative and court authorities have significant discretion in interpreting and implementing
statutory provisions and contractual terms, it may be difficult to evaluate the outcome of administrative and court proceedings and the
level of legal protection we enjoy. These uncertainties may affect our judgment on the relevance of legal requirements and our ability
to enforce our contractual rights or tort claims. In addition, the regulatory uncertainties may be exploited through unmerited or frivolous
legal actions or threats in attempts to extract payments or benefits from us.
Furthermore,
the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or
at all and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime
after the violation. In addition, any administrative and court proceedings in China may be protracted, resulting in substantial costs
and diversion of resources and management attention.
From
time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. However, since PRC administrative
and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult
to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal
systems. Furthermore, the PRC legal system is based in part on government policies and internal rules (some of which are not published
in a timely manner or at all) that may have retroactive effect. As a result, we may not be aware of our violation of these policies and
rules until sometime after the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property
(including intellectual property) and procedural rights, and any failure to respond to changes in the regulatory environment in China
could materially and adversely affect our business and impede our ability to continue our operations.
Recently,
the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued
the “Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law,” or the Opinions, which
was made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities
activities, and the need to strengthen the supervision over overseas listings by Chinese companies. Effective measures, such as promoting
the construction of relevant regulatory systems will be taken to deal with the risks and incidents of China-concept overseas listed companies,
and cybersecurity and data privacy protection requirements and similar matters. The Opinions and any related implementing rules to be
enacted may subject us to compliance requirement in the future.
Changes
in China’s macroeconomic, socio-political conditions or government policies could have a material adverse effect on our business
and results of operations.
All
of our operations are located in China. Accordingly, our business, prospects, financial condition and results of operations are affected
significantly by the political, economic and social climate in China and continuously by the economic performance of China as a whole.
The
Chinese economy is unique from the economies of most developed countries in many respects, the more salient aspects include the amount
of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the Chinese
government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership
of productive assets and the establishment of improved corporate governance in business enterprises, a substantial portion of productive
assets in China is still state-owned. In addition, the Chinese government continues to play a significant role in regulating industry
development by imposing industrial policies. The Chinese government also exercises significant control over China’s economic growth
through allocating resources, controlling payment of foreign currency-denominated obligations, setting the monetary policy, and determining
the different levels of treatment accorded to different industries and companies in accordance with its national development policy.
While
the Chinese economy has experienced significant growth over the past decades, the growth rate has had sporadic bursts, across geographically
and among various sectors and industries. The Chinese government has implemented various measures to encourage economic growth and guide
the allocation of resources. Some of these measures may benefit the overall Chinese economy, but may have a negative effect on us. For
example, our financial condition and results of operations may be adversely affected by government control over capital investments or
changes in tax regulations. In addition, in the past the Chinese government has implemented certain measures, including interest rate
increases, to control the pace of economic growth. These measures may cause decreased economic activity in China, and since 2012, China’s
economic growth has slowed down. Any prolonged slowdown in the Chinese economy may reduce the demand for our products and services and
materially and adversely affect our business and results of operations.
Substantial
uncertainties exist with respect to the interpretation and implementation of the newly enacted PRC Foreign Investment Law and how it
may impact the viability of our current corporate structure, corporate governance and business operations.
On
March 15, 2019, the National People’s Congress approved the Foreign Investment Law, which came into effect on January 1, 2020
and replaced the trio of existing laws regulating foreign investment in China, namely, the Sino-foreign Equity Joint Venture Enterprise
Law, the Sino-foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-invested Enterprise Law, together with their implementation
rules and ancillary regulations. The Foreign Investment Law embodies an expected PRC regulatory trend to rationalize its foreign
investment regulatory regime in line with prevailing international practice and the legislative efforts to unify the corporate legal
requirements for both foreign and domestic investments. However, since the Foreign Investment Law is relatively new, uncertainties still
exist in relation to its interpretation and implementation. For instance, under the Foreign Investment Law, “foreign investment”
refers to the investment activities directly or indirectly conducted by foreign individuals, enterprises or other entities in China.
Although it does not explicitly classify contractual arrangements as a form of foreign investment, there is no assurance that foreign
investment via contractual arrangement would not be interpreted as a type of indirect foreign investment activities under the definition
in the future. In addition, the definition contains a catch-all provision which includes investments made by foreign investors through
means stipulated in laws or administrative regulations or other methods prescribed by the State Council. Therefore, it still leaves leeway
for future laws, administrative regulations or provisions promulgated by the State Council to provide for contractual arrangements as
a form of foreign investment. In any of these cases, it will be uncertain whether our contractual arrangements will be deemed to be in
violation of the market access requirements for foreign investment under the PRC laws and regulations. Furthermore, if future laws, administrative
regulations or provisions prescribed by the State Council mandate further actions to be taken by companies with respect to existing contractual
arrangements, we may face substantial uncertainties as to whether we can complete such actions in a timely manner, or at all. Failure
to take timely and appropriate measures to cope with any of these or similar regulatory compliance challenges could materially and adversely
affect our current corporate structure, corporate governance and business operations.
We
may be adversely affected by the complexity, uncertainties and changes in PRC regulation of Internet-related businesses and companies,
and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business
and results of operations.
The
PRC government extensively regulates the Internet industry, including foreign ownership of, and the licensing and permit requirements
pertaining to, companies in the Internet industry. These Internet-related laws and regulations are relatively new and evolving, and their
interpretation and enforcement involve significant uncertainties. As a result, in certain circumstances it may be difficult to determine
what actions or omissions may be deemed to be in violation of applicable laws and regulations.
We
have only contractual control over our website. We do not directly own the website due to the restriction of foreign investment in businesses
providing value-added telecommunication services in China, including Internet information provision services. This may significantly
disrupt our business, subject us to sanctions, compromise enforceability of related contractual arrangements, or have other harmful effects
on us.
The
evolving PRC regulatory system for the Internet industry may lead to the establishment of new regulatory agencies. For example, in May 2011,
the State Council announced the establishment of a new department, the State Internet Information Office (with the involvement of the
State Council Information Office, the Ministry of Industry and Information Technology, or the MIIT, and the Ministry of Public Security).
The primary role of this new agency is to facilitate the policy-making and legislative development in this field, to direct and coordinate
with the relevant departments in connection with online content administration and to deal with cross-ministry regulatory matters in
relation to the Internet industry.
Fluctuations
in exchange rates could have a material adverse effect on our results of operations and the value of your investment.
A
portion of our revenues and expenditures are denominated in RMB, and the functional currency for our PRC subsidiary and consolidated
variable interest entities is RMB, whereas our reporting currency is the U.S. dollar. Any significant revaluation of RMB may materially
and adversely affect our cash flows, revenues, earnings and financial position, and the value of, and any dividends payable on, our ADSs
in U.S. dollars. For example, to the extent that we need to convert U.S. dollars we receive from our initial public offering into
RMB to pay our operating expenses, appreciation of the RMB against the U.S. dollar would have an adverse effect on the RMB amount
we would receive from the conversion. If we decide to convert our RMB into U.S. dollars for the purpose of making payments for dividends
on our ordinary shares or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect
on the U.S. dollar amount available to us. Moreover, a significant depreciation of the RMB against the U.S. dollar may significantly
reduce our earnings translated in the U.S. dollars, which in turn could adversely affect the price of our ADSs. Furthermore, fluctuations
in currencies relative to the periods in which the earnings are generated may make it more difficult to perform period-to-period comparisons
of our reported results of operations.
The
value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in China’s
political and economic conditions and foreign exchange policies. It is difficult to predict how market forces or PRC or U.S. government
policy may impact the exchange rate between the RMB and the U.S. dollar in the future. In the year ended March 31, 2022, the value of
the RMB appreciated approximately by 3.2% against of the U.S dollar. In the year ended March 31, 2023, the value of the RMB depreciated
by approximately 8.3% against the U.S. dollar. And in the year ended March 31, 2024, the value of the RMB depreciated by approximately
5.1% against the U.S. dollar. With the development of the foreign exchange market and progress towards interest rate liberalization and
RMB internationalization, the PRC government may in the future announce further changes to the exchange rate system and there is no guarantee
that the RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future.
Very
limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into
any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging
transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge
our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict
our ability to convert RMB into foreign currency. As a result, fluctuations in exchange rates may have a material adverse effect on your
investment.
Governmental
control of currency conversion may limit our ability to utilize our net revenues effectively and affect the value of your investment.
The
PRC government imposes controls on the convertibility of the RMB into foreign currencies and, in certain cases, the remittance of currency
out of China. We receive substantially all of our net revenues in RMB. Under our current corporate structure, our company in the Cayman
Islands relies on dividend payments from our PRC subsidiary to fund any cash and financing requirements we may have. Under existing PRC
foreign exchange regulations, payments of current account items, such as profit distributions and trade and service-related foreign exchange
transactions, can be made in foreign currencies without prior approval from SAFE by complying with certain procedural requirements. Therefore,
our PRC subsidiary is able to pay dividends in foreign currencies to us without prior approval from SAFE, subject to the condition that
the remittance of such dividends outside of the PRC complies with certain procedures under PRC foreign exchange regulation, such
as the overseas investment registrations by the beneficial owners of our company who are PRC residents. However, approval from or registration
with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay
capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may also at its discretion restrict
access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from
obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies
to our shareholders, including holders of our ADSs.
Failure
to make adequate contributions to various employee benefit plans as required by PRC regulations may subject us to penalties.
We
are required under PRC laws and regulations to participate in various government sponsored employee benefit plans, including certain
social insurance, housing funds and other welfare-oriented payment obligations, and contribute to the plans in amounts equal to certain
percentages of salaries, including bonuses and allowances, of our employees up to a maximum amount specified by the local government
from time to time at locations where we operate our businesses. The requirement of employee benefit plans has not been implemented consistently
by the local governments in China given the different levels of economic development in different locations. We have not made adequate
employee benefit payments. We may be required to make up the contributions for these plans as well as to pay late fees and fines. If
we are subject to late fees or fines in relation to the underpaid employee benefits, our financial condition and results of operations
may be adversely affected.
The
M&A Rules and certain other PRC regulations establish complex procedures for some acquisitions of Chinese companies by foreign
investors, which could make it more difficult for us to pursue growth through acquisitions in China.
The
Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors, or the M&A Rules, adopted by six PRC regulatory
agencies in 2006 and amended in 2009, and some other regulations and rules concerning mergers and acquisitions established additional
procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex, including
requirements in some instances that the MOC be notified in advance of any change-of-control transaction in which a foreign investor takes
control of a PRC domestic enterprise. Moreover, the Anti-Monopoly Law requires that the MOC shall be notified in advance of any concentration
of undertaking if certain thresholds are triggered. In addition, the security review rules issued by the MOC that became effective
in September 2011 specify that mergers and acquisitions by foreign investors that raise “national defense and security”
concerns and mergers and acquisitions through which foreign investors may acquire de facto control over domestic enterprises that raise
“national security” concerns are subject to strict review by the MOC, and the rules prohibit any activities attempting
to bypass a security review, including by structuring the transaction through a proxy or contractual control arrangement. In the future,
we may grow our business by acquiring complementary businesses. Complying with the requirements of the above-mentioned regulations and
other relevant rules to complete such transactions could be time-consuming, and any required approval processes, including obtaining
approval from the MOC or its local counterparts may delay or inhibit our ability to complete such transactions, which could affect our
ability to expand our business or maintain our market share.
PRC
regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiary’s ability to increase its
registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties
under PRC law.
SAFE
promulgated the Circular on Relevant Issues Relating to Domestic Resident’s Investment and Financing and Roundtrip Investment through
Special Purpose Vehicles, or SAFE Circular 37, in July 2014 that requires PRC residents or entities to register with SAFE or
its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas investment
or financing. In addition, such PRC residents or entities must update their SAFE registrations when the offshore special purpose vehicle
undergoes material events relating to any change of basic information (including change of such PRC citizens or residents, name and operation
term), increases or decreases in investment amount, transfers or exchanges of shares, or mergers or divisions. SAFE Circular 37
is issued to replace the Notice on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents Engaging in Financing
and Roundtrip Investments via Overseas Special Purpose Vehicles, or SAFE Circular 75. SAFE promulgated the Notice on Further Simplifying
and Improving the Administration of the Foreign Exchange Concerning Direct Investment in February 2015, which took effect on June 1,
2015. This notice has amended SAFE Circular 37 requiring PRC residents or entities to register with qualified banks rather than
SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas
investment or financing.
If
our shareholders who are PRC residents or entities do not complete their registration as required, our PRC subsidiary may be prohibited
from distributing its profits and proceeds from any reduction in capital, share transfer or liquidation to us, and we may be restricted
in our ability to contribute additional capital to our PRC subsidiary. Moreover, failure to comply with the SAFE registration described
above could result in liability under PRC laws for evasion of applicable foreign exchange restrictions.
All
of our shareholders who directly or indirectly hold shares in our Cayman Islands holding company and who are known to us as being PRC
residents have completed the foreign exchange registrations required in connection with our recent corporate restructuring.
However,
we may not be informed of the identities of all the PRC residents or entities holding direct or indirect interest in our company, nor
can we compel our beneficial owners to comply with SAFE registration requirements. As a result, we cannot assure you that all of our
shareholders or beneficial owners who are PRC residents or entities have complied with, and will in the future make or obtain any applicable
registrations or approvals required by, SAFE regulations. Failure by such shareholders or beneficial owners to comply with SAFE regulations,
or failure by us to amend the foreign exchange registrations of our PRC subsidiary, could subject us to fines or legal sanctions, restrict
our overseas or cross-border investment activities, limit our PRC subsidiary’s ability to make distributions or pay dividends to
us or affect our ownership structure, which could adversely affect our business and prospects.
Any
failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC
plan participants or us to fines and other legal or administrative sanctions.
In
February 2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating
in Stock Incentive Plan of Overseas Publicly-Listed Company, replacing earlier rules promulgated in March 2007. Pursuant to
these rules, PRC citizens and non-PRC citizens who reside in China for a continuous period of not less than one year who participate
in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through
a domestic qualified agent, which could be the PRC subsidiary of such overseas listed company, and complete certain other procedures.
In addition, an overseas entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options
and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or who have
resided in the PRC for a continuous period of not less than one year and who have been granted options or other awards are subject to
these regulations. Failure to complete the SAFE registrations may subject them to fines and legal sanctions and may also limit our ability
to contribute additional capital into our PRC subsidiary and limit our PRC subsidiary’s ability to distribute dividends to us.
We also face regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our directors, executive
officers and employees under PRC law. See “Item 4. Information on the Company-B. Business Overview-Regulation-Regulations
Relating to Foreign Exchange - Regulations on Stock Incentive Plans.”
If
we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences
to us and our non-PRC shareholders or ADS holders.
Under
the EIT Law and its implementation rules, an enterprise established outside of the PRC with a “de facto management body”
within the PRC is considered a resident enterprise and will be subject to the enterprise income tax on its global income at the rate
of 25%. The implementation rules define the term “de facto management body” as the body that exercises full and substantial
control over and overall management of the business, productions, personnel, accounts and properties of an enterprise. In April 2009,
the State Administration of Taxation, or the SAT, issued a circular, known as Circular 82, which provides certain specific criteria
for determining whether the “de facto management body” of a PRC-controlled enterprise that is incorporated offshore
is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups,
not those controlled by PRC individuals or foreigners like us, the criteria set forth in Circular 82 may reflect the SAT’s
general position on how the “de facto management body” test should be applied in determining the tax resident status of all
offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise
group will be regarded as a PRC tax resident by virtue of having its “de facto management body” in China and will be subject
to PRC enterprise income tax on its global income only if all of the following conditions are met: (i) the primary location of the
day-to-day operational management is in the PRC; (ii) decisions relating to the enterprise’s financial and human resource
matters are made or are subject to approval by organizations or personnel in the PRC; (iii) the enterprise’s primary assets,
accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv) at
least 50% of voting board members or senior executives habitually reside in the PRC.
We
believe none of our entities outside of China is a PRC resident enterprise for PRC tax purposes. See “Item 10. Additional
Information-E. Taxation-People’s Republic of China Taxation.” However, the tax resident status of an enterprise is subject
to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term “de facto management
body.” As substantially all of our management members are based in China, it remains unclear how the tax residency rule will
apply to our case. If the PRC tax authorities determine that we or any of our subsidiaries outside of China is a PRC resident enterprise
for PRC enterprise income tax purposes, then we or such subsidiary could be subject to PRC tax at a rate of 25% on its world-wide
income, which could materially reduce our net income. In addition, we will also be subject to PRC enterprise income tax reporting obligations.
Furthermore, if the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, dividends
we pay to non-PRC holders may be subject to PRC withholding tax, and gains realized on the sale or other disposition of ADSs or ordinary
shares may be subject to PRC tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each
case, subject to the provisions of any applicable tax treaty), if such dividends or gains are deemed to be from PRC sources. It is unclear
whether non-PRC shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence
and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in
the ADSs.
We
may not be able to obtain certain benefits under relevant tax treaty on dividends paid by our PRC subsidiary to us through our Hong Kong
subsidiary.
We
are a holding company incorporated under the laws of the Cayman Islands and as such rely on dividends and other distributions on equity
from our PRC subsidiary to satisfy part of our liquidity requirements. Pursuant to the EIT Law, a withholding tax rate of 10% currently
applies to dividends paid by a PRC “resident enterprise” to a foreign enterprise investor, unless any such foreign investor’s
jurisdiction of incorporation has a tax treaty with China that provides for preferential tax treatment. Pursuant to the Arrangement between
the Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or
the Double Tax Avoidance Arrangement, such withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns at least
25% of a PRC enterprise. Pursuant to the Notice of the State Administration of Taxation on the Issues concerning the Application of the
Dividend Clauses of Tax Agreements, or Circular 81, the 5% withholding tax rate does not automatically apply and certain requirements
must be satisfied, including without limitation that (a) the Hong Kong enterprise must be the beneficial owner of the relevant dividends;
and (b) the Hong Kong enterprise must directly hold at least 25% share ownership in the PRC enterprise during the 12 consecutive
months preceding its receipt of the dividends. However, a transaction or arrangement entered into for the primary purpose of enjoying
a favorable tax treatment should not be a reason for the application of the favorable tax treatment under the Double Tax Avoidance Arrangement.
If a taxpayer inappropriately is entitled to such favorable tax treatment, the competent tax authority has the power to make appropriate
adjustments.
In
August 2015, the State Administration of Taxation promulgated the Administrative Measures for Non-Resident Taxpayers to Enjoy Treatments
under Tax Treaties, or Circular 60, which became effective on November 1, 2015. Circular 60 provides that non-resident
enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced withholding tax rate.
Instead, non-resident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria
to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, and file necessary forms and supporting documents
when performing tax filings, which will be subject to post-tax filing examinations by the relevant tax authorities. However, if a competent
tax authority finds out that it is necessary to apply the general anti-tax avoidance rules, it may start general investigation procedures
for anti-tax avoidance and adopt corresponding measures for subsequent administration. Accordingly, Hexindai Hong Kong Limited, or Hexindai
HK, our Hong Kong subsidiary, may be able to enjoy the 5% withholding tax rate for the dividends they receive from Hexin Yongheng, our
PRC subsidiary, if it satisfies the conditions prescribed under Circular 81 and other relevant tax rules and regulations. However,
according to Circular 81 and Circular 60, if the relevant tax authorities consider the transactions or arrangements we have
are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable withholding
tax in the future.
Enhanced
scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue
in the future.
In
connection with the EIT Law, the SAT issued the Circular on Strengthening the Administration of Enterprise Income Tax on Non-resident
Enterprises’ Equity Transfer Income, or Circular 698, which became effective as of January 1, 2008, the Notice on
Issues Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59 on April 30, 2009,
and the Announcement of the State Administration of Taxation on Several Issues concerning the Enterprise Income Tax on the Indirect Transfers
of Properties by Non-Resident Enterprises, or the SAT Announcement 7, on February 3, 2015. By promulgating and implementing
the above, the PRC tax authorities have strengthened their scrutiny over the direct or indirect transfer of equity interest in a PRC
resident enterprise by a non-PRC resident enterprise. Pursuant to SAT Announcement 7, if a non-resident enterprise, or referred
to as a transferor, transfers its equity in an offshore enterprise which directly or indirectly owns PRC taxable assets, including ownership
interest in PRC resident companies, or the Taxable Properties, without a “reasonable commercial purpose”, such transfer shall
be deemed as a direct transfer of such Taxable Properties. The payer, or referred as a transferee, in such transfer shall be the withholding
agent, and is obligated to withhold and remit the enterprise income tax to the relevant PRC tax authority. If a transferor fails to declare
for payment timely or in full of the tax due on proceeds from indirect transfer of PRC taxable assets and the withholding agent also
fails to withhold such tax, the tax authority shall, in addition to supplementary collection of such tax, also charge for interest on
a daily basis from the transferor according to the EIT Law and its implementation rules. Factors that may be taken into consideration
when determining whether there is a reasonable commercial purpose include, among other factors, the value of the transferred equity,
offshore taxable situation of the transaction, the offshore structure’s economic essence and duration and trading fungibility.
If an equity transfer transaction satisfies all the requirements mentioned above, such transaction will be considered an arrangement
with reasonable commercial purpose. On October 17, 2017, the SAT issued the Bulletin of SAT on Issues Concerning the Withholding
of Non-resident Enterprise Income Tax at Source, or Bulletin 37, which came into effect on December 1, 2017 and was amended
in June 2018, which, among others, repeals certain rules stipulated in Circular 7. Bulletin 37 further details and
clarifies the tax withholding methods in respect of the income of non-resident enterprises.
Accordingly,
we and non-resident enterprise investors face uncertainties on the reporting and consequences on future private equity-financing transactions,
share exchange or other transactions involving the transfer of shares in our company by investors that are non-PRC resident enterprises.
The PRC tax authorities may pursue such non-resident enterprises with respect to a filing or the transferees with respect to withholding
obligation, and request our PRC subsidiaries to assist in the filing. As a result, we and non-resident enterprises in such transactions
may become at risk of being subject to filing obligations or being taxed, under Circular 59, Circular 698, the SAT Announcement 7
and Bulletin 37, and we may be required to expend valuable resources to comply with Circular 59, Circular 698, the SAT
Announcement 7 and Bulletin 37 or to establish that we and our non-resident enterprises should not be taxed under these circulars,
which may have a material adverse effect on our financial condition and results of operations.
Additionally,
the PRC tax authorities have the discretion under SAT Circular 59, Circular 698, the SAT Announcement 7 and Bulletin 37
to make adjustments to the taxable capital gains based on the difference between the fair value of the taxable assets transferred and
the cost of investment. Although we currently have no plans to pursue any acquisitions in China or elsewhere in the world, we may pursue
acquisitions in the future that may involve complex corporate structures. If we are considered a non-resident enterprise under the EIT
Law and if the PRC tax authorities make adjustments to the taxable income of the transactions under SAT Circular 59, Circular 698,
the SAT Announcement 7 and Bulletin 37, our income tax costs associated with such potential acquisitions will be increased,
which may have an adverse effect on our financial condition and results of operations.
Any
actions by the Chinese government, including any decision to intervene or influence the operations of the operating entities or to exert
control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material
changes to the operations of the PRC operating entities, may limit or completely hinder our ability to offer or continue to offer securities
to investors, and may cause the value of such securities to significantly decline or be worthless.
We
are a Cayman Islands holding company and are not a Chinese company. As a holding company with no material operations of our own, we conduct
all of our operations through our PRC operating entities in China. As such, our corporate structure involves unique risks to investors.
There are legal and operational risks associated with having operations in mainland China, and the Chinese regulatory authorities could
disallow this ownership structure, which would likely result in a material change in our operations and/or a material change in the value
of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or
become worthless.
In
the meeting of the Political Bureau of the CPC Central Committee held on July 30, 2021, the improvement of the regulatory system
for overseas listing of enterprises was first proposed. On February 17, 2023, the CSRC released the Trial Administrative Measures of
Overseas Securities Offering and Listing by Domestic Companies, or the Overseas Listing Trial Measures, and five supporting guidelines,
which came into effect on March 31, 2023. Pursuant to the Overseas Listing Trial Measures, domestic companies that seek to offer or list
securities overseas, whether directly or indirectly, should fulfil the filing procedures and submit relevant information to the CSRC.
Although
the detailed implementations are still unclear, the supervision of overseas listing of Chinese stocks may continue to tighten. The Chinese
government has exercised, and continues to exercise, substantial control over virtually every sector of the Chinese economy through regulation
and state ownership. The ability of our operating entities to operate in China may be impaired by changes in its laws and regulations,
including those relating to taxation, environmental regulations, land use rights, foreign investment limitations, and other matters.
The central or local governments of China may impose new, stricter regulations or interpretations of existing regulations that would
require additional expenditures and efforts on our part to our compliance with such regulations or interpretations. As such, we may be
subject to various government and regulatory interference in the provinces in which we operate. We could be subject to regulation by
various political and regulatory entities, including various local and municipal agencies and government sub-divisions. We may incur
increased costs necessary to comply with existing and newly adopted laws and regulations or penalties for any failure to comply.
Furthermore,
it is uncertain when and whether we will be required to obtain permission from the PRC government to list on U.S. exchanges in the
future, and even when such permission is obtained, whether it will be denied or rescinded. Although we believe that we are currently
not required to obtain permission from any Chinese authorities and have not received any notice of denial of permission to list on the
U.S. exchange, our operations could be adversely affected, directly or indirectly, by existing or future laws and regulations relating
to the PRC operating entities’ business or industry, particularly in the event permission to list on U.S. exchanges may be
later required, or withheld or rescinded once given.
Accordingly,
government actions in the future, including any decision to intervene or influence our operations at any time or to exert control over
an offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes
to our operations, may limit or completely hinder our ability to offer or continue to offer securities to investors, and/or may cause
the value of such securities to significantly decline or be worthless.
There
are uncertainties regarding the enforcement of laws and rules and regulations in China, which can change quickly with little advance
notice, and there is a risk that the Chinese government may intervene or influence our operations at any time, exert more oversight and
control over offerings that are conducted overseas and/or foreign investment in China-based issuers, which could materially and adversely
affect our business and hinder our ability to offer or continue our operations, and cause the value of our securities to significantly
decline or become worthless.
There
are substantial uncertainties regarding the interpretation and application of PRC laws and regulations including, but not limited to,
the laws and regulations related to our business and the enforcement and performance of our arrangements with customers in certain circumstances.
The laws and regulations are sometimes vague and may be subject to future changes, and their official interpretation and enforcement
may involve substantial uncertainty. The effectiveness and interpretation of newly enacted laws or regulations, including amendments
to existing laws and regulations, may be delayed, and our business may be affected if we rely on laws and regulations which are subsequently
adopted or interpreted in a manner different from our understanding of these laws and regulations. New laws and regulations that affect
existing and proposed future businesses may also be applied retroactively. We cannot predict what effect the interpretation of existing
or new PRC laws or regulations may have on our business. The uncertainties regarding the enforcement of laws and the fact that rules
and regulations in mainland China can change quickly with little advance notice could result in a material change in our operations,
financial performance and/or cause the value of our securities to significantly decline or become worthless and/or impair our ability
to raise money.
The
Chinese government may exercise significant oversight and discretion over the conduct of business in the PRC and may intervene in or
influence our operations at any time, which could result in a material change in our operations and/or the value of our securities. We
are also currently not required to obtain approval from Chinese authorities to list on U.S. exchanges, however, if we are required to
obtain approval in the future and are denied permission from Chinese authorities to list on U.S. exchanges, we will not be able to continue
listing on U.S. exchange, which would materially affect the interest of the investors. The PRC government may intervene or influence
our business operations at any time or may exert more control over offerings conducted overseas and foreign investment in China-based
issuers, which could result in a material change in our business operations or the value of our securities. Additionally, the governmental
and regulatory interference could significantly limit or completely hinder our ability to offer or continue to offer securities to investors
and cause the value of such securities to significantly decline or be worthless.
To
the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in mainland China or Hong Kong, such cash or assets
may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions in or the imposition of
restrictions and limitations by the PRC government to the transfer of cash or assets.
The
transfer of funds and assets among the Company, its Hong Kong and PRC subsidiaries is subject to governmental control and restriction.
The competent PRC government imposes controls on the conversion of the RMB into foreign currencies and the remittance of currencies out
of mainland China. In addition, the PRC EIT Law and its implementation rules provide that a withholding tax at a rate of 10% will be
applicable to dividends payable by Chinese companies to enterprises that are not mainland China resident enterprises, unless reduced
under treaties or arrangements between the PRC central government and the governments of other countries or regions where the enterprises
that are not mainland China resident enterprises are tax resident.
As
of the date of this report, there are no restrictions or limitations imposed by the Hong Kong government on the transfer of capital within,
into and out of Hong Kong (including funds from Hong Kong to the PRC), except for the transfer of funds involving money laundering and
criminal activities. However, there is no guarantee that the Hong Kong government will not promulgate new laws or regulations that may
impose such restrictions in the future.
As
a result of the above, to the extent cash or assets of our business, or of our PRC or Hong Kong subsidiaries, is in mainland China or
Hong Kong, such funds or assets may not be available to fund operations or for other use outside of the PRC or Hong Kong, due to interventions
in or the imposition of restrictions and limitations by the competent government to the transfer of cash or assets.
RISKS RELATED
TO OUR ADSs
The
trading price of our ADSs may be volatile, which could result in substantial losses to investors.
The
trading price of our ADSs has ranged from US$0.25 to US$2.90 per ADS in fiscal year 2024. The trading prices of our
ADSs are likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market
and industry factors, like the performance and fluctuation in the market prices or the underperformance or deteriorating financial results
of Internet or other companies based in China that have listed their securities in the United States in recent years. The securities
of some of these companies have experienced significant volatility since their initial public offerings, including, in some cases, substantial
decline in their trading prices. The trading performances of other Chinese companies’ securities after their offerings may affect
the attitudes of investors toward Chinese companies listed in the United States, which consequently may impact the trading performance
of our ADSs, regardless of our actual operating performance. In addition, any negative news or perceptions about inadequate corporate
governance practices or fraudulent accounting, corporate structure or other matters of us or other Chinese companies may also negatively
affect the attitudes of investors towards Chinese companies in general, including us, regardless of whether we have conducted any inappropriate
activities. In addition, securities markets may from time to time experience significant price and volume fluctuations that are not related
to our operating performance, such as the large decline in share prices in the United States, China and other jurisdictions in late 2008,
early 2009, the second half of 2011, the third quarter of 2015 and the first quarter of 2016, which may have a material adverse
effect on the market price of our ADSs.
In
addition to market and industry factors, the price and trading volume for our ADSs may be highly volatile for factors specific to our
own operations, including the following:
| ● | regulatory
developments affecting us, our customers or our industry; |
| ● | announcements
of studies and reports relating to our products and service offerings or those of our competitors; |
| ● | changes
in the economic performance or market valuations of other social e-commerce platforms; |
| ● | actual
or anticipated fluctuations in our quarterly results of operations and changes or revisions
of our expected results; |
| ● | changes
in financial estimates by securities research analysts; |
| ● | conditions
in the Internet and unsecured consumer finance industries; |
| ● | announcements
of new product, service and expansions by us or our competitors; |
| ● | replacement
of existing third-party service providers; |
| ● | additions
to or departures of our senior management; |
| ● | detrimental
negative publicity about us, our management or our industry; |
| ● | fluctuations
of exchange rates between the RMB and the U.S. dollar; |
| ● | release
or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or
ADSs; and |
| ● | sales
or perceived potential sales of additional ordinary shares or ADSs. |
Any
of these factors may result in large and sudden changes in the volume and price at which our ADSs will trade.
Techniques
employed by short sellers may drive down the market price of our ADSs.
Short
selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention
of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value
of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects
to pay less in that purchase than it received in the sale. As it is in the short seller’s interest for the price of the security
to decline, many short sellers publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business
prospects in order to create negative market momentum and generate profits for themselves after selling a security short. These short
attacks have, in the past, led to selling of shares in the market.
We
have been the subject of short selling, and it is not clear what long-term effect such negative publicity could have on us. We may also
be subject to short seller attacks from time to time in the future. If we were to become the subject of any unfavourable allegations,
whether such allegations are proven to be true or untrue, we may have to expend a significant amount of resources to investigate such
allegations and/or defend ourselves. While we would strongly defend against any such short seller attacks, we may be constrained in the
manner in which we can proceed against the relevant short sellers by principles of freedom of speech, applicable state law or issues
of commercial confidentiality. Such a situation could be costly and time-consuming, and could divert management’s attention from
the day-to-day operations of our company. Even if such allegations are ultimately proven to be groundless, allegations against us could
severely impact the market price of our ADSs and our business operations.
If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market
price for our ADSs and trading volume could decline.
The
trading market for our ADSs will depend in part on the research and reports that securities or industry analysts publish about us or
our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who cover
us downgrade our ADSs or publish inaccurate or unfavourable research about our business, the market price for our ADSs would likely decline.
If one or more of these analyst’s cease coverage of our company or fail to publish reports on us regularly, we could lose visibility
in the financial markets, which, in turn, could cause the market price or trading volume of our ADSs to decline.
We
cannot assure you that our existing dividend policy will not change in the future or the amount the dividends that you may receive, and
as such, you must rely on price appreciation of our ADSs for return on your investment.
On
July 19, 2018, our board of directors approved an annual dividend policy. Under this policy, annual dividends will be set at an
amount equivalent to approximately 15-25% of our anticipated net income after tax in each year commencing from the fiscal year ended
March 31, 2019. On July 19, 2018, our board of directors also approved a special cash dividend of US$0.13 per ordinary
share of our company (or US$0.13 per ADS), in addition to an annual dividend pursuant to the newly adopted annual dividend policy of
US$0.27 per ordinary share (or US$0.27 per ADS), for a total dividend of US$0.40 per ordinary share (or US$0.40 per ADS). No dividends
have been declared or distributed since August 2018.
Our
annual dividend policy is subject to change at any time at the discretion of our board of directors, and our board of directors
has complete discretion as to whether to distribute dividends in the future. If our board of directors decides to continue to declare
and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of
operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries,
our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. As such, the amount of
dividends that you will receive is subject to change. In addition, there can be no assurance that we will not adjust our dividend policy
in the future. Accordingly, you should not rely on an investment in our ADSs as a source for any future dividend income, and the return
on your investment in our ADSs will likely depend entirely upon any future price appreciation of our ADSs. There is no guarantee that
our ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment
in our ADSs and you may even lose your entire investment.
Any
declaration and payment, as well as the amount, of dividends will be subject to our constitutional documents and applicable Chinese and
U.S. state and federal laws and regulations, including the approval from the shareholders of each subsidiary which intends to declare
such dividends, if applicable.
Substantial
future sales or perceived potential sales of our ADSs in the public market could cause the price of our ADSs to decline.
Sales
of our ADSs in the public market, or the perception that these sales could occur, could cause the market price of our ADSs to decline.
As of March 31, 2024, we had 437,170,960 ordinary shares outstanding. Among these shares, 42,341,432 ordinary shares are in the form
of ADSs. All our ADSs are freely transferable without restriction or additional registration under the Securities Act. The remaining
ordinary shares outstanding are available for sale, subject to volume and other restrictions as applicable under Rules 144 and 701 under
the Securities Act. To the extent shares are sold into the market, the market price of our ADSs could decline.
Certain
holders of our ordinary shares may cause us to register under the Securities Act the sale of their shares. Registration of these shares
under the Securities Act would result in ADSs representing these shares becoming freely tradable without restriction under the Securities
Act immediately upon the effectiveness of the registration. Sales of these registered shares in the form of ADSs in the public market
could cause the price of our ADSs to decline.
We
have adopted our 2023 Equity Incentive Plan which was approved by our shareholders at our 2023 annual general meeting of shareholders
held on June 19, 2023, under which we have the discretion to grant a broad range of equity-based awards to eligible participants. See
“Item 6. Directors, Senior Management and Employees—B. Compensation—Share Incentive Plan.” We have registered
certain ordinary shares that we may issue under our share incentive plans and intend to register all ordinary shares that we may issue
under our share incentive plans. Once we register these ordinary shares, they can be freely sold in the public market in the form of
ADSs upon issuance, subject to volume limitations applicable to affiliates and relevant lock-up agreements. If a large number of our
ordinary shares or securities convertible into our ordinary shares are sold in the public market in the form of ADSs after they become
eligible for sale, the sales could reduce the trading price of our ADSs and impede our ability to raise future capital. In addition,
any ordinary shares that we issue under our share incentive plans would dilute the percentage ownership held by the investors who purchased
ADSs.
We
may be classified as a passive foreign investment company for U.S. federal income tax purposes, which could result in adverse U.S. federal
income tax consequences to U.S. Holders of our ADSs or ordinary shares.
Depending
upon the value of our assets, which is determined in part by the market value of our ADSs or ordinary shares, and the composition of
our assets and income over time, we could be classified as a passive foreign investment company, or PFIC, for U.S. federal income
tax purposes. Based on the projected composition of our assets and income, we do not believe that we were a PFIC for our taxable year
ended March 31, 2024 and we do not anticipate becoming a PFIC in the foreseeable future. While we do not anticipate becoming
a PFIC, fluctuations in the market price of our ADSs or ordinary shares may cause us to become a PFIC for the current or any subsequent
taxable year.
A
non-U.S. corporation, such as our company, will be classified as a PFIC for U.S. federal income tax purposes for any taxable
year, if either (i) 75% or more of its gross income for such year consists of certain types of “passive” income or (ii) 50%
or more of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production
of passive income. Whether we are a PFIC is a factual determination and we must make a separate determination each taxable year as to
whether we are a PFIC (after the close of each taxable year). Accordingly, we cannot assure you that we will not be a PFIC for our taxable
year ending March 31, 2024 or any future taxable year.
If
we were to be classified as a PFIC for any taxable year during which a U.S. Holder (as defined in “Item 10. Additional
Information-E. Taxation-U.S. Federal Income Tax Considerations”) holds an ADS or an ordinary share, such U.S. Holder
would generally be subject to reporting requirements and might incur significantly increased U.S. federal income tax on gain recognized
on the sale or other disposition of the ADSs or ordinary shares and on the receipt of distributions on the ADSs or ordinary shares to
the extent such gain or distribution is treated as an “excess distribution” under the applicable U.S. federal income
tax rules. Further, if we were to be classified as a PFIC for any year during which a U.S. Holder holds our ADSs or ordinary shares,
we generally would continue to be treated as a PFIC for all succeeding years during which such U.S. Holder holds our ADSs or ordinary
shares even if we cease to qualify as a PFIC under the rules set forth above. You are urged to consult your tax advisor concerning
the U.S. federal income tax consequences of acquiring, holding, and disposing of ADSs or ordinary shares if we were to be classified
as a PFIC. For more information, see “Item 10. Additional Information—E. Taxation—U.S. Federal Income Tax
Considerations—PFIC Rules.”
The
second amended and restated memorandum and articles of association contain anti-takeover provisions that could have a material adverse
effect on the rights of holders of our ordinary shares and ADSs.
We
have adopted a second amended and restated memorandum and articles of association. Our second amended and restated memorandum and articles
of association contains provisions to limit the ability of others to acquire control of our company or cause us to engage in change-of-control
transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium
over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar
transaction. In addition, our board of directors has the authority, without further action by our shareholders, to issue preferred shares
in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special
rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption
and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares underlying the ADSs.
Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal
of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting
and other rights of the holders of our ordinary shares underlying the ADSs may be materially and adversely affected.
You
may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited,
because we are incorporated under Cayman Islands law.
We
are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed
by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands and the common law of the Cayman
Islands. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary duties of
our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of
the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common
law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The
rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they
would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has
a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed
and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have standing
to initiate a shareholder derivative action in a federal court of the United States.
Shareholders
of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records (other than
copies of the memorandum and articles, register of mortgages and charges and special resolutions passed by the shareholders) or to obtain
copies of register of members of these companies. Our directors have discretion under our articles of association to determine whether
or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available
to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a
shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.
Certain
corporate governance practices in the Cayman Islands, which is our home country, differ significantly from requirements for companies
incorporated in other jurisdictions such as the U.S. Currently, we rely on home country practices with respect to certain corporate
governance matters, please see “Item 16.G—Corporate Governance.” As a result, our shareholders may be afforded less
protection than they otherwise would under rules and regulations applicable to U.S. domestic issuers.
As
a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken
by our management, members of the board of directors or controlling shareholders than they would as public shareholders of a company
incorporated in the United States.
Certain
judgments obtained against us by our shareholders may not be enforceable.
We
are a Cayman Islands exempted company and substantially all of our assets are located outside of the United States. Substantially
all of our current operations are conducted in China. In addition, a majority of our current directors and officers are nationals and
residents of countries other than the United States. Substantially all of the assets of these persons are located outside the United States.
As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States
in the event that you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if
you are successful in bringing an action of this kind, the laws of the Cayman Islands and of China may render you unable to enforce a
judgment against our assets or the assets of our directors and officers.
There
is no statutory enforcement in the Cayman Islands of judgments obtained in the federal or state courts of the United States (and the
Cayman Islands are not a party to any treaties for the reciprocal enforcement or recognition of such judgments), a judgment obtained
in such jurisdiction will be recognized and enforced in the courts of the Cayman Islands at common law, without any re-examination of
the merits of the underlying dispute, by an action commenced on the foreign judgment debt in the Grand Court of the Cayman Islands, provided
such judgment (a) is given by a foreign court of competent jurisdiction, (b) imposes on the judgment debtor a liability to
pay a liquidated sum for which the judgment has been given, (c) is final and conclusive, (d) is not in respect of taxes, a
fine or a penalty, and (e) was not obtained in a manner and is not of a kind the enforcement of which is contrary to natural justice
or the public policy of the Cayman Islands. However, the Cayman Islands courts are unlikely to enforce a judgment obtained from the U.S.
courts under civil liability provisions of the U.S. federal securities law if such judgment is determined by the courts of the Cayman
Islands to give rise to obligations to make payments that are penal or punitive in nature. Because such a determination has not yet been
made by a court of the Cayman Islands, it is uncertain whether such civil liability judgments from U.S. courts would be enforceable in
the Cayman Islands.
The
recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce
foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the
country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other forms
of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition,
according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our director and officers
if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or public interest. As a
result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States.
We
are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions
applicable to United States domestic public companies.
Because
we are a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules and regulations
in the United States that are applicable to U.S. domestic issuers, including:
| ● | the
rules under the Exchange Act requiring the filing of quarterly reports on Form 10-Q
or current reports on Form 8-K with the SEC; |
| ● | the
sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations
in respect of a security registered under the Exchange Act; |
| ● | the
sections of the Exchange Act requiring insiders to file public reports of their stock ownership
and trading activities and liability for insiders who profit from trades made in a short
period of time; and |
| ● | the
selective disclosure rules by issuers of material non-public information under Regulation FD. |
We
are required to file an annual report on Form 20-F within four months of the end of each fiscal year. In addition, we intend to
publish our results periodically through press releases, distributed pursuant to the rules and regulations of the NASDAQ Global
Market. Press releases relating to financial results and material events will also be furnished to the SEC on Form 6-K. However,
the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to
be filed with the SEC by U.S. domestic issuers. As a result, you may not be afforded the same protections or information, which
would be made available to you, were you investing in a U.S. domestic issuer.
The
voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise any right to
vote the ordinary shares which are represented by your ADSs.
As
a holder of our ADSs, you will only be able to direct the exercise of the voting rights attaching to the ordinary shares which are represented
by your ADSs in accordance with the provisions of the deposit agreement. Under the deposit agreement, you must vote by giving voting
instructions to the depositary. Upon receipt of your voting instructions, the depositary will use its best endeavors to vote the ordinary
shares which are represented by your ADSs in accordance with your instructions. You will not be able to directly exercise any right to
vote with respect to the shares represented by your ADSs unless you withdraw the shares from the ADR facility prior to the applicable
share record date. Under our second amended and restated memorandum and articles of association, the minimum notice period required for
convening a general meeting is ten calendar days. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call
shareholders’ annual general meetings. Our second amended and restated memorandum and articles of association provide that we may,
but are not obliged to, in each year hold a general meeting as our annual general meeting. When a general meeting is convened, you may
not receive sufficient advance notice to withdraw the underlying shares represented by your ADSs to allow you to vote with respect to
any specific resolution or matter to be considered and voted upon at such general meeting. If we give notice to our shareholders of any
general meeting, the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We cannot
assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying shares
represented by your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions
or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to vote and
you may have no legal remedy if the underlying shares represented by your ADSs are not voted as you requested.
The
depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares represented by your ADSs if you do not give proper
or timely voting instructions to the depositary, except in limited circumstances, which could adversely affect your interests.
Under
the deposit agreement for the ADSs, if you do not give proper or timely voting instructions to the depositary, the depositary will give
us a discretionary proxy to vote the ordinary shares represented by your ADSs at shareholders’ meetings unless:
| ● | we
have failed to timely provide the depositary with notice of meeting and related voting materials; |
| ● | we
have instructed the depositary that we do not wish a discretionary proxy to be given; |
| ● | we
have informed the depositary that there is substantial opposition as to a matter to be voted
on at the meeting; |
| ● | a
matter to be voted on at the meeting would have a material adverse impact on shareholders; or |
| ● | the
voting at the meeting is to be made on a show of hands. |
The
effect of the foregoing is that if you do not give proper or timely voting instructions to the depositary as to how to vote at shareholders’
meetings, a discretionary proxy to vote the ordinary shares represented by your ADSs will be given to a person designated by us, except
under the circumstances described above. This may make it more difficult for shareholders and holders of ADSs to influence the management
of our company. Holders of our ordinary shares are not subject to this discretionary proxy.
You
may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them if it is illegal or
impracticable to make them available to you.
The
depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares
or other deposited securities which are represented by your ADSs, after deducting its fees and expenses. You will receive these distributions
in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it
is unlawful or impracticable to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution
to a holder of ADSs if it consists of securities that require registration under the Securities Act but that are not properly registered
or distributed under an applicable exemption from registration. The depositary may also determine that it is not practicable to distribute
certain property through the mail. Additionally, the value of certain distributions may be less than the cost of mailing them. In these
cases, the depositary may determine not to distribute such property. We have no obligation to register under U.S. securities laws
any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other
action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive
distributions we make on our ordinary shares or any value for them if it is illegal or impracticable for us to make them available to
you. These restrictions may cause a material decline in the value of our ADSs.
You
may experience dilution of your holdings due to inability to participate in rights offerings.
We
may, from time to time, distribute rights to our shareholders, including rights to acquire securities. Under the deposit agreement, the
depositary will not distribute rights to holders of ADSs unless the distribution and sale of rights and the securities to which these
rights relate are either exempt from registration under the Securities Act with respect to all holders of ADSs, or are registered under
the provisions of the Securities Act. The depositary may, but is not required to, attempt to sell these undistributed rights to third
parties, and may allow the rights to lapse. We may be unable to establish an exemption from registration under the Securities Act, and
we are under no obligation to file a registration statement with respect to these rights or underlying securities or to endeavour
to have a registration statement declared effective. Accordingly, holders of ADSs may be unable to participate in our rights offerings
and may experience dilution of their holdings as a result.
You
may be subject to limitations on transfer of your ADSs.
Your
ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when
it deems expedient in connection with the performance of its duties. The depositary may close its books from time to time for a number
of reasons, including in connection with corporate events such as a rights offering, during which time the depositary needs to maintain
an exact number of ADS holders on its books for a specified period. The depositary may also close its books in emergencies, or on weekends
and public holidays. The depositary may refuse to deliver, transfer or register transfers of our ADSs generally when our share register
or the books of the depositary are closed, or at any time if we or the depositary thinks it is advisable to do so because of any requirement
of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.
We
will incur significantly increased costs and devote substantial management time as a result of being a public company.
As
a public company, we incur additional legal, accounting and other expenses as a public reporting company. For example, we will be required
to comply with additional requirements of the rules and regulations of the SEC and requirements of the NASDAQ Global Market, including
applicable corporate governance practices. We expect that compliance with these requirements will increase our legal and financial compliance
costs and will make some activities more time-consuming and costlier. In addition, we expect that our management and other personnel
will need to divert attention from operational and other business matters to devote substantial time to these public company requirements.
We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
In
addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations
and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty
regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to
invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative
expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our
efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due
to ambiguities related to their application and practice, regulatory authorities may also initiate legal proceedings against us and our
business may be adversely affected.
In
the past, shareholders of public companies have often brought securities class action suits against those companies following periods
of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount
of our management’s attention and other resources from our business and operations and require us to incur significant expenses
to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our
reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be
required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.
USE OF PROCEEDS
Except as described in any
prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds
from the sale of the securities offered under this prospectus for working capital and general corporate purposes.
We have not determined the
amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the
allocation of the net proceeds and investors will be relying on the judgment of our management regarding the application of the proceeds
of any sale of the securities.
DILUTION
If required, we will set forth
in a prospectus supplement the following information regarding any material dilution of the equity interests of investors purchasing securities
in an offering under this prospectus:
| ● | the net tangible book value
per share of our equity securities before and after the offering; |
| ● | the
amount of the increase in such net tangible book value per share attributable to the cash
payments made by purchasers in the offering; and |
| ● | the
amount of the immediate dilution from the public offering price which will be absorbed by
such purchasers. |
DESCRIPTION OF SHARE CAPITAL
We are a Cayman Islands
exempted company with limited liability and our affairs are governed by our second amended and restated memorandum and articles of association,
the Companies Act (As Revised) of the Cayman Islands, which is referred to as the Companies Act below, and the common law of the Cayman
Islands.
As of the date of this
prospectus, our authorized share capital is US$500,000 divided into 5,000,000,000 ordinary shares of a par value of US$0.0001 each, comprising
(i) 4,500,000,000 Class A ordinary shares of a par value of US$0.0001 each and (ii) 500,000,000 Class B ordinary shares of a par value
of US$0.0001 each. As of the date of this prospectus, the Company has 1,188,483,130 Class A Ordinary Shares and 7,980,800 Class B Ordinary
Shares outstanding.
Our Memorandum and Articles of Association
The following are summaries
of material provisions of our currently effective second amended and restated memorandum and articles of association and the Companies
Act insofar as they relate to the material terms of our ordinary shares.
General Our authorized
share capital is US$500,000 divided into 5,000,000,000 ordinary shares of a par value of US$0.0001 each, comprising (i) 4,500,000,000
Class A ordinary shares of a par value of US$0.0001 each and (ii) 500,000,000 Class B ordinary shares of a par value of US$0.0001 each.
All of our issued and outstanding ordinary shares are fully paid and non-assessable. Our ordinary shares are issued in registered form,
and are issued when registered in our register of members. Our shareholders who are non-residents of the Cayman Islands may freely hold
and vote their ordinary shares. Under our second amended and restated memorandum and articles of association, our company may issue only
non-negotiable shares and may not issue bearer shares.
Dividends The holders
of our ordinary shares are entitled to such dividends as may be declared by our board of directors. In addition, our shareholders may
by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law,
our company may declare and pay a dividend only out of funds legally available therefor, namely out of either profit or our share premium
account, provided that in no circumstances may we pay a dividend if this would result in our company being unable to pay its debts as
they fall due in the ordinary course of business.
Voting Rights The
holders of Class A Ordinary Shares and Class B Ordinary Shares shall at all times vote together as one class on all resolutions submitted
to a vote by the Members. Subject to any rights or restrictions as to voting attached to any shares, unless any share carries special
voting rights, on a show of hands every shareholder who is present in person and every person representing a shareholder by proxy shall
have one vote per Class A Ordinary Share and one vote per Class B Ordinary Share. On a poll, every shareholder who is present in person
and every person representing a shareholder by proxy shall have one vote for each Class A Ordinary Share and twenty votes per Class B
Ordinary Share of which he or the person represented by proxy is the holder. Votes may be given either personally or by proxy.
At
any general meeting a resolution put to the vote of the meeting shall be decided by a show of hands unless a poll is demanded. A poll
may be demanded by the chairman of such meeting or any one or more shareholders who together hold not less than 10% of the votes attaching
to all issued and outstanding shares of our company entitled to vote at general meetings.
An
ordinary resolution to be passed by the shareholders requires the affirmative vote of a simple majority of the votes attached to the
ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special
resolution requires the affirmative vote of no less than two-thirds of the votes attached to the ordinary shares cast by those shareholders
entitled to vote who are present in person or by proxy at a general meeting. A special resolution is required for important matters such
as a change of name or any amendment to our memorandum and articles of association. Holders of our ordinary shares may effect certain
changes by ordinary resolution, including increasing the amount of our authorized share capital, consolidating all or any of our share
capital into shares of larger amount than our existing shares, sub-dividing our shares or any of them into shares of an amount smaller
than that fixed by our memorandum, and cancelling any unissued shares. Both ordinary resolution and special resolution may also be passed
by a unanimous written resolution signed by all the shareholders of our company, as permitted by the Companies Act and our second amended
and restated memorandum and articles of association.
General Meetings of
Shareholders and Shareholder Proposals As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders’
annual general meetings. Our second amended and restated memorandum and articles of association provide that we may, but are not obliged
to, in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting as such in the notices
calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors.
Shareholders’ annual
general meetings and any other general meetings of our shareholders may be convened by a majority of our board of directors or the chairman
of the board. Advance notice of at least ten calendar days is required for the convening of our annual general shareholders’ meeting
and any other general meeting of our shareholders. A quorum required for a general meeting of shareholders consists of one or more shareholders
present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative, who hold in aggregate
not less than one-third of the votes attaching to all issued and outstanding shares of our company entitled to vote at general meetings.
Cayman Islands law provides
shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal
before a general meeting. However, these rights may be provided in a company’s articles of association. Our second amended and
restated memorandum and articles of association allow any two or more of our shareholders holding in the aggregate not less than one-third
of the votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings, to requisition an extraordinary
general meeting of the shareholders, in which case our directors are obliged to call such meeting and to put the resolutions so requisitioned
to a vote at such meeting; however, our second amended and restated memorandum and articles of association do not provide our shareholders
with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders.
Transfer of Shares
Subject to the restrictions of our second amended and restated memorandum and articles of association set out below, as applicable,
any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or ordinary form
or any other form approved by our board of directors.
Our board of directors may,
in its sole discretion, decline to register any transfer of any ordinary share which is not fully paid up. Our directors may also decline
to register any transfer of any ordinary share unless (a) the instrument of transfer is lodged with us, accompanied by the certificate
for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right
of the transferor to make the transfer; (b) the instrument of transfer is properly stamped, if required; (c) in the case of a transfer
to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four; (d) the share to be
transferred is free of any lien in favor of us; (e) a fee of such maximum sum as NASDAQ may determine to be payable, or such lesser sum
as our board of directors may from time to time require, is paid to us in respect thereof; and (f) the instrument of transfer is in respect
of only one class of shares.
If our directors refuse to
register a transfer they shall, within two months after the date on which the instrument of transfer was lodged, send to each of the transferor
and the transferee notice of such refusal. The registration of transfers may, after compliance with any notice required of NASDAQ, be
suspended and our register of members closed at such times and for such periods as our board of directors may from time to time determine,
provided, however, that the registration of transfers shall not be suspended nor the register of members closed for more than 30 days
in any year as our board of directors may determine.
Conversion
Rights Each Class B Ordinary Share is convertible into one (1) Class A Ordinary Share at any time at the option of the holder
thereof. The right to convert shall be exercisable by the holder of the Class B Ordinary Share delivering a written notice to the Company
that such holder elects to convert a specified number of Class B Ordinary Shares into Class A Ordinary Shares. In no event shall Class
A Ordinary Shares be convertible into Class B Ordinary Shares.
All
conversions of Class B Ordinary Shares to Class A Ordinary Shares shall be effected by way of the re-designation of each relevant Class
B Ordinary Share as a Class A Ordinary Share.
Upon any direct or indirect
sale, transfer, assignment or disposition of the legal and beneficial title to any Class B Ordinary Share by the holder thereof or the
direct or indirect transfer or assignment of the voting power attached to such number of Class B Ordinary Shares through voting proxy
or otherwise to any person that is neither an affiliate of such holder nor another holder of Class B Ordinary Shares or an affiliate
of such another holder, such Class B Ordinary Share shall be automatically and immediately converted into the same number of Class A
Ordinary Share.
Liquidation
On a winding up of our company, if the assets available for distribution among our shareholders shall be more than sufficient to repay
the whole of the share capital at the commencement of the winding up, the surplus shall be distributed among our shareholders on a pro
rata basis in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from
those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets
available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are
borne by our shareholders in proportion to the par value of the shares held by them.
The
liquidator may, with the sanction of a special resolution of our shareholders, divide amongst the shareholders in species or in kind the
whole or any part of the assets of our company, and may for that purpose value any assets and determine how the division shall be carried
out as between our shareholders or different classes of shareholders.
We are a “limited liability”
company registered under the Companies Act, and under the Companies Act, the liability of our members is limited to the amount, if any,
unpaid on the shares respectively held by them. Our memorandum of association contains a declaration that the liability of our members
is so limited.
Calls on Shares and
Forfeiture of Shares Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their
ordinary shares in a notice served to such shareholders at least 14 days prior to the specified time and place of payment. The ordinary
shares that have been called upon and remain unpaid on the specified time are subject to forfeiture.
Redemption, Repurchase
and Surrender of Shares We may issue shares on terms that such shares are subject to redemption, at our option or at the option
of the holders, on such terms and in such manner as may be determined by our board of directors, before the issue of such shares, or by
a special resolution of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such
purchase have been approved by our board of directors or by ordinary resolution of our shareholders, or are otherwise authorized by our
memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company’s
profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including
share premium account and capital redemption reserve) if the company can, immediately following such payment, pay its debts as they fall
due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a) unless it
is fully paid up, (b) if such redemption or repurchase would result in there being no shares outstanding, or (c) if the company has commenced
liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.
Variations of Rights
of Shares If at any time, our share capital is divided into different classes of shares, all or any of the special rights attached
to any class of shares may be varied either with the written consent of the holders of two-thirds in nominal value of the issued shares
of that class, or with the sanction of a special resolution passed at a general meeting of the holders of shares of that class. The rights
conferred upon the holders of the shares of any class issued with preferred or other rights will not, unless otherwise expressly provided
by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking pari passu
with such existing class of shares.
Inspection of Books
and Records Holders of our ordinary shares will have no general right under Cayman Islands law to inspect or obtain copies of
our list of shareholders or our corporate records (other than our memorandum and articles of association, register of mortgages and charges,
and copies of special resolutions passed by our shareholders). However, at the discretion of our board of directors, we intend to provide
our shareholders with annual audited financial statements. See “Where You Can Find Additional Information.
Changes in Capital Our
shareholders may from time to time by ordinary resolution:
| ● | increase our share capital by
such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe; |
| ● | consolidate and divide all or
any of our share capital into shares of a larger amount than our existing shares |
| ● | sub-divide our existing shares,
or any of them into shares of a smaller amount, provided that in the subdivision the proportion between the amount paid and the amount,
if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; or |
| ● | cancel any shares that, at the
date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital
by the amount of the shares so cancelled. |
Our shareholders may, by special
resolution and subject to confirmation by the Grand Court of the Cayman Islands on an application by our company for an
order confirming such reduction, reduce our share capital and any capital redemption reserve in any manner authorized by law.
Issuance of Additional
Shares Our second amended and restated memorandum and articles of association authorizes our board of directors to issue additional
ordinary shares from time to time as our board of directors shall determine, to the extent there are available authorized but unissued
shares.
Our second amended and
restated memorandum and articles of association authorizes our board of directors to establish from time to time one or more series of
convertible redeemable preferred shares and to determine, with respect to any series of convertible redeemable preferred shares, the
terms and rights of that series, including:
| ● | designation of the series; |
| ● | the number of shares of the
series; |
| ● | the dividend rights, conversion
rights and voting rights; and |
| ● | the rights and terms of redemption
and liquidation preferences. |
The issuance of convertible
redeemable preferred shares may be used as an anti-takeover device without further action on the part of the shareholders. Issuance of
these shares may dilute the voting power of holders of ordinary shares.
Anti-Takeover Provisions
Some provisions of our second amended and restated memorandum and articles of association may discourage, delay or prevent a
change of control of our company or management that shareholders may consider favorable, including provisions that:
| ● | authorize our board of directors
to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such
preferred shares without any further vote or action by our shareholders; and |
| ● | limit the ability of shareholders
to requisition and convene general meetings of shareholders. |
However, under Cayman
Islands law, our directors may only exercise the rights and powers granted to them under our second amended and restated memorandum and
articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company.
Exempted Company We
are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies
and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands
may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary
company except that an exempted company:
| ● | does not have to file an annual
return of its shareholders with the Registrar of Companies; |
| ● | is not required to open its
register of members for inspection; |
| ● | does not have to hold an annual
general meeting; |
| ● | may issue negotiable or bearer
shares or shares with no par value; |
| ● | may obtain an undertaking against
the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance); |
| ● | may register by way of continuation
in another jurisdiction and be deregistered in the Cayman Islands; |
| ● | may register as a limited duration
company; and |
| ● | may register as a segregated
portfolio company. |
Limited liability”
means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except
in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose
or other circumstances in which a court may be prepared to pierce or lift the corporate veil). Our second amended and restated memorandum
and articles of association contains a declaration that the liability of our members is so limited.
Register of Members
Under the Companies Act, we must keep a register of members and there should be entered therein:
| ● | the names and addresses of our
members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of each
member, whether each class of shares held by a member carries voting rights under our articles of association, and if so, whether such
voting rights are conditional; |
| ● | the date on which the name of
any person was entered on the register as a member; and |
| ● | the date on which any person
ceased to be a member. |
Under Cayman Islands law,
the register of members of our company is prima facie evidence of the matters set out therein (i.e. the register of members will raise
a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as
a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members. Upon the completion
of this offering, our company’s register of members will be immediately updated to record and give effect to the issue of ordinary
shares by us to the custodian (or its nominee) as the custodian. Once our register of members has been updated, the shareholders recorded
in the register of members will be deemed to have legal title to the shares set against their name in the register of members.
If the name of any person
is incorrectly entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the
register the fact of any person having ceased to be a member of our company, the person or member aggrieved (or any member of our company
or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may
either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register.
Differences
in Corporate Law
The Companies Act is derived,
to a large extent, from the older Companies Acts of England, but does not follow recent United Kingdom statutory enactments, and accordingly
there are significant differences between the Companies Act and the current Companies Act of England. In addition, the Companies Act differs
from laws applicable to United States corporations and their shareholders. Set forth below is a summary of certain significant differences
between the provisions of the Companies Act applicable to us and the comparable provisions of the laws applicable to companies incorporated
in the State of Delaware and their shareholders.
Mergers and Similar
Arrangements The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands
companies and non-Cayman Islands companies. For these purposes, (a) “merger” means the merging of two or more constituent
companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company and (b) a “consolidation”
means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and
liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent
company must approve a written plan of merger or consolidation, which must then be authorized by (i) a special resolution of the shareholders
of each constituent company and (ii) such other authorization, if any, as may be specified in such constituent company’s articles
of association. The written plan of merger or consolidation must be filed with the Registrar of Companies together with a declaration
as to the solvency of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking
that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that
notification of the merger will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation
effected in compliance with these statutory procedures.
A merger between a Cayman
parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman
subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise.
For this purpose a company is a “parent” of a subsidiary if it holds issued shares that together represent at least 90% of
the votes at a general meeting of the subsidiary.
The consent of each holder
of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman
Islands.
Save in certain limited circumstances,
a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of
his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or
consolidation, provided that the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise
of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be
entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.
Separate from the statutory
provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction
and amalgamation of companies, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors
with whom the arrangement is to be made, and who must, in addition, represent three-fourths in value of each such class of shareholders
or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that
purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While
a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be
expected to approve the arrangement if it determines that:
| ● | the statutory provisions as
to the required majority vote have been met; |
| ● | the shareholders have been fairly
represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests
adverse to those of the class; |
| ● | the arrangement is such that
may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and |
| ● | the arrangement is not one that
would more properly be sanctioned under some other provision of the Companies Act. |
The Companies Act also contains
a statutory power of compulsory acquisition which may facilitate the “squeeze out” of dissentient minority shareholder upon
a tender offer. When a take-over offer is made and accepted by holders of 90.0% of the shares affected (within four months after the offer),
the offeror may, within a two-month period commencing on the expiration of such four months period, require the holders of the remaining
shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is
unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.
If an arrangement and reconstruction
is thus approved, the dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be
available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined
value of the shares.
Shareholders’
Suits In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule
a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood
be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to apply and follow common law principles
(namely the rule in Foss v Harbottle and the expectations thereto) that a non-controlling shareholder may be permitted to commence a class
action against the company or a derivative action in the name of the company to challenge certain acts, including the following:
| ● | an act which is ultra vires
or illegal and is therefore incapable of ratification by the shareholders; |
| ● | an act which, although not ultra
vires, could only be effected if duly authorized by a resolution with a qualified or special majority (i.e., more than a simple majority)
that has not been obtained; and |
| ● | an act which constitutes a “fraud
on the minority” where the wrongdoers are themselves in control of the company. |
Indemnification of Directors
and Executive Officers and Limitation of Liability Cayman Islands law does not limit the extent to which a company’s memorandum
and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be
held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences
of committing a crime.
Our second amended and
restated memorandum and articles of association provide that our directors and officers shall be indemnified and secured harmless against
all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such director or officer,
other than by reason of such person’s own dishonesty, willful default or fraud, in or about the conduct of our company’s
business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities
or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by
such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs
in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware
General Corporation Law for a Delaware corporation. In addition, we intend to enter into indemnification agreements with our directors
and senior executive officers that will provide such persons with additional indemnification beyond that provided in our second amended
and restated memorandum and articles of association.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing
provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.
Directors’ Fiduciary
Duties Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders.
This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with
the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself
of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty
requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must
not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that
the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling
shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed
basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption
may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by
a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.
As a matter of Cayman Islands
law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered
that he owes the following duties to the company—a duty to act bona fide in the best interests of the company, a duty not to make
a profit based on his or her position as director (unless the company permits him to do so), a duty not to put himself in a position where
the interests of the company conflict with his or her personal interest or his or her duty to a third party and a duty to exercise powers
for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill
and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree of skill
than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved
towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman
Islands.
Shareholder Action
by Written Consent Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by
written consent by amendment to its certificate of incorporation. As permitted by Cayman Islands law, our second amended and restated
memorandum and articles of association provide that our shareholders may approve corporate matters by way of a unanimous written resolution
signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting
being held.
Shareholder Proposals
Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders,
provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors
or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.
Cayman Islands law provides
shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal
before a general meeting. However, these rights may be provided in a company’s articles of association. Our second amended and
restated memorandum and articles of association allow any two or more of our shareholders holding in the aggregate not less than one-third
of the votes attaching to all issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary
meeting of the shareholders, in which case the directors are obliged to call such meeting and to put the resolutions so requisitioned
to a vote at such meeting. However, our second amended and restated memorandum and articles of association do not provide our shareholders
with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders.
As an exempted Cayman
Islands company, we are not obliged by law to call shareholders’ annual general meetings. Our second amended and restated memorandum
and articles of association provides that we may in each year to hold a general meeting as our annual general meeting, and to specify
the meeting as such in the notice calling it.
Cumulative Voting
Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation’s
certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders
on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single
director, which increases the shareholder’s voting power with respect to electing such director. There are no prohibitions in relation
to cumulative voting under Cayman Islands law, but our second amended and restated memorandum and articles of association do not provide
for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders
of a Delaware corporation.
Removal of Directors
Under the Delaware General Corporation Law, a director of a corporation with a classified board of directors may be removed only
for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides
otherwise. Under our second amended and restated memorandum and articles of association, directors may be removed by ordinary resolution
of our shareholders.
Transactions with Interested
Shareholders The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations
whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation,
it is prohibited from engaging in certain business combinations with an “interested shareholder” for three years following
the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns
or owned 15% or more of the target’s outstanding voting stock within the past three years. This has the effect of limiting the ability
of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does
not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors
approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages
any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target’s board of
directors.
Cayman Islands law has no
comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute.
However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide
that such transactions must be entered into bona fide in the best interests of the company, for a proper corporate purpose and not with
the effect of constituting a fraud on the minority shareholders.
Dissolution; Winding
up Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must
be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board
of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation
to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board
of directors. Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special
resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The
court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just
and equitable to do so.
Under the Companies Act of
the Cayman Islands, our company may be dissolved, liquidated or wound up voluntarily by a special resolution, or by an ordinary resolution
on the basis that we are unable to pay our debts as they fall due.
Variation of Rights
of Shares Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval
of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under our second amended
and restated memorandum and articles of association, and as permitted by Cayman Islands law, if our share capital is divided into more
than one class of shares, we may vary the rights attached to any class either with the written consent of the holders of two-thirds in
nominal value of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders
of the shares of that class.
Amendment of Governing
Documents Under the Delaware General Corporation Law, a corporation’s governing documents may be amended with the approval
of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under Cayman Islands
law, our second amended and restated memorandum and articles of association may only be amended by special resolution of our shareholders.
Inspection of Books
and Records Under the Delaware General Corporation Law, any shareholder of a corporation may for any proper purpose inspect or
make copies of the corporation’s stock ledger, list of shareholders and other books and records.
Holders
of our shares will have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate
records (other than our memorandum and articles of association, register of mortgages and charges, and copies of special resolutions passed
by our shareholders). However, we intend to provide our shareholders with annual reports containing audited financial statements.
Anti-takeover Provisions
in Our Memorandum and Articles of Association Some provisions of our second amended and restated memorandum and articles of association
may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including
a provision that authorizes our board of directors to issue preference shares in one or more series and to designate the price, rights,
preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders.
Such shares could be issued
quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If
our board of directors decides to issue these preference shares, the price of our ADSs may fall and the voting and other rights of the
holders of our ordinary shares underlying the ADSs may be materially and adversely affected.
However,
under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our second amended and restated
memorandum and articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our
company.
Rights of Non-resident
or Foreign Shareholders There are no limitations imposed by our second amended and restated memorandum and articles of association
on the rights of non-resident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions
in our second amended and restated memorandum and articles of association governing the ownership threshold above which shareholder ownership
must be disclosed.
DESCRIPTION OF AMERICAN
DEPOSITARY SHARES
American
depositary shares
The
name of the depositary is Citibank, N.A. The depositary’s office is located at 388 Greenwich Street, 23rd Floor, New York, New York
10013 USA. American Depositary Shares are frequently referred to as “ADSs” and represent ownership interests in securities
that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as “American Depositary
Receipts” or “ADRs.” The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this
case, the custodian is Citibank, N.A.—Hong Kong, located at 9/F, Citi Tower, One Bay East, 83 Hoi Bun Road, Kwun Tong, Kowloon,
Hong Kong.
Each
ADS represents the right to receive and to exercise the beneficial ownership interests in three ordinary shares that are on deposit with
the depositary bank and/or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other
property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners
of ADSs because of legal restrictions or practical considerations.
If
you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound by its terms and to the terms
of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and
obligations as owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to act on your behalf
in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of
the ordinary shares will continue to be governed by the laws of the Cayman Islands, which may be different from the laws of the United
States.
In
addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain
circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary
bank, the custodian, us, or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your
behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.
We
will not treat ADS holders as our shareholders and accordingly, you, as an ADS holder, will not have shareholder rights. The depositary
bank will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs, you will
be able to exercise the shareholder rights for the ordinary shares represented by your ADSs through the depositary bank only to the extent
contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS
owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.
The
registration of the ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable
law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership
and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares.
The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property,
in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property.
The
following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire
deposit agreement and the amendments thereto and the form of American Depositary Receipt. This summary does not purport to be complete
and is subject to and qualified in its entirety by our Form F-6 and its amendments, as filed on October 16, 2017 and August 10, 2020 (File
No.333-220966). For directions on how to obtain copies of those documents, see “Where You Can Find Additional Information”
in our prospectus.
Holding
the ADSs
How
will you hold your ADSs?
As
an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account,
or through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly on the
books of the depositary bank (common referred to as the “direct registration system” or “DRS”). The direct registration
system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration
system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration
system includes automated transfers between the depositary bank and the Depository Trust Company (“DTC”), the central book-entry
clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping
account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities
such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement system may limit
your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning
these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description
assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the “holder”.
When we refer to “you”, we assume the reader owns ADSs and will own ADSs at the relevant time.
Dividends
and Other Distributions
How
will you receive dividends and other distributions on the ordinary shares?
As
a holder of ADSs, you generally have the right to receive distributions we make on the securities deposited with the custodian. Your receipt
of these distributions may be limited, however, by practical considerations and legal limitations. You will receive these distributions
in proportion to the number of ordinary shares your ADSs represent as of the record date (which will be as close as practicable to the
record date for our ordinary shares) set by the depositary with respect to the ADSs, after deduction of the applicable fees, taxes, and
expenses.
| ● | Cash. The depositary
will convert any cash dividend or other cash distribution we pay on the ordinary shares or any net proceeds from the sale of any ordinary
shares, rights, securities or other entitlements into U.S. dollars if it can do so on a practicable basis, and can transfer the U.S.
dollars to the United States. If that is not practical or lawful or if any government approval is needed and cannot be obtained, the
deposit agreement allows the depositary either to distribute the foreign currency to the ADS holders or to hold the foreign currency
for the account of the ADS holders, in which case it will not invest the foreign currency and it will not be liable for any interest.
Before making a distribution, any taxes or other governmental charges, together with fees and expenses of the depositary, that must be
paid, will be deducted. See “Description of American Depositary Shares—Fees and Expenses” and “Description of
American Depositary Shares—Payment of Taxes” in our prospectus. It will distribute only such amount as can be distributed
without attributing to any holder a fraction of one cent, and any balance not so distributed shall be held by the depositary (without
liability for interest thereon) and shall be added to and become part of the next sum received by the depositary for distribution to
holders of ADSs outstanding at the time of the next distribution. If the exchange rates fluctuate during a time when the depositary cannot
convert the foreign currency, you may lose some or all of the value of the distribution. |
| ● | Shares. The depositary
may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary will
only distribute whole ADSs. It will sell any ordinary shares that would require it to deliver a fractional ADS and distribute the net
proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will, to the
extent permissible by law, also represent the new ordinary shares. The depositary may sell all or a portion of the ordinary shares that
it has not distributed, and distribute the net proceeds in the same way as it does with cash. Additionally, the depositary may sell a
portion of the distributed ordinary shares sufficient to pay its fees and expenses, and any taxes and governmental charges, in connection
with that distribution. |
| ● | Elective Distributions
in Cash or Shares. If we offer holders of our ordinary shares the option to receive dividends in either cash or shares, the depositary,
after consultation with us and having received timely notice as described in the deposit agreement of such elective distribution by us,
will determine to what extent such elective distribution will be made available to you as a holder of the ADSs. We must first instruct
the depositary to make such elective distribution available to you and furnish it with satisfactory evidence that it is legal to do so.
The depositary could decide it is not legal or reasonably practical to make such elective distribution available to you. In such case,
the depositary shall, on the basis of the same determination as is made in respect of the ordinary shares for which no election is made,
distribute either cash, in the same way as it does in a cash distribution, or additional ADSs representing ordinary shares, in the same
way as it does in a share distribution. The depositary is not obligated to make available to you a method to receive the elective dividend
in shares rather than in ADSs. You may not be given the opportunity to receive elective distributions on the same terms and conditions
as the holders of our ordinary shares. |
| ● | Rights to Subscribe for
Additional Shares. If we offer holders of our ordinary shares any rights to subscribe for additional shares or any other rights,
the depositary may after consultation with us and having received timely notice as described in the deposit agreement of such distribution
by us, make these rights available to you. We must first instruct the depositary to make such rights available to you and furnish the
depositary with satisfactory evidence that it is legal to do so. If the depositary decides it is not legal and practicable to make the
rights available, or if rights have been made available but have not been exercised and appear to be about to lapse, the depositary may,
if it determines it is lawful and practicable to do so, endeavor to sell the rights and distribute the net proceeds, in the same way
as it does with cash. If the depositary is not able to distribute the rights or arrange for their sale, it will allow such rights that
are not distributed or sold to lapse. In that case, you will receive no value for them. If the depositary makes rights available to you,
it will exercise the rights and purchase the shares on your behalf. The depositary will then deposit the shares and deliver ADSs to you.
It will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay. The depositary will
sell shares that would require it to deliver a fractional ADS and distribute the net proceeds in the same way as it does with cash. |
The
depositary may sell a portion of the distributed rights sufficient to pay its fees and expenses, and any taxes and governmental charges,
in connection with that distribution.
You
may not be given the opportunity to exercise rights on the same terms and conditions as the holders of ordinary shares or be able to exercise
such rights.
U.S.
securities laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For example,
you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted depositary shares
that have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.
The
depositary bank is under no obligation to make available to you a method of exercising your rights to subscribe for Shares (rather than
ADSs).
| ● | Other Distributions.
Subject to receipt of timely notice, as described in the deposit agreement, from us with the request to make any such distribution available
to you, and provided the depositary has determined such distribution is lawful and reasonably practicable and in accordance with the
terms of the deposit agreement, the depositary will send to you anything else we distribute on deposited securities by any means it thinks
is practicable. If the depositary cannot make a distribution in this way, it may endeavor to sell what we distributed and distribute
the net proceeds in the same way as it does with cash. If the depositary is unable to sell what we distribute, it may dispose of such
property in any way it deems reasonably practicable under the circumstances for nominal or no consideration. The depositary may sell
a portion of the distributed securities or property sufficient to pay its fees and expenses and any taxes and governmental charges in
connection with that distribution. |
| ● | Redemption. Whenever
we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable
and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption
to the holders. |
The
custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary
bank will convert the redemption funds into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable
holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees,
expenses, taxes, and other governmental charges upon the redemption of your ADSs. If less than all of the ADSs are being redeemed, the
ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary bank may determine.
The
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We
have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any
other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the
distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.
Changes
Affecting Ordinary Shares
The
ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value,
split-up, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger,
consolidation or sale of assets of the Company.
If
any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver
new ADSs to you, amend the deposit agreement, the applicable ADRs and the applicable Registration Statement(s) on Form F-6, call for the
exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting
the ordinary shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and distribute
the net proceeds to you as in the case of a cash distribution.
Deposit,
Withdrawal and Cancellation
How
are ADSs issued?
The
depositary may create ADSs on your behalf if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares
with the custodian or its nominee. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer
taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon
the order of the person or persons entitled thereto. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and
Cayman Islands legal considerations applicable at the time of deposit
When
you make a deposit of the ordinary shares, you will be responsible for transferring good and valid title to the depositary bank. As such,
you will be deemed to represent and warrant that:
| ● | The ordinary shares are duly
authorized, validly issued, fully paid, non-assessable, and legally obtained. |
| ● | All preemptive (and similar)
rights, if any, with respect to such ordinary shares have been validly waived or exercised. |
| ● | You are duly authorized to deposit
the ordinary shares. |
| ● | The ordinary shares presented
for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage, or adverse claim, and are not, and the
ADSs issuable upon such deposit will not be, “restricted securities” (as defined in the deposit agreement). |
| ● | The ordinary shares presented
for deposit have not been stripped of any rights or entitlements. |
If
any of the representations or warranties is incorrect in any way, we and the depositary bank may, at your cost and expense, take any and
all actions necessary to correct the consequences of the misrepresentations
How
do ADS holders cancel an American Depositary Share and Receive the Ordinary Shares(s) Underlying such ADS?
As
a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number
of underlying ordinary shares at the custodian’s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs
may be limited by U.S. and Cayman Islands considerations applicable at the time of withdrawal. Upon payment of its fees and expenses
and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the ordinary shares and
any other deposited securities underlying the ADSs to you or a person you designate, subject to the terms and conditions of the deposit
agreement, of the ADRs evidencing the ADSs so cancelled, our second amended and restated memorandum and articles of association, and
of any applicable laws and regulations of the DTC, and the terms and conditions of or governing the deposited securities. The depositary
may make delivery of any cash distributions, dividends, or proceeds in respect of deposited securities represented by ADSs surrendered
for cancellation and withdrawal, at its principal office. At your request, risk and expense, the depositary will deliver any deposited
property (other than deposited securities) held by the Custodian in respect of such ADSs at its principal office, if practicable and
not illegal.
If
you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and
such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of ordinary shares represented
by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all pplicable laws and regulations.
Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit.
You
have the right to cancel your ADSs and withdraw the underlying ordinary shares at any time except in the following instances:
| ● | when temporary delays arise
because: (1) the depositary has closed its transfer books or we have closed our transfer books; (2) the transfer of ordinary shares is
blocked to permit voting at a shareholders’ meeting; or (3) we are paying a dividend on our ordinary shares; |
| ● | when you owe money to pay fees,
taxes and similar charges; or |
| ● | when it is necessary to prohibit
withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or
other deposited securities. |
| ● | other circumstances specifically
contemplated by Instruction I.A(1) of the General Instructions to Form F-6 (as such General Instructions may be amended from time to
time). |
The
deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory
provisions of law.
How
do ADS holders interchange between Certificated ADSs and Uncertificated ADSs?
You
may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. Upon payment of applicable fees
and expenses and if permitted by law, the depositary will cancel that ADR and will send you a statement confirming that you are the owner
of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a holder of uncertificated ADSs requesting
the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs.
Voting
Rights
How
do you vote?
As
a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in “Description of Share
Capital” in the prospectus.
At
our request, the depositary bank will distribute to you any notice of shareholders’ meeting received from us together with information
explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs.
If
the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by
proxy) represented by the holder’s ADSs in accordance with the voting instructions received from the holders of ADSs as follows:
| ● | In the event of voting by
show of hands, the depositary bank will vote (or cause the custodian to vote) all ordinary shares held on deposit at that time in
accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. |
| ● | In the event of voting by
poll, the depositary bank will vote (or cause the custodian to vote) the ordinary shares held on deposit in accordance with the voting
instructions received from the holders of ADSs. |
In
the event of voting by poll, holders of ADSs in respect of which no timely voting instructions have been received shall be deemed to have
instructed the depositary to give a discretionary proxy to a person designated by us to vote the ordinary shares represented by such holders’
ADSs; provided, that no such instructions shall be deemed given and no such discretionary proxy shall be given with respect to any matter
as to which we inform the depositary that we do not wish such proxy to be given; provided, further, that no such discretionary proxy shall
be given (x) with respect to any matter as to which we inform the depositary that (i) there exists substantial opposition, or (ii) the
rights of holders of ADSs or the shareholders of our company will be materially adversely affected, and (y) in the event that the vote
is on a show of hands.
Please
note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the
terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting
instructions to the depositary bank in a timely manner.
Payment
of Taxes
You
will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any
of your ADSs. The depositary may refuse to register any transfer your ADSs or allow you to withdraw the deposited securities represented
by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by
your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will,
if appropriate, reduce the number of ADSs to reflect the sale and pay to you any net proceeds, or send to you any property, remaining
after it has paid the taxes. You agree to indemnify us, the depositary, the custodian and each of our and their respective agents, directors,
employees and affiliates for, and hold each of them harmless from, any claims with respect to taxes (including applicable interest and
penalties thereon) arising from any refund of taxes, reduced rate or withholding or other tax benefit obtained for you and any claims
by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced
rate withholding at source or other tax benefit obtained.
Reclassifications,
Recapitalizations and Mergers
If we: |
|
Then: |
● |
Change the par value of our ordinary shares |
|
● |
The cash, shares or other securities received by the depositary will become deposited securities, to the extent permitted by law, and each ADS will automatically represent its equal share of the new deposited securities. |
|
|
|
|
|
● |
Reclassify, split up, subdivide or consolidate any of the deposited securities |
|
● |
The depositary may deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. |
|
|
|
|
|
● |
Distribute securities on the ordinary shares that are not distributed to you |
|
● |
If any securities received by the depositary may not be lawfully distributed to some or all holders of ADSs, the depositary may sell such securities and distribute the net proceeds in the same way it does cash. |
Amendment
and Termination
How
may the deposit agreement be amended?
We
may agree with the depositary to amend the deposit agreement and the form of ADR without your consent for any reason. If an amendment
adds or increases fees or charges (except for taxes and other governmental charges or expenses of the depositary for registration fees,
facsimile costs, delivery charges or similar items, including expenses incurred in connection with foreign exchange control regulations)
or materially prejudices a substantial existing right of ADS holders, it will not become effective for outstanding ADSs until 30 days
after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing
to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended. If any new laws are adopted
that would require the deposit agreement to be amended in order to comply therewith, we and the depositary may amend the deposit agreement
in accordance with such laws and such amendment may become effective before notice thereof is given to ADS holders.
How
may the deposit agreement be terminated?
The
depositary will terminate the deposit agreement if we ask it to do so, in which case the depositary will give notice to you at least 30
days prior to termination. The depositary may also terminate the deposit agreement if the depositary has told us that it would like to
resign, or if we have removed the depositary, and in either case we have not appointed a new depositary within 90 days. In either such
case, the depositary must notify you at least 30 days before termination.
After
termination, the depositary and its agents will do the following under the deposit agreement but nothing else:
|
● |
Collect distributions on the deposited securities. |
|
● |
Sell rights and other property. |
|
● |
Deliver ordinary shares and other deposited securities upon cancellation of ADSs after payment of any fees, charges, taxes or other governmental charges. At any time after termination, the depositary may sell any remaining deposited securities by public or private sale. |
After
that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement,
for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability for
interest. The depositary’s only obligations will be to account for the money and other cash. After termination, our only obligations
under the deposit agreement will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay.
Books
of Depositary
The
depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business
hours but solely for the purpose of communicating with other holders in the interest of the business of our company or matters relating
to the ADSs or the deposit agreement.
The
depositary will maintain facilities in the Borough of Manhattan, the City of New York to record and process the issuance, cancellation,
combination, split-up and transfer of ADRs. The depositary may close the transfer books with respect to the ADSs at any time or from time
to time, when deemed necessary or advisable by it in good faith in connection with the performance of its duties hereunder, or at the
reasonable written request of us, subject to the depositary’s compliance with U.S. securities laws.
Limitations
on Obligations and Liability
Limits
on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs
The
deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability
of the depositary as follows:
|
● |
We and the depositary are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith. |
|
● |
We and the depositary are not liable if either of us is prevented
or delayed by law or circumstances beyond our control from performing our obligations under the deposit agreement, including, without
limitation, requirements of any present or future law, regulation, governmental or regulatory authority or share exchange of any
applicable jurisdiction, any present or future provisions of our second amended and restated memorandum and articles of association,
on account of possible civil or criminal penalties or restraint, any provisions of or governing the deposited securities or any act
of God, war or other circumstances beyond our control as set forth in the deposit agreement. |
|
● |
We and the depositary are not liable if either of us exercises, or fails to exercise, discretion permitted under the deposit agreement. |
|
● |
We and the depositary are not liable for the inability of any holder of ADSs to benefit from any distribution, offering, right or other benefit made available to holders of deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement. |
|
● |
We and the depositary have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other party if in our or the depositary’s opinion such proceeding may involve us or the depositary in expense or liability, unless satisfactory indemnity against all expenses and liabilities is furnished as often as may be required. |
|
● |
We and the depositary may rely upon any documents we believe in good faith to be genuine and to have been signed or presented by the proper party. |
|
● |
We and the depositary disclaim any liability for any action/inaction in reliance on the advice or information of legal counsel, accountants, any person presenting ordinary shares for deposit, holders and beneficial owners (or authorized representatives) of ADSs, or any other person believed in good faith to be competent to give such advice or information. We and the depositary disclaim any liability for any consequential or punitive damages (including lost profits) for any breach of the terms of the deposit agreement or otherwise. |
|
● |
The holders and the beneficial owners are responsible for the taxes payable or in connection with the ownership of ADSs, ordinary shares or deposited securities. |
The
depositary and any of its agents also disclaim any liability for any of the following:
|
● |
A failure to carry out any instructions to vote, the manner in which any vote is cast or the effect of any vote, provided that any such action or omission is in good faith and without negligence in accordance with the deposit agreement. |
|
● |
The manner in which any vote is cast. |
|
● |
The effect of any vote. |
|
● |
A failure to accurately determine that any distribution or action may be lawful or reasonably practicable or for allowing any rights to lapse in accordance with the provisions of the deposit agreement. |
|
● |
A failure or timeliness of any notice from us, the content of any information submitted to it by us for distribution to you or for any inaccuracy of any translation thereof. |
|
● |
Any investment risk associated with the acquisition of an interest in the deposited securities. |
|
● |
The validity or worth of the deposited securities. |
|
● |
The credit-worthiness of any third party. |
|
● |
Allowing any rights to lapse under the terms of the deposit agreement. |
|
● |
Any action or failure to act by, or any information provided or not provided by, DTC or any DTC participant. |
The
depositary and its agents shall not be liable for any acts or omissions made by a successor depositary, provided that in connection with
any issue out of which a potential liability arises the depositary performed its obligations without negligence or bad faith while it
acted as depositary.
In
addition, the deposit agreement provides that each party to the deposit agreement (including each holder, beneficial owner and holder
of interests in the ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury
in any lawsuit or proceeding against the depositary or our company related to our shares, the ADSs or the deposit agreement.
In
the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.
Foreign
Currency Conversion
The
depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical and
it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred
in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental
requirements.
If
the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable
cost or within a reasonable period, the depositary bank may take the following actions in its discretion:
|
● |
Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical. |
|
● |
Distribute the foreign currency to holders for whom the distribution is lawful and practical. |
|
● |
Hold the foreign currency (without liability for interest) for the applicable holders. |
Governing
Law/Waiver of Jury Trial
The
deposit agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of the
ordinary shares (including the ordinary shares represented by ADSs) is governed by the laws of the Cayman Islands.
DESCRIPTION OF DEBT
SECURITIES
As used in this prospectus,
the term “debt securities” means the debentures, notes, bonds and other evidences of indebtedness that we may issue from time
to time. The debt securities will either be senior debt securities, senior subordinated debt or subordinated debt securities. We may also
issue convertible debt securities. Debt securities issued under an indenture (which we refer to herein as an Indenture) will be entered
into between us and a trustee to be named therein. It is likely that convertible debt securities will not be issued under an Indenture.
The Indenture or forms of
Indentures, if any, will be filed as exhibits to the registration statement of which this prospectus is a part.
As you read this section,
please remember that for each series of debt securities, the specific terms of your debt security as described in the applicable prospectus
supplement will supplement and, if applicable, may modify or replace the general terms described in the summary below. The statement we
make in this section may not apply to your debt security.
Events of Default Under the Indenture
Unless we provide otherwise
in the prospectus supplement or free writing prospectus applicable to a particular series of debt securities, the following are events
of default under the indentures with respect to any series of debt securities that we may issue:
|
● |
if we fail to pay the principal or premium, if any, when due and payable at maturity, upon redemption or repurchase or otherwise; |
|
● |
if we fail to pay interest when due and payable and our failure continues for certain days; |
|
● |
if we fail to observe or perform any other covenant contained in the Securities of a Series or in this Indenture, and our failure continues for certain days after we receive written notice from the trustee or holders of at least certain percentage in aggregate principal amount of the outstanding debt securities of the applicable series. The written notice must specify the Default, demand that it be remedied and state that the notice is a “Notice of Default”; |
|
● |
if specified events of bankruptcy, insolvency or reorganization occur; and |
|
● |
if any other event of default provided with respect to securities of that series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officers’ Certificate as defined in the Form of Indenture. |
We covenant in the Form of
Indenture to deliver a certificate to the trustee annually, within certain days after the close of the fiscal year, to show that we are
in compliance with the terms of the indenture and that we have not defaulted under the indenture.
Nonetheless, if we issue debt
securities, the terms of the debt securities and the final form of indenture will be provided in a prospectus supplement. Please refer
to the prospectus supplement and the form of indenture attached thereto for the terms and conditions of the offered debt securities. The
terms and conditions may or may not include whether or not we must furnish periodic evidence showing that an event of default does not
exist or that we are in compliance with the terms of the indenture.
The statements and descriptions
in this prospectus or in any prospectus supplement regarding provisions of the Indentures and debt securities are summaries thereof, do
not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of the Indentures
(and any amendments or supplements we may enter into from time to time which are permitted under each Indenture) and the debt securities,
including the definitions therein of certain terms.
General
Unless otherwise specified
in a prospectus supplement, the debt securities will be direct secured or unsecured obligations of our company. The senior debt securities
will rank equally with any of our other unsecured senior and unsubordinated debt. The subordinated debt securities will be subordinate
and junior in right of payment to any senior indebtedness.
We may issue debt securities
from time to time in one or more series, in each case with the same or various maturities, at par or at a discount. Unless indicated in
a prospectus supplement, we may issue additional debt securities of a particular series without the consent of the holders of the debt
securities of such series outstanding at the time of the issuance. Any such additional debt securities, together with all other outstanding
debt securities of that series, will constitute a single series of debt securities under the applicable Indenture and will be equal in
ranking.
Should an indenture relate
to unsecured indebtedness, in the event of a bankruptcy or other liquidation event involving a distribution of assets to satisfy our outstanding
indebtedness or an event of default under a loan agreement relating to secured indebtedness of our company or its subsidiaries, the holders
of such secured indebtedness, if any, would be entitled to receive payment of principal and interest prior to payments on the senior indebtedness
issued under an Indenture.
Prospectus Supplement
Each prospectus supplement
will describe the terms relating to the specific series of debt securities being offered. These terms will include some or all of the
following:
|
● |
the title of debt securities and whether they are subordinated, senior subordinated or senior debt securities; |
|
● |
any limit on the aggregate principal amount of debt securities of such series; |
|
● |
the percentage of the principal amount at which the debt securities of any series will be issued; |
|
● |
the ability to issue additional debt securities of the same series; |
|
● |
the purchase price for the debt securities and the denominations of the debt securities; |
|
● |
the specific designation of the series of debt securities being offered; |
|
● |
the maturity date or dates of the debt securities and the date or dates upon which the debt securities are payable and the rate or rates at which the debt securities of the series shall bear interest, if any, which may be fixed or variable, or the method by which such rate shall be determined; |
|
● |
the basis for calculating interest if other than 360-day year or twelve 30-day months; |
|
● |
the date or dates from which any interest will accrue or the method by which such date or dates will be determined; |
|
● |
the duration of any deferral period, including the maximum consecutive period during which interest payment periods may be extended; |
|
● |
whether the amount of payments of principal of (and premium, if any) or interest on the debt securities may be determined with reference to any index, formula or other method, such as one or more currencies, commodities, equity indices or other indices, and the manner of determining the amount of such payments; |
|
● |
the dates on which we will pay interest on the debt securities and the regular record date for determining who is entitled to the interest payable on any interest payment date; |
|
● |
the place or places where the principal of (and premium, if any) and interest on the debt securities will be payable, where any securities may be surrendered for registration of transfer, exchange or conversion, as applicable, and notices and demands may be delivered to or upon us pursuant to the applicable Indenture; |
|
● |
the rate or rates of amortization of the debt securities; |
|
● |
if we possess the option to do so, the periods within which and the prices at which we may redeem the debt securities, in whole or in part, pursuant to optional redemption provisions, and the other terms and conditions of any such provisions; |
|
● |
our obligation or discretion, if any, to redeem, repay or purchase debt securities by making periodic payments to a sinking fund or through an analogous provision or at the option of holders of the debt securities, and the period or periods within which and the price or prices at which we will redeem, repay or purchase the debt securities, in whole or in part, pursuant to such obligation, and the other terms and conditions of such obligation; |
|
● |
the terms and conditions, if any, regarding the option or mandatory conversion or exchange of debt securities; |
|
● |
the period or periods within which, the price or prices at which and the terms and conditions upon which any debt securities of the series may be redeemed, in whole or in part at our option and, if other than by a board resolution, the manner in which any election by us to redeem the debt securities shall be evidenced; |
|
● |
any restriction or condition on the transferability of the debt securities of a particular series; |
|
● |
the portion, or methods of determining the portion, of the principal amount of the debt securities which we must pay upon the acceleration of the maturity of the debt securities in connection with any event of default if other than the full principal amount; |
|
● |
the currency or currencies in which the debt securities will be denominated and in which principal, any premium and any interest will or may be payable or a description of any units based on or relating to a currency or currencies in which the debt securities will be denominated; |
|
● |
provisions, if any, granting special rights to holders of the debt securities upon the occurrence of specified events; |
|
● |
any deletions from, modifications of or additions to the events of default or our covenants with respect to the applicable series of debt securities, and whether or not such events of default or covenants are consistent with those contained in the applicable Indenture; |
|
● |
any limitation on our ability to incur debt, redeem stock, sell our assets or other restrictions; |
|
● |
the application, if any, of the terms of the applicable Indenture relating to defeasance and covenant defeasance (which terms are described below) to the debt securities; |
|
● |
what subordination provisions will apply to the debt securities; |
|
● |
the terms, if any, upon which the holders may convert or exchange the debt securities into or for our Ordinary Shares, preferred shares or other securities or property; |
|
● |
whether we are issuing the debt securities in whole or in part in global form; |
|
● |
any change in the right of the trustee or the requisite holders of debt securities to declare the principal amount thereof due and payable because of an event of default; |
|
● |
the depositary for global or certificated debt securities, if any; |
|
● |
any material federal income tax consequences applicable to the debt securities, including any debt securities denominated and made payable, as described in the prospectus supplements, in foreign currencies, or units based on or related to foreign currencies; |
|
● |
any right we may have to satisfy, discharge and defease our obligations under the debt securities, or terminate or eliminate restrictive covenants or events of default in the Indentures, by depositing money or U.S. government obligations with the trustee of the Indentures; |
|
● |
the names of any trustees, depositories, authenticating or paying agents, transfer agents or registrars or other agents with respect to the debt securities; |
|
● |
to whom any interest on any debt security shall be payable, if other than the person in whose name the security is registered, on the record date for such interest, the extent to which, or the manner in which, any interest payable on a temporary global debt security will be paid if other than in the manner provided in the applicable Indenture; |
|
● |
if the principal of or any premium or interest on any debt securities is to be payable in one or more currencies or currency units other than as stated, the currency, currencies or currency units in which it shall be paid and the periods within and terms and conditions upon which such election is to be made and the amounts payable (or the manner in which such amount shall be determined); |
|
● |
the portion of the principal amount of any debt securities which shall be payable upon declaration of acceleration of the maturity of the debt securities pursuant to the applicable Indenture if other than the entire principal amount; |
|
● |
if the principal amount payable at the stated maturity of any debt security of the series will not be determinable as of any one or more dates prior to the stated maturity, the amount which shall be deemed to be the principal amount of such debt securities as of any such date for any purpose, including the principal amount thereof which shall be due and payable upon any maturity other than the stated maturity or which shall be deemed to be outstanding as of any date prior to the stated maturity (or, in any such case, the manner in which such amount deemed to be the principal amount shall be determined); and |
|
● |
any other specific terms of the debt securities, including any modifications to the events of default under the debt securities and any other terms which may be required by or advisable under applicable laws or regulations. |
Unless otherwise specified
in the applicable prospectus supplement, the debt securities will not be listed on any securities exchange. Holders of the debt securities
may present registered debt securities for exchange or transfer in the manner described in the applicable prospectus supplement. Except
as limited by the applicable Indenture, we will provide these services without charge, other than any tax or other governmental charge
payable in connection with the exchange or transfer.
Debt securities may bear interest
at a fixed rate or a variable rate as specified in the prospectus supplement. In addition, if specified in the prospectus supplement,
we may sell debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing market rate,
or at a discount below their stated principal amount. We will describe in the applicable prospectus supplement any special federal income
tax considerations applicable to these discounted debt securities.
We may issue debt securities
with the principal amount payable on any principal payment date, or the amount of interest payable on any interest payment date, to be
determined by referring to one or more currency exchange rates, commodity prices, equity indices or other factors. Holders of such debt
securities may receive a principal amount on any principal payment date, or interest payments on any interest payment date, that are greater
or less than the amount of principal or interest otherwise payable on such dates, depending upon the value on such dates of applicable
currency, commodity, equity index or other factors. The applicable prospectus supplement will contain information as to how we will determine
the amount of principal or interest payable on any date, as well as the currencies, commodities, equity indices or other factors to which
the amount payable on that date relates and certain additional tax considerations.
DESCRIPTION OF WARRANTS
We may issue warrants for
the purchase of ordinary shares. Warrants may be offered independently or together with ordinary shares offered by any prospectus supplement
and may be attached to or separate from those securities. While the terms we have summarized below will apply generally to any warrants
that we may offer under this prospectus, we will describe in particular the terms of any series of warrants that we may offer in more
detail in the applicable prospectus supplement and any applicable free writing prospectus. The terms of any warrants offered under a prospectus
supplement may differ from the terms described below.
We will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with
the SEC, the form of warrant and/or warrant agreement, which may include a form of warrant certificate, as applicable, that describes
the terms of the particular series of warrants we may offer before the issuance of the related series of warrants. We may issue the warrants
under a warrant agreement that we will enter into with a warrant agent to be selected by us. The warrant agent will act solely as our
agent in connection with the warrants and will not assume any obligation or relationship of agency or trust for or with any registered
holders of warrants or beneficial owners of warrants. The following summary of material provisions of the warrants and warrant agreements
is subject to, and qualified in its entirety by reference to, all the provisions of the form of warrant and/or warrant agreement and warrant
certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any related free
writing prospectus, as well as the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, that
contain the terms of the warrants.The particular terms of any issue of warrants will be described in the prospectus supplement relating
to the issue. Those terms may include:
|
● |
the title of the warrants; |
|
● |
the price or prices at which the warrants will be issued; |
|
● |
the designation, amount and terms of the securities or other rights for which the warrants are exercisable; |
|
● |
the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants issued with each other security; |
|
● |
the aggregate number of warrants; |
|
● |
any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants; |
|
● |
the price or prices at which the securities or other rights purchasable upon exercise of the warrants may be purchased; |
|
● |
if applicable, the date on and after which the warrants and the securities or other rights purchasable upon exercise of the warrants will be separately transferable; |
|
● |
a discussion of any material U.S. federal income tax considerations applicable to the exercise of the warrants; |
|
● |
the date on which the right to exercise the warrants will commence, and the date on which the right will expire; |
|
|
|
|
● |
the maximum or minimum number of warrants that may be exercised at any time; |
|
● |
information with respect to book-entry procedures, if any; and |
|
● |
any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. |
Exercise of Warrants
Each warrant will entitle
its holder to purchase the number of ordinary shares at the exercise price set forth in, or calculable as set forth in, the applicable
prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless
we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the close of business on the
expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration
date, unexercised warrants will become void.
We will specify the place
or places where, and the manner in which, warrants may be exercised in the form of warrant, warrant agreement or warrant certificate and
applicable prospectus supplement. Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and
duly executed at the corporate trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus
supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the
warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable,
will be issued for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants
may surrender securities as all or part of the exercise price for warrants.
Prior to the exercise of any
warrants to purchase ordinary shares, holders of the warrants will not have any of the rights of holders of ordinary shares purchasable
upon exercise, including the right to vote or to receive any payments of dividends or payments upon our liquidation, dissolution or winding
up on the ordinary shares purchasable upon exercise, if any.
DESCRIPTION OF RIGHTS
We may issue rights to purchase
our securities. The rights may or may not be transferable by the persons purchasing or receiving the rights. In connection with any rights
offering, we may enter into a standby underwriting or other arrangement with one or more underwriters or other persons pursuant to which
such underwriters or other persons would purchase any offered securities remaining unsubscribed for after such rights offering. Each series
of rights will be issued under a separate rights agent agreement to be entered into between us and one or more banks, trust companies
or other financial institutions, as rights agent, that we will name in the applicable prospectus supplement. The rights agent will act
solely as our agent in connection with the rights and will not assume any obligation or relationship of agency or trust for or with any
holders of rights certificates or beneficial owners of rights.
The prospectus supplement
relating to any rights that we offer will include specific terms relating to the offering, including, among other matters:
|
● |
the date of determining the security holders entitled to the rights distribution; |
|
● |
the aggregate number of rights issued and the aggregate amount of securities purchasable upon exercise of the rights; |
|
● |
the conditions to completion of the rights offering; |
|
● |
the date on which the right to exercise the rights will commence and the date on which the rights will expire; and |
|
● |
any applicable federal income tax considerations. |
Each right would entitle the
holder of the rights to purchase for cash the principal amount of securities at the exercise price set forth in the applicable prospectus
supplement. Rights may be exercised at any time up to the close of business on the expiration date for the rights provided in the applicable
prospectus supplement. After the close of business on the expiration date, all unexercised rights will become void.
If less than all of the rights
issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than our security holders,
to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby arrangements, as
described in the applicable prospectus supplement.
DESCRIPTION OF UNITS
The following description,
together with the additional information we may include in any applicable prospectus supplement, summarizes the material terms and provisions
of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that
we may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus
supplement and any related free writing prospectus. The terms of any units offered under a prospectus supplement may differ from the terms
described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer
a security that is not registered and described in this prospectus at the time of its effectiveness.
We will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report we file with the
SEC, the form of unit agreement that describes the terms of the series of units we may offer under this prospectus, and any supplemental
agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units
are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements
applicable to a particular series of units. We urge you to read the applicable prospectus supplement and any related free writing prospectus,
as well as the complete unit agreement and any supplemental agreements that contain the terms of the units.
We may issue units consisting
of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each series of
units by unit certificates that we may issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit
agent, if any, may be a bank or trust company that we select. We will indicate the name and address of the unit agent, if any, in the
applicable prospectus supplement relating to a particular series of units. Specific unit agreements, if any, will contain additional important
terms and provisions. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate
by reference from a current report that we file with the SEC, the form of unit and the form of each unit agreement, if any, relating to
units offered under this prospectus.
If we offer any units, certain
terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the following,
as applicable
|
● |
the title of the series of units; |
|
● |
identification and description of the separate constituent securities comprising the units; |
|
● |
the price or prices at which the units will be issued; |
|
● |
the date, if any, on and after which the constituent securities comprising the units will be separately transferable; |
|
● |
a discussion of certain United States federal income tax considerations applicable to the units; and |
|
● |
any other material terms of the units and their constituent securities. |
The provisions described in
this section, as well as those described under “Description of Share Capital - Ordinary Shares” and “Description of
Warrants” will apply to each unit and to any Ordinary Shares or warrant included in each unit, respectively.
Issuance in Series
We may issue units in such
amounts and in numerous distinct series as we determine.
Transfer Agent and Registrar
The transfer agent and registrar
for our Ordinary Shares is Maples Fund Services (Cayman) Limited. Their mailing address is 16/F Central Plaza, 18 Harbour Road, Hong Kong.
Their phone number is +852 3655 9000.
NASDAQ Capital Market Listing
Our ADSs are listed on the
NASDAQ Capital Market under the symbol “AHG.”
PLAN OF DISTRIBUTION
We may sell the securities
offered through this prospectus (i) to or through underwriters or dealers, (ii) directly to purchasers, including our affiliates, (iii)
through agents, or (iv) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which
may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices. The
prospectus supplement will include the following information:
|
● |
the terms of the offering; |
|
● |
the names of any underwriters or agents; |
|
● |
the name or names of any managing underwriter or underwriters; |
|
● |
the purchase price of the securities; |
|
● |
any over-allotment options under which underwriters may purchase additional securities from us; |
|
● |
the net proceeds from the sale of the securities; |
|
● |
any delayed delivery arrangements; |
|
● |
any underwriting discounts, commissions and other items constituting underwriters’ compensation; |
|
● |
any initial public offering price; |
|
● |
any discounts or concessions allowed or reallowed or paid to dealers; |
|
● |
any commissions paid to agents; and |
|
● |
any securities exchange or market on which the securities may be listed. |
Sale Through Underwriters or Dealers
Only underwriters named in
the prospectus supplement are underwriters of the securities offered by the prospectus supplement. If underwriters are used in the sale,
the underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase
agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions.
Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described in this prospectus
or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject
to certain conditions, and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The
underwriters may change from time to time any public offering price and any discounts or concessions allowed or reallowed or paid to dealers.
If dealers are used in the
sale of securities offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities
to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the
dealers and the terms of the transaction.
We will provide in the applicable
prospectus supplement any compensation we will pay to underwriters, dealers or agents in connection with the offering of the securities,
and any discounts, concessions or commissions allowed by underwriters to participating dealers.
Direct Sales and Sales Through Agents
We may sell the securities
offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold
through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered
securities and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent
will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.
We may sell the securities
directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect
to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.
Delayed Delivery Contracts
If the prospectus supplement
indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities
at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date
in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus
supplement will describe the commission payable for solicitation of those contracts.
Market Making, Stabilization and Other Transactions
Unless the applicable prospectus
supplement states otherwise, other than our Ordinary Shares, all securities we offer under this prospectus will be a new issue and will
have no established trading market. We may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters
that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time
without notice. Therefore, we cannot assure you that the securities will have a liquid trading market.
Any underwriter may also engage
in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Securities Exchange
Act. Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or
maintaining the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after
the distribution has been completed in order to cover syndicate short positions.
Penalty bids permit the underwriters
to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a
syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty
bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters may, if
they commence these transactions, discontinue them at any time.
General Information
Agents, underwriters, and
dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities
under the Securities Act. Our agents, underwriters, and dealers, or their affiliates, may be customers of, engage in transactions with
or perform services for us, in the ordinary course of business.
LEGAL MATTERS
Except as otherwise set forth
in the applicable prospectus supplement, certain legal matters in connection with the securities offered pursuant to this prospectus will
be passed upon for us by Hunter Taubman Fischer & Li LLC to the extent governed by the laws of the State of New York, and by Maples
and Calder (Hong Kong) LLP to the extent governed by the laws of the Cayman Islands. If legal matters in connection with offerings made
pursuant to this prospectus are passed upon by counsel to underwriters, dealers or agents, such counsel will be named in the applicable
prospectus supplement relating to any such offering.
EXPERTS
The financial statements
incorporated by reference in this prospectus for the year ended March 31, 2024, March 31, 2023 and March 31, 2022 have been audited by
Onestop Assurance PAC, an independent registered public accounting firm, as set forth in its report thereon included therein, and incorporated
herein by reference, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
FINANCIAL INFORMATION
The financial statements
for the fiscal years ended March 31, 2024, 2023, and 2022 are included in our Annual Report on Form 20-F for the year ended March 31,
2024, filed on July 30, 2024, which are incorporated by reference into this prospectus.
INFORMATION INCORPORATED BY REFERENCE
The SEC allows us to “incorporate
by reference” into this prospectus the information we file with the SEC. This means that we can disclose important information to
you by referring you to those documents. Any statement contained in a document incorporated by reference in this prospectus shall be deemed
to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in any subsequently filed
document, which also is incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
We hereby incorporate by reference
into this prospectus the following documents that we have filed with the SEC under the Exchange Act:
| (1) | the
Company’s Annual Report on Form
20-F, as amended for the fiscal year ended March 31, 2024, filed with the SEC on July
30, 2024; |
| (2) | the
Company’s Reports on Form 6-K, filed with the SEC on October
2, 2023, October
18, 2023, November
17, 2023, November
22, 2023, January
3, 2024, January
22, 2024, January
29, 2024, March
8, 2024, March
26, 2024, May
2, 2024, November
8, 2024; and |
| (3) | The
description of our ordinary shares contained in our registration statement on Form
8-A (File No. 000-38245), filed with the SEC on October 16, 2017, and any amendment or
report filed for the purpose of updating such description; |
All documents that we file
with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (and in the case of a Report on Form 6-K, so long as they
state that they are incorporated by reference into this prospectus, and other than Reports on Form 6-K, or portions thereof, furnished
under Form 6-K) (i) after the initial filing date of the registration statement of which this prospectus forms a part and prior to the
effectiveness of such registration statement and (ii) after the date of this prospectus and prior to the termination of the offering shall
be deemed to be incorporated by reference in this prospectus from the date of filing of the documents, unless we specifically provide
otherwise. Information that we file with the SEC will automatically update and may replace information previously filed with the SEC.
To the extent that any information contained in any Report on Form 6-K or any exhibit thereto, was or is furnished to, rather than filed
with the SEC, such information or exhibit is specifically not incorporated by reference.
Upon request, we will provide,
without charge, to each person who receives this prospectus, a copy of any or all of the documents incorporated by reference (other than
exhibits to the documents that are not specifically incorporated by reference in the documents). Please direct written or oral requests
for copies to us at Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, No. 44, Moscow Road, Qianwan Bonded Port Area, Qingdao Pilot Free
Trade Zone, China (Shandong).
WHERE YOU CAN FIND MORE INFORMATION
As permitted by SEC rules,
this prospectus omits certain information and exhibits that are included in the registration statement of which this prospectus forms
a part. Since this prospectus may not contain all of the information that you may find important, you should review the full text of these
documents. If we have filed a contract, agreement or other document as an exhibit to the registration statement of which this prospectus
forms a part, you should read the exhibit for a more complete understanding of the document or matter involved. Each statement in this
prospectus, including statements incorporated by reference as discussed above, regarding a contract, agreement or other document is qualified
in its entirety by reference to the actual document.
We are subject to the information
reporting requirements of the Exchange Act that are applicable to foreign private issuers, and, in accordance with these requirements,
we file annual and current reports and other information with the SEC. You may inspect, read (without charge) and copy the reports and
other information we file with the SEC at the SEC’s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains
an internet website at www.sec.gov that contains our filed reports and other information that we file electronically with the SEC.
We maintain a corporate website
at http://www.ahgtop.com/en/index.html. Information contained on, or that can be accessed through, our website does not constitute a part
of this prospectus.
ENFORCEABILITY OF CIVIL LIABILITIES
We are incorporated under
the laws of the Cayman Islands as an exempted company with limited liability. We incorporated in the Cayman Islands because of certain
benefits associated with being a Cayman Islands exempted company, such as political and economic stability, an effective judicial system,
a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability of professional and support
services. However, the Cayman Islands have a less developed body of securities laws that provide significantly less protection to investors
as compared to the securities laws of the United States. In addition, Cayman Islands companies may not have standing to sue before the
federal courts of the United States.
All of our assets are located
in China. In addition, some of our directors and officers are residents of jurisdictions other than the United States and all or a substantial
portion of their assets are located outside the United States. As a result, it may be difficult for investors to effect service of process
within the United States upon us or our directors and officers, or to enforce against us or them judgments obtained in United States courts,
including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United
States.
According to our local Cayman
Islands’ counsel, there is uncertainty with regard to Cayman Islands law relating to whether a judgment obtained from the United
States or Hong Kong courts under civil liability provisions of the securities laws will be determined by the courts of the Cayman Islands
as penal or punitive in nature. If such a determination is made, the courts of the Cayman Islands will not recognize or enforce the judgment
against a Cayman Islands’ company. The courts of the Cayman Islands in the past determined that disgorgement proceedings brought
at the instance of the Securities and Exchange Commission are penal or punitive in nature and such judgments would not be enforceable
in the Cayman Islands. Other civil liability provisions of the securities laws may be characterized as remedial, and therefore enforceable
but the Cayman Islands’ Courts have not yet ruled in this regard. Our Cayman Islands’ counsel has further advised us that
a final and conclusive judgment in the federal or state courts of the United States under which a sum of money is payable other than a
sum payable in respect of taxes, fines, penalties or similar charges, may be subject to enforcement proceedings as a debt in the courts
of the Cayman Islands.
As of the date hereof, no
treaty or other form of reciprocity exists between the Cayman Islands and Hong Kong governing the recognition and enforcement of judgments.
Cayman Islands’ counsel
further advised that although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States or Hong
Kong, a judgment obtained in such jurisdictions will be recognized and enforced in the courts of the Cayman Islands at common law, without
any re-examination of the merits of the underlying dispute, by an action commenced on the foreign judgment debt in the Grand Court of
the Cayman Islands, provided such judgment (1) is given by a foreign court of competent jurisdiction, (2) imposes on the judgment debtor
a liability to pay a liquidated sum for which the judgment has been given, (3) is final, (4) is not in respect of taxes, a fine or a penalty,
and (5) was not obtained in a manner and is of a kind the enforcement of which is contrary to natural justice or the public policy of
the Cayman Islands.
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing
provisions, or otherwise, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed
in the Securities Act and is, therefore, unenforceable.
AKSO HEALTH GROUP
$400,000,000
Class A Ordinary Shares
Class A Ordinary Shares in the Form of American
Depositary Shares,
Debt Securities,
Warrants,
Rights and
Units
PROSPECTUS
November 26, 2024
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 8. Indemnification of Directors and Officers
Cayman Islands law does not
limit the extent to which a company’s M&A may provide for indemnification of officers and directors, except to the extent any
such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil
fraud or the consequences of committing a crime. Our M&A requires us to indemnify our officers and directors for actions, proceedings,
claims, losses, damages, costs, liabilities and expenses (“Indemnified Losses”) incurred in their capacities as such unless
such Indemnified Losses arise from dishonesty of such directors or officers. This standard of conduct is generally the same as permitted
under the Delaware General Corporation Law for a Delaware corporation.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling
us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.
Item 9. Exhibits
** | To be filed by amendment or as an exhibit to a filing with
the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934 and incorporated by reference in connection with the offering
of securities to the extent required for any such offering. |
Item 10 Undertakings
(a) | The undersigned registrant
hereby undertakes: |
| (1) | To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement: |
| (i) | To include any prospectus required
by Section 10(a)(3) of the Securities Act of 1933; |
| (ii) | To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee”
table in the effective registration statement. |
| (iii) | To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement. |
provided, however,
that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant
pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement,
or is contained in a form of prospectus filed pursuant to Rule 424(b).
| (2) | That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. |
| (3) | To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| (4) | That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser: |
| (i) | Each prospectus filed by the
registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and |
| (ii) | Each prospectus required to
be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering
made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities
Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus
is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus.
As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such effective date. |
| (5) | That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned
registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser: |
| (i) | Any preliminary prospectus or
prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
| (ii) | Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
| (iii) | The portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and |
| (iv) | Any other communication that
is an offer in the offering made by the undersigned registrant to the purchaser. |
(b) | That, for purposes of determining
any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section
15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant
to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof. |
(c) | Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Qingdao, the People’s Republic of China, on November 26, 2024.
|
Akso Health Group |
|
|
|
By: |
/s/ Yilin (Linda) Wang |
|
|
Name: |
Yilin (Linda) Wang |
|
|
Title: |
Chief Executive Officer and
Chairwoman of the Board |
POWER OF ATTORNEY
Each person whose signature
appears below hereby constitutes and appoints Yilin (Linda) Wang as his or her true and lawful attorneys-in-fact and agents, with full
power of substitution and resubstitution, in his or her name, place and stead, in any and all capacities (including his capacity as a
director and/or officer of the registrant), to sign any and all amendments and post-effective amendments and supplements to this registration
statement, and including any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b)
under the U.S. Securities Act of 1933, as amended, and to file the same, with all exhibits thereto and other documents in connection therewith,
with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could
do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute, may lawfully
do or cause to be done by virtue hereof.
Pursuant to the requirements
of the U.S. Securities Act of 1933, as amended, this Form F-3 registration statement has been signed by the following persons in the capacities
and on the date indicated.
Name |
|
Position |
|
Date |
|
|
|
|
|
/s/ Yilin (Linda) Wang |
|
Chief Executive Officer and Chairwoman of the Board |
|
November 26, 2024 |
Yilin (Linda) Wang |
|
(principal executive officer) |
|
|
|
|
|
|
|
/s/ Rui (Kerrie) Zhang |
|
Chief Financial Officer |
|
November 26, 2024 |
Rui (Kerrie) Zhang |
|
(principal financial officer and principal accounting officer) |
|
|
|
|
|
|
|
/s/ Wenjuan (Vivian) Liu |
|
Director |
|
November 26, 2024 |
Wenjuan (Vivian) Liu |
|
|
|
|
|
|
|
|
|
/s/ Stephen P. Brown |
|
Director |
|
November 26, 2024 |
Stephen P. Brown |
|
|
|
|
|
|
|
|
|
/s/ Zhe Liu |
|
Director |
|
November 26, 2024 |
Zhe Liu |
|
|
|
|
/s/ Gerald (Jerry) T. Neal |
|
Director |
|
November 26, 2024 |
Gerald (Jerry) T. Neal |
|
|
|
|
SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE
UNITED STATES
Pursuant to the Securities
Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration
statement thereto in Newark, Delaware on November 26, 2024.
|
By: |
/s/ Donald J. Puglisi |
|
Name: |
Donald J. Puglisi |
|
Title: |
Managing Director |
|
|
Puglisi & Associates |
Exhibit 5.1
Our ref |
KKZ/727103-000004/30803472v2 |
Akso Health Group
Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building,
No. 44, Moscow Road, Qianwan Bonded Port Area,
Qingdao Pilot Free Trade Zone,
Shandong, China
21 November 2024
Dear Sir or Madam
Akso
Health Group
We have acted as Cayman Islands
legal advisers to Akso Health Group (the “Company”) in
connection with the Company’s registration statement on Form F-3, including all amendments or supplements thereto (the “Registration
Statement”), filed on 21 November 2024 with the Securities and Exchange Commission under the U.S. Securities Act of 1933,
as amended to date relating to future issuance and sale by the Company, on a delayed or continuous basis, from time to time in one or
more offerings, up to US$400,000,000 of the following securities:
| (i) | Class A ordinary shares of the Company of a par value of
US$0.0001 each (the “Shares”), including in the form
of American depositary shares, each representing three Shares (the “ADSs”); |
| (ii) | certain debt securities of the Company, which may include
debt securities exchangeable for or convertible into Shares (collectively the “Debt
Securities”), each series of Debt Securities to be issued under indentures to be entered into by the Company and the
trustee for such Debt Securities (the “Indentures”); |
| (iii) | warrants to subscribe for Shares, including in the form of
ADSs, Debt Securities, or any combination of these securities of the Company (the “Warrants”)
to be issued under warrant agreements to be entered into between the Company and the warrant agent for such Warrants thereunder (the
“Warrant Agreements”); |
| (iv) | subscription rights to purchase Shares, including in the
form of ADSs, in the Company (the “Subscription Rights”)
to be issued under standby underwriting agreements to be entered into among the Company and one or more underwriters or rights agreements
to be entered into among the Company and a rights agent for such Subscription Rights thereunder (the “Subscription
Rights Agreements”); |
| (v) | units comprising of one or more of the Shares, including
in the form of ADSs, Debt Securities, Warrants, or Subscription Rights in any combination (the “Units”)
to be issued under unit agreements to be entered into between the Company and the unitholder for such Units thereunder (the “Unit
Agreements”). |
We are furnishing this opinion as Exhibits
5.1 and 23.2 to the Registration Statement.
1 Documents Reviewed
For the purposes of this opinion,
we have reviewed only originals, copies or final drafts of the following documents:
1.1 The certificate of incorporation of the Company dated 25 April 2016 and the certificates of incorporation on change of name of the Company dated 17 December 2020 and 10 December 2021 issued by the Registrar of Companies in the Cayman Islands.
1.2 The second amended and restated memorandum and articles of association of the Company as adopted by a special resolution passed on 30 April 2024 (the “Memorandum and Articles”).
1.3 The written resolutions of the board of directors of the Company dated 22 February 2024 (the “Directors’ Resolutions”), and the corporate records of the Company maintained at its registered office in the Cayman Islands.
1.4 A certificate from a director of the Company, a copy of which is attached hereto (the “Director’s Certificate”).
1.5 A certificate of good standing dated 23 February 2024, issued by the Registrar of Companies in the Cayman Islands (the “Certificate of Good Standing”).
1.6 The Registration Statement.
2 Assumptions
The following opinions are given
only as to, and based on, circumstances and matters of fact existing and known to us on the date of this opinion letter. These opinions
only relate to the laws of the Cayman Islands which are in force on the date of this opinion letter. In giving these opinions we have
relied (without further verification) upon the completeness and accuracy, as of the date of this opinion letter, of the Director’s Certificate
and the Certificate of Good Standing. We have also relied upon the following assumptions, which we have not independently verified:
2.1 Copies of documents, conformed copies or drafts of documents provided to us are true and complete copies of, or in the final forms of, the originals.
2.2 All signatures, initials and seals are genuine.
2.3 There is no contractual or other prohibition or restriction (other than as arising under Cayman Islands law) binding on the Company prohibiting or restricting it from entering into and performing its obligations under the Registration Statement and a duly authorised, executed and delivered Indenture, Warrant Agreement, Subscription Rights Agreement or Unit Agreement.
2.4 The Company will have sufficient Shares authorised for issue under the Memorandum and Articles at the time of issuance.
2.5 The Indentures and the Debt Securities, the Warrant Agreements and the Warrants, the Subscription Rights Agreements and the Subscription Rights, and the Unit Agreements and the Units are, or will be, legal, valid, binding and enforceable against all relevant parties in accordance with their terms under the laws of the State of New York and all other relevant laws (other than, with respect to the Company, the laws of the Cayman Islands).
2.6 The choice of the laws of the State of New York as the governing law of the Indentures and the Debt Securities, Warrant Agreements and the Warrants, the Subscription Rights and the Subscription Rights Agreements and the Units and the Unit Agreements, will be made in good faith and would be regarded as a valid and binding selection which will be upheld by the courts of the State of New York and any other relevant jurisdiction (other than the Cayman Islands) as a matter of the laws of the State of New York and all other relevant laws (other than the laws of the Cayman Islands).
2.7 The capacity, power, authority and legal right of all parties under all relevant laws and regulations (other than, with respect to the Company, the laws and regulations of the Cayman Islands) to enter into, execute, unconditionally deliver and perform their respective obligations under the Indentures and the Debt Securities, Warrants and the Warrant Agreements, the Subscription Rights Agreements and the Subscription Rights, and the Units and the Unit Agreements.
2.8 No monies paid to or for the account of the Company in respect of the Shares, the Debt Securities, the Warrants, the Subscription Rights or the Units represent or will represent proceeds of criminal conduct or criminal property or terrorist property (as defined in the Proceeds of Crime Act (As Revised) and the Terrorism Act (As Revised) respectively).
2.9 There is nothing under any law (other than the law of the Cayman Islands), which would or might affect the opinions set out below.
3 Opinion
Based upon the foregoing and subject to the qualifications
set out below and having regard to such legal considerations as we deem relevant, we are of the opinion that:
3.1 The Company has been duly incorporated as an exempted company with limited liability and is validly existing and in good standing with the Registrar of Companies under the laws of the Cayman Islands.
3.2 The authorised share capital of the Company is US$500,000 divided into 5,000,000,000 ordinary shares of a par value of US$0.0001 each, comprising (i) 4,500,000,000 Class A ordinary shares of a par value of US$0.0001 each and (ii) 500,000,000 Class B ordinary shares of a par value of US$0.0001 each.
3.3 With respect to the Shares, including those represented by ADSs, when (i) the Board has taken all necessary corporate action to approve the issue thereof, the terms of the offering thereof and related matters; (ii) the issue of such Shares has been recorded in the Company’s register of members (shareholders); and (iii) the subscription price of such Shares (being not less than the par value of the Shares) has been fully paid in cash or other consideration approved by the Board, the Shares will be duly authorised, validly issued, fully paid and non-assessable.
3.4 With respect to each issue of the Debt Securities, when (i) the Board has taken all necessary corporate action to approve the creation and terms of the Debt Securities and to approve the issue thereof, the terms of the offering thereof and related matters; (ii) an Indenture relating to the Debt Securities and the Debt Securities shall have been authorised and duly executed and delivered by and on behalf of the Company and all the relevant parties thereunder in accordance with all relevant laws; and (iii) when such Debt Securities issued thereunder have been duly executed and delivered on behalf of the Company and authenticated in the manner set forth in the Indenture relating to such issue of Debt Securities and delivered against due payment therefor pursuant to, and in accordance with, the terms of the Registration Statement and any relevant prospectus supplement, such Debt Securities issued pursuant to the Indenture will have been duly executed, issued and delivered.
3.5 With respect to each issue of Warrants, when (i) the Board has taken all necessary corporate action to approve the creation and terms of the Warrants and to approve the issue thereof, the terms of the offering thereof and related matters; (ii) a Warrant Agreement relating to the Warrants shall have been duly authorised and validly executed and delivered by the Company and the warrant agent thereunder; and (iii) the certificates representing the Warrants have been duly executed, countersigned, registered and delivered in accordance with the Warrant Agreement relating to the Warrants and the applicable definitive purchase, underwriting or similar agreement approved by the Board upon payment of the consideration therefor provided therein, the Warrants will be duly authorised, and constitute legal and binding obligations of the Company.
3.6 With respect to each issue of the Subscription Rights, when (i) the Board has taken all necessary corporate action to approve the creation and terms of the Subscription Rights and to approve the issue thereof, the terms of the offering thereof and related matters; (ii) a Subscription Rights Agreement relating to the Subscription Rights and the Subscription Rights shall have been authorised and duly executed and delivered by and on behalf of the Company and all the relevant parties thereunder in accordance with all relevant laws; and (iii) when such Subscription Rights issued thereunder have been duly executed and delivered on behalf of the Company and authenticated in the manner set forth in the Subscription Rights Agreement relating to such issue of Subscription Rights and delivered against due payment therefor pursuant to, and in accordance with, the terms of the Registration Statement and any relevant prospectus supplement, such Subscription Rights issued pursuant to the Subscription Rights Agreement will have been duly executed, issued and delivered, and constitute legal and binding obligations of the Company.
3.7 With respect to each issue of the Units, when (i) the Board has taken all necessary corporate action to approve the creation and terms of the Units and to approve the issue thereof, the terms of the offering thereof and related matters; (ii) a Unit Agreement relating to the Units and the Units shall have been authorised and duly executed and delivered by and on behalf of the Company and all the relevant parties thereunder in accordance with all relevant laws; and (iii) when such Units issued thereunder have been duly executed and delivered on behalf of the Company and authenticated in the manner set forth in the Unit Agreement relating to such issue of Units and delivered against due payment therefor pursuant to, and in accordance with, the terms of the Registration Statement and any relevant prospectus supplement, such Units issued pursuant to the Unit Agreement will have been duly executed, issued and delivered, and constitute legal and binding obligations of the Company.
4 Qualifications
The opinions expressed above are subject
to the following qualifications:
4.1
To maintain the Company in good standing under the laws of the Cayman Islands, annual filing fees must be paid and returns made
to the Registrar of Companies within the time frame prescribed by law.
4.2
The obligations assumed by the Company under the Indentures, Warrant Agreements, the Subscription Rights Agreements, the Unit
Agreements or the Debt Securities, the Warrants, Subscription Rights, and Units issued thereunder will not necessarily be
enforceable in all circumstances in accordance with their terms. In particular:
| (a) | enforcement may be limited by bankruptcy, insolvency, liquidation,
reorganisation, readjustment of debts or moratorium or other laws of general application relating to, protecting or affecting the rights
of creditors and/or contributories; |
| (b) | enforcement may be limited by general principles of equity.
For example, equitable remedies such as specific performance may not be available, inter
alia, where damages are considered to be an adequate remedy; |
| (c) | some claims may become barred under relevant statutes of
limitation or may be or become subject to defences of set off, counterclaim, estoppel and similar defences; |
| (d) | where obligations are to be performed in a jurisdiction outside
the Cayman Islands, they may not be enforceable in the Cayman Islands to the extent that performance would be illegal under the laws
of that jurisdiction; |
| (e) | the courts of the Cayman Islands have jurisdiction to give
judgment in the currency of the relevant obligation and statutory rates of interest payable upon judgments will vary according to the
currency of the judgment. If the Company becomes insolvent and is made subject to a liquidation proceeding, the courts of the Cayman
Islands will require all debts to be proved in a common currency, which is likely to be the “functional currency” of the Company
determined in accordance with applicable accounting principles. Currency indemnity provisions have not been tested, so far as we are
aware, in the courts of the Cayman Islands; |
| (f) | arrangements that constitute penalties will not be enforceable; |
| (g) | enforcement may be prevented by reason of fraud, coercion,
duress, undue influence, misrepresentation, public policy or mistake or limited by the doctrine of frustration of contracts; |
| (h) | provisions imposing confidentiality obligations may be overridden
by compulsion of applicable law or the requirements of legal and/or regulatory process; |
| (i) | the courts of the Cayman Islands may decline to exercise
jurisdiction in relation to substantive proceedings brought in matters where they determine that such proceedings may be tried in a more
appropriate forum; |
| (j) | we reserve our opinion as to the enforceability of the relevant
provisions of the documents to the extent that they purport to grant exclusive jurisdiction as there may be circumstances in which the
courts of the Cayman Islands would accept jurisdiction notwithstanding such provisions; and |
| (k) | a company cannot, by agreement or in its articles of association,
restrict the exercise of a statutory power and there is doubt as to the enforceability of any provision in the Indentures, Warrant Agreements,
the Subscription Rights Agreements and the Unit Agreements whereby the Company covenants to restrict the exercise of powers specifically
given to it under the Companies Act (As Revised) of the Cayman Islands (the “Companies
Act”), including, without limitation, the power to increase its authorised share capital, amend its memorandum and articles
of association or present a petition to a Cayman Islands court for an order to wind up the Company. |
4.3
We express no opinion as to the meaning, validity or effect of any references to foreign (i.e. non-Cayman Islands) statutes, rules,
regulations, codes, judicial authority or any other promulgations and any references to them in the Indentures or the Debt Securities,
Warrant Agreements or the Warrants, the Subscription Rights Agreements or the Subscription Rights, and the Unit Agreements or the Units.
4.4
We have not reviewed the final form of any of the Indentures, Warrant Agreements, the Subscription Rights Agreements, the Unit
Agreements or the Debt Securities, Warrants, Subscription Rights, and Units to be issued thereunder, and our opinions are qualified accordingly.
4.5
We reserve our opinion as to the extent to which the courts of the Cayman Islands would, in the event of any relevant illegality
or invalidity, sever the relevant provisions of the Indentures or the Debt Securities, Warrant Agreements or the Warrants, the Subscription
Rights Agreements or the Subscription Rights, and the Unit Agreements or the Units and enforce the remainder or the transaction of which
such provisions form a part, notwithstanding any express provisions in this regard.
4.6
Under the Companies Act, the register of members of a Cayman Islands company is by statute regarded as prima facie evidence of
any matters which the Companies Act directs or authorises to be inserted in it. A third party interest in the shares in question would
not appear. An entry in the register of members may yield to a court order for rectification (for example, in the event of fraud or manifest
error).
4.7
In this opinion the phrase “non-assessable” means, with respect to the Shares in the Company, that a shareholder shall
not, solely by virtue of its status as a shareholder, and in absence of a contractual arrangement, or an obligation pursuant to the memorandum
and articles of association, to the contrary, be liable for additional assessments or calls on the Shares by the Company or its creditors
(except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose
or other circumstances in which a court may be prepared to pierce or lift the corporate veil).
Except as specifically stated herein,
we make no comment with respect to any representations and warranties which may be made by or with respect to the Company in any of the
documents or instruments cited in this opinion or otherwise with respect to the commercial terms of the transactions, which are the subject
of this opinion.
We hereby consent to the filing
of this opinion as an exhibit to the Registration Statement and to the reference to our name under the heading “Legal Matters”
and elsewhere in the prospectus included in the Registration Statement. In giving such consent, we do not thereby admit that we come within
the category of persons whose consent is required under Section 7 of the U.S. Securities Act of 1933, as amended, or the Rules and Regulations
of the Commission thereunder.
Yours faithfully
/s/ Maples and Calder (Hong Kong) LLP
Maples and Calder (Hong Kong) LLP
Director’s Certificate
November 12,
2024
To: | Maples and Calder (Hong Kong) LLP |
26th Floor, Central Plaza
18 Harbour Road
Wanchai, Hong Kong
Dear Sir or Madam
Akso Health Group (the “Company”)
I, the undersigned, being a director
of the Company, am aware that you are being asked to provide a legal opinion (the “Opinion”)
in relation to certain aspects of Cayman Islands law. Capitalised terms used in this certificate have the meaning given to them in the
Opinion. I hereby certify that:
| 1 | The Memorandum and Articles remain in full and effect and
are otherwise unamended. |
| 2 | The Resolutions were duly passed in the manner prescribed
in Memorandum and Articles (including, without limitation, with respect to the disclosure of interests (if any) by directors of the Company)
and have not been amended, varied or revoked in any respect. |
| 3 | The authorised share capital of the Company is US$500,000
divided into 5,000,000,000 ordinary shares of a par value of US$0.0001 each, comprising (i) 4,500,000,000 Class A ordinary shares of
a par value of US$0.0001 each and (ii) 500,000,000 Class B ordinary shares of a par value of US$0.0001 each. |
| 4 | All of the issued shares in the capital of the Company have
been duly and validly authorised and issued and are fully paid and non-assessable (meaning that no further sums are payable to the Company
on such shares and the Company has received payment therefor). |
| 5 | The shareholders of the Company have not restricted or limited
the powers of the directors in any way and there is no contractual or other prohibition (other than as arising under Cayman Islands law)
binding on the Company prohibiting it from issuing and allotting the Shares or otherwise performing its obligations under the Registration
Statement. |
| 6 | The directors of the Company at the date of the Resolutions
and as at the date of this certificate were and are as follows: |
Wenjuan Liu
Linda (Yilin) Wang
Stephen P. Brown
Gerald (Jerry) T. Neal
Zhe Liu
| 7 | Each director considers the transactions contemplated by
the Registration Statement to be of commercial benefit to the Company and has acted bona fide in the best interests of the Company, and for a proper purpose of the Company in relation
to the transactions which are the subject of the Opinion. |
| 8 | To the best of my knowledge and belief, having made due inquiry,
the Company is not the subject of legal, arbitral, administrative or other proceedings in any jurisdiction and neither the directors
nor Shareholders have taken any steps to have the Company struck off or placed in liquidation. Further, no steps have been taken to wind
up the Company or to appoint restructuring officers or interim restructuring officers, and no receiver has been appointed in relation
to any of the Company’s property or assets. |
| 9 | No interest in the Company constituting shares, voting rights
or ultimate effective control over management in the Company is currently subject to a restrictions notice issued under the Beneficial
Ownership Transparency Act (As Revised) of the Cayman Islands. |
I confirm that you may continue to
rely on this certificate as being true and correct on the day that you issue the Opinion unless I shall have previously notified you in
writing personally to the contrary.
[signature
page follows]
Signature: |
/s/ Yiling Wang
| |
Name: |
Yiling Wang |
|
Title: |
Director |
|
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
We consent to the incorporation by
reference in this Amendment No. 1 to Form F-3/A of our report dated July 14, 2023, relating to the consolidated financial statements of
Akso Health Group (formerly known as “Xiaobai Maimai Inc.”), its subsidiaries and consolidated variable interest entities,
appearing in its Annual Report on Form 20-F for the year ended March 31, 2023. Our report contains an explanatory paragraph regarding
the Company’s ability to continue as a going concern.
We also consent to the reference to our firm under the heading
“Experts” in the Registration Statement.
/s/ OneStop Assurance PAC
Singapore
November 21, 2024
Akso Health (NASDAQ:AHG)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Akso Health (NASDAQ:AHG)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024